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ABSTRACT
The immune system has the ability to discriminate self from non-self proteins and also make appropriate
immune responses to pathogens. A fundamental problem is to understand the genomic differences and
similarities among the sets of self peptides and non-self peptides. The sequencing of human, mouse and
numerous pathogen genomes and cataloging of their respective proteomes allows host self and non-self
peptides to be identified. T-cells make this determination at the peptide level based on peptides displayed by
MHC molecules.
In this project, peptides of specific lengths (k-mers) are generated from each protein in the proteomes
of various model organisms. The set of unique k-mers for each species is stored in a library and defines its
“immunological self”. Using the libraries, organisms can be compared to determine the levels of peptide
overlap. The observed levels of overlap can also be compared with levels which can be expected “at random”
and statistical conclusions drawn.
A problem with this procedure is that sequence information in public protein databases (Swiss-PROT,
UniProt, PIR) often contains ambiguities. Three strategies for dealing with such ambiguities have been
explored in earlier work and the strategy of removing ambiguous k-mers is used here.
Peptide fragments (k-mers) which elicit immune responses are often localized within the sequences of
proteins from pathogens. These regions are known as “immunodominants” (i.e., hot spots) and are important
in immunological work. After investigating the peptide universes and their overlaps, the question of whether
known regions of immunological significance (e.g., epitope) come from regions of low host-similarity is
explored. The known regions of epitopes are compared with the regions of low host-similarity (i.e., non-
overlaps) between HIV-1 and human proteomes at the 7-mer level. Results show that the correlation between
these two regions is not statistically significant. In addition, pairs involving human and human viruses are
explored. For these pairs, one graph for each k-mer level is generated showing the actual numbers of matches
between organisms versus the expected numbers. From graphs for 5-mer and 6-mer level, we can see that
the number of overlapping occurrences increases as the size of the viral proteome increases.
A detailed investigation of the overlaps/non-overlaps between viral proteome and human proteome re-
veals that the distribution of the locations of these overlaps/non-overlaps may have “structure” (e.g. locality
clustering). Thus, another question that is explored is whether the locality clustering is statistically sig-
nificant. A chi-square analysis is used to analyze the locality clustering. Results show that the locality
clusterings for HIV-1, HIV-2 and Influenza A virus at the 5-mer, 6-mer and 7-mer levels are statistically
significant. Also, for self-similarity of human protein Desmoglein 3 to the remaining human proteome, it
shows that the locality clustering is not statistically significant at the 5-mer level while it is at the 6-mer and
7-mer levels.
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CHAPTER 1
INTRODUCTION
Immuno-informatics is an area where people use bioinformatics tools to understand the immune system
better as well as to improve the development of immunotherapies. Just as DNA is the information system for
life, peptides are the information system for the adaptive immune system. The immune system has multiple
layers of defense to protect against pathogens. The initiation, regulation and termination of an immune re-
sponse involves a large number of cells of different types and several stimulatory/inhibitory signals delivered
locally and systemically [4, 22].
The immune system has the ability to discriminate self from non-self proteins and then make appropriate
immune responses to pathogens. Such an ability is an important property in maintaining tissue/organism
integrity. Breakage this self-tolerance is one of the main bases for autoimmune diseases [10, 13, 21]. Self
proteins are proteins from the organism itself while non-self proteins are proteins not from the organism but
from such sources as invading pathogens. According to this characteristic of proteins, the immune system
decides whether or not to respond to infections, and which type of response to make. An infected cell
can “present” peptides that are generated from the degradation of non-self proteins to immune cells in the
organism. The presentation of peptides to the T-cells is done by MHC molecules, which have one of the
largest degrees of polymorphisms among mammalian proteins. That is, within the “groove” of the MHC
molecules where the peptide fragments bind, there may be various shapes in order to bind peptides.
Vertebrate immune systems process self and non-self proteins into peptide fragments 8 - 25 amino acids
long, which are presented to the T-cell repertoire by surface MHCmolecules [7, 9]. There are different types
of MHC molecules such as MHC class I and MHC class II molecules. They have different conformational
shapes, and different binding preferences. The typical length of peptides presented to CD8+ T cells by MHC
class I molecules is 9 residues; the peptides presented to CD4+ T cells by MHC class II molecules tend to
be longer, with a typical length of 12 - 20 residues. In addition, the typical length of peptides presented to
B cells is 5 - 6 residues. Thus, in this work, self and non-self proteins are computationally fragmented into
sets of peptides of specific lengths (k-mers).
In this research, “host proteome” refers to the human proteome. Host self consists of all the possible
peptides that can be generated from the host proteome, while non-self consists of all the possible peptides
that can be generated from the proteome of a foreign organism. Overlaps refer to the occurrence of identical
peptides within the proteomes of different organisms [3].
1
The MHC-I and MHC-II as well as B cell immune response mechanisms are important to this work.
Chapter 2 therefore presents a review of the immune system and discusses relevant details of the T-cell and
B-cell immune response mechanisms. The function of the immune system as well as its components are
discussed.
Having the knowledge of immune response mechanisms, we may consider the question of how to use
computers and information techniques to help to understand the role of the immune system in infectious
diseases, autoimmune diseases and cancers. Therefore, in the following chapters, such techniques are pro-
posed, investigated, or compared. Two topic problems are proposed: one is to investigate the correlation
between regions of immunological significance and regions of low host-similarity; the other is to explore
the statistical significance of locality clustering of the overlapping occurrences within the viral proteome.
In Chapter 3, we introduce the idea of “peptide universe” and its role in immunoinformatics study. The
chapter goes on to present how the peptide universes for various species are generated, including detail
about the data structures and algorithms involved. Finally, the chapter discusses how the overlaps between
proteomes of pathogen and host is determined. These overlaps include unique ones as well as occurrences
involving duplicates.
Unfortunately, the protein sequences in protein databases are not perfect. Sometimes there are ambigui-
ties as to which amino acid occurs at a particular position. Presence of ambiguities can affect the results of
comparisons of self, non-pathogenic non-self and pathogenic non-self peptide universes. In Chapter 4, three
types of filtering strategies for dealing with such ambiguities are introduced and compared based on time
efficiency at the 9-mer level. For each strategy, advantages and disadvantages as well as potential problems
are discussed. The strategy of removing only generated k-mers which contain ambiguous amino acids (B,
X or Z) is used in subsequent stages of our work.
Within the sequences of antigens, there exist regions of peptide fragments which elicit immune re-
sponses. These regions are known as “immunodominants” and are important in immunological work. In
chapter 5, the question of whether known regions of immunological significance (e.g. epitopes, agretopes) in
pathogenic proteomes come from regions of low host-similarity is explored. If the answer is “yes”, it means
that the levels of peptide overlap may be used to predict possible regions of immunological significance.
The known regions of epitopes are compared with the regions of low host-similarity (i.e., non-overlaps) be-
tween HIV-1 and human proteomes at the 7-mer level. Results show that the correlation between these two
regions is not statistically significant. In addition, pairs of organisms involving human and human viruses
are explored. For these pairs, one graph for each k-mer level is generated showing the actual numbers of
matches between organisms versus the expected numbers. At random, one would expect an approximate
linear relationship between the size of the viral proteome (m) and the number of viral k-mers including
repeats occurring in the human proteome providing thatm 20k. From graphs for 5-mer and 6-mer level,
we can see that the number of overlapping occurrences increases as the size of the viral proteome increases.
Such an observation motivates further bench and computational investigation.
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In chapter 6, a detailed investigation of the overlaps/non-overlaps between viral proteome and human
proteome reveals that the distribution of the locations of these overlaps/non-overlaps has “structure”. Here
“structure” refers to locality clustering. Thus, another question that is investigated is whether the locality
clustering is statistically significant. A chi-square analysis is used to analyze the locality clustering. Results
show that there exists structure for HIV-1, HIV-2 and Influenza A virus at the 5-mer, 6-mer and 7-mer
levels. Also, for self-similarity of human protein Desmoglein 3 to the remaining human proteome, it shows
that there is structure at the 7-mer level.
Extended research and future work are discussed in chapter 7. For instance, the degrees of overlap
between the generated peptide universes could be used as for building phylogenetic trees especially relevant
to the immunological context.
The complete list of all the proteomes and raw data that are used in the research work are listed in
Appendices.
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CHAPTER 2
OVERVIEW OF IMMUNE SYSTEM
This chapter is a general introduction of the immune system. Readers who are familiar with the immune
system may skip this chapter. Those who would like further information are referred to texts by Janeway et
al. [11], Coico et al. [4], or Thomas et al. [12].
2.1 Immune System
The major assignment of an immune system is to defend against infections. The evolution of pathogens
induces strong selection pressure on host immune systems. The most advanced result of this co-evolution
is found in higher vertebrates. Vertebrate immune systems provide rapid, specific, protective immune re-
sponses to infectious bodies without causing damage to the hosts themselves. In addition, these immune
systems can “remember” a pathogen and induce a protective response in the event of subsequent exposure.
Vertebrate immune systems have two branches: innate and adaptive immunity. The former is phyloge-
netically older and exists in a primitive form in all multicellular organisms. The later is about 400 million
years old and is found in cartilaginous and bony fish, amphibians, reptiles, birds and mammals [26]. The
innate immune system distinguishes between self and non-self according to complexes such as carbohydrate
signals [8]. Compared to this relatively non-specific approach, adaptive immunity, which is induced by
lymphocytes, generates a very large repertoire of antigen receptors (either T Cell Antigen Receptor (TCR)
or B Cell Antigen Receptor (BCR)) with the potential to recognize different antigens. Adaptive immunity
can be further divided into two types. One type is called humoral immunity, which is mediated by antibody
molecules secreted by B lymphocytes. The other type is called cellular immunity, which is mediated by
T lymphocytes. An essential difference between these two types of immunity is the means by which they
recognize pathogens.
Adaptive immunity is an acquired and highly specific immunity. Its main characteristic is the use of
antigen-specific receptors on T and B cells to drive targeted, two-stage effector responses. As shown in
Figure 2.1, in the first stage, the antigen is presented to and recognized by the antigen specific T or B cell
leading to cell priming, activation and differentiation. These processes usually occur within the specialized
environment of lymphoid tissue. In the second stage, the effector response takes place, either due to the
activated T cells leaving the lymphoid tissue and going to the disease site, or due to the release of antibodies
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from activated B cells into blood and tissue fluids, and hence to the infective part. The specificity of the
antigen receptors can be predicted from the amino acid sequence. This specificity can be used to select
epitopes in making some vaccines. Portions from antigen molecules with which an antibody or lymphocyte
react are called epitopes. T cells show high antigen specificity, but also a vast receptor diversity. The antigen
specificity in T cells is similar to B cells. Finally, the T cells only recognize antigens that are presented on
other cells in association with MHC molecules, the receptor should be a membrane-bound molecule.
Figure 2.1: The role of T and B lymphocytes in specific immunity. The figure is taken
from Rammensee et al. [22].
All the components of an immune system work together in order to make efficient and effective defenses.
For instance, the innate immunity may instruct the adaptive immunity system regarding that to what com-
ponent it responds [8]. Thus, the decisions of whether and how to defend are influenced by multiple factors
and each of them are controlled by one or more parts of the host immune system.
In addition to defense, another important assignment of vertebrate immune system is tolerance to host
self and homeostasis. Host self consists of all the possible peptides that can be generated from the host
proteome. Even though self-reactive lymphocytes are created constantly, they are removed within the thy-
mus gland so as to prevent auto-immune disease. Homeostasis is the ability or tendency of an organism or a
cell to maintain internal equilibrium by adjusting its physiological processes. The immune system maintains
such an equilibrium state where the number of immune cells is roughly the same as it was before the defense,
although it is continuously being exposed to self antigens and generating responses to a diverse collection
of microbes. To maintain this homeostasis, the repertoire of immune cells is altered in a way that ensures a
protective response to a particular antigen.
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2.2 MHC Class I and MHC Class II Antigen Processing and Presen-
tation Pathways
As shown in Figure 2.2, there are two main pathways to process and present antigens to lymphocytes.
The MHC class I pathway, or the endogenous pathway, stimulates cell-mediated immunity. In order to
present endogenous antigens to CD8+ T cells, a precursor peptide must be generated by some proteasome.
This peptide may be trimmed at the N-terminal by other peptidases in the cytosol [24]. It must then bind
to a transporter molecule called “transporter associated with antigen processing (TAP)” in order to be trans-
located to the endoplasmic reticulum (ER). Here its N-terminal can be trimmed by the amino-peptidase
associated with antigen processing. Then it binds to an MHC I molecule and the complex is transported to
the cell surface [25]. Once there, this complex is recognized by MHC class I restricted CD8+ cytotoxic T
cells which in turn are activated, amplified and attack cells containing the antigen. This allows for a cell-
mediated immune response to “see” foreign proteins within all nucleated cells. In this way, cells infected
with a virus may be detected and destroyed. Selectivity is exercised at all of the previous steps. For instance,
only about half of the peptides that are presented on the cell surface by MHC molecules are recognized
by TCRs. The most selective step is binding to the MHC I molecule, wherein only 0.5% of the total 20k
peptides bind with an affinity strong enough to generate an immune response [29]. Therefore, in order for a
peptide to be immunogenic (immunological significant), it must be “special” as compared to other peptides
produced in a given cell.
The presentation on Class II MHC molecules follows a different pathway [2]. It is also called the
antibody pathway or the exogenous pathway. This pathway processes exogenous antigens that are taken up
by cells and presented in such a way as to stimulate helper T cells, which then stimulate B lymphocytes and
antibody production (the humoral pathway). Precursor MHC class II molecules accumulate in endosomal
compartments in the Golgi complex. Here one chain of the molecules is degraded, leaving the MHC-II
molecules free to bind peptides derived from endocytosed antigens. The peptide class II complexes are
subsequently transported to the cell surface for presentation to CD4+ T cells. CD4+ activation leads to
production of cytokines which in turn activate a wide range of cells around them. The reaction therefore
needs to be kept in check, which is achieved by only a small number of class II antigen-presenting cells
being able to drive the response. MHC-II molecules are much like antibodies in that they bind to antigens.
The exogenous pathway is well-suited for detecting bacterial infections, which are primarily extracellular.
Viral infections are primarily intra-cellular and more easily detected by the MHC I pathway.
2.3 Length of Peptides Recognized by Lymphocytes
Both MHC I and MHC II are highly polymorphic. They have different conformational shapes and
binding preferences. The typical length of peptides presented to CD8+ T cells by MHC class I molecules
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Figure 2.2: I. Presentation of antigens to the immune system. The MHC class I system
mediates presentation of endogenous or intra-cellularly-produced proteins. The MHC class
II system mediates presentation of exogenous or externally-produced antigens. The MHC I
pathway is used predominantly for immune presentation of endogenously synthesized pro-
teins. Intra-cellular or endogenously produced proteins (1) are broken down into peptides
(8 to 13 amino acids long) by spliceosomes and then directed into the endoplasmic retic-
ulum (ER) through transport associated protein (TAP) molecules (2). Once in the ER, the
peptide antigens bind to activated MHC class I molecules (3), which subsequently trans-
port the complexes through the Golgi complex toward the cell surface (4). This pathway
generates an immune response biased toward cell-mediated/cytotoxic CD8+ lymphocyte
activation. II. Following endocytosis, the MHC II pathway presents peptide antigens which
originated outside of the cell. Extracellular or exogenous antigens are taken up into spe-
cialized antigen presenting cells (APCs) by endocytosis (5). The antigen is degraded in a
lysosome (6) into immunogenic peptides which bind to MHC class II molecules (7). To
produce an antibody biased immune response, the MHC class II-peptide antigen complex
is transported to the cell surface (8) where it binds to CD4+ helper T cells. The figure is
taken from Rammensee et al. [22].
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is 9 residues; the peptides presented to CD4+ T cells by MHC class II molecules tend to be longer, with a
typical length of 12 - 20 residues. For class I MHC molecules, at least two of the nine residues are known
as “anchor residues” and have decisive effects in the binding process. Once the peptides have bound to the
corresponding positions in the groove of the MHC class I molecules, the peptide-MHC complex will be
transported to the surface of the cell and presented to CD8+ T cells. The T cells then recognize the peptide-
MHC complex and initiate cell destruction. Each MHC class I molecule is able to bind various peptides,
but will bind certain peptides with greater affinity. The binding mechanisms of MHC class II molecules are
similar to those of MHC class I molecules, but with longer peptides and the fragments are normally derived
from endocytosed antigens.
The B cell receptors recognize antigen differently than T cell receptors. The antibody recognizes the
conformational structure (shape) of epitopes, and such antigens do not require processing. The typical
length of peptides presented to B cells is 5 - 6 residues.
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CHAPTER 3
PEPTIDE UNIVERSES AND CORRESPONDING OVERLAPS
This chapter describes the data which is used in the study, as well as the methodology by which it is
derived. The generation of a peptide universe is presented in Section 3.1. Overlap data, which is the set of
k-mers that occur in two proteomes, is described in Section 3.2 and its derivation is discussed in Section 3.3.
In Section 3.4, the research goals to be answered using the above data are stated.
3.1 Peptide Universe Generation
The various immunological pathways operate on peptide fragments of different lengths. For example,
MHC I molecules bind peptides ranging from 8 to 13 amino acids long, with preference for those of length
9. On the other hand, 5 - 6 amino acids are the minimum requisite to induce an antibody response in B cells.
To study the peptides that are involved in one of these pathways, it is necessary to derive the sets of peptides
of specific lengths. A peptide universe is the set of all possible unique peptide fragments of a specific length
k derived from an organism’s proteome. Each proteome of an organism will have multiple peptide universes,
one for each length k.
All the steps in generating a peptide universe are shown in Figure 3.1. A “FASTA” file (i.e., a file
whose name ends in “.FASTA”) contains the protein sequences of an organism. From it, a list of k-mers is
generated for every protein (of length n) by choosing each position (except the last n − 1) in the sequence
as the starting point. The resulting set of k-mers is stored in an “nmerext” file (name ends in “.nmerext”),
which contains all the k-mers that occurred at consecutive locations in all sequences. Specific k-mers may
occur multiple times, and such repeated k-mers are included in the “nmerext” file. Based on the latter
file, an “intraseq repeats” file (name ends in “.intraseq repeats”) and an “interseq repeats” file (name ends
in “.interseq repeats”) are produced. These files contain all the k-mers that are repeated within a protein
sequence, and all the k-mers that are repeated in two or more protein sequences, respectively. Combining
the above two sets of k-mers yields an “all repeats” file (name ends in “.all repeats”), which contains all
k-mers that are repeated in the k-mer universe of an organism, as either an inter-sequence or intra-sequence
repeats. Finally, by including a unique instance of all k-mers from the “nmerext” file, a “library” file (name
ends in “.library”) is generated. This “library” file defines the peptide universe (for a given k) of a given
species in our study. The “library” file contains all the unique k-mers in the proteome of an organism.
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3.2 Overlaps Between Two Proteomes
After the peptide universe for each organism is obtained, the overlaps and non-overlaps between two
proteomes can be determined. The flow chart in Figure 3.2 shows the process in detail. The method is to use
the “library” file of one species (a list of all k-mers in its peptide universe) to scan through the proteome of
the other species (stored in a “FASTA” file) looking for k-mers which occur in both. These k-mers are called
overlaps or matches. Here the species whose “library” file is used is known as “BUG” and the species whose
“FASTA” file is used is known as “HOST”. For each k-mer in the peptide universe of “BUG”, an indication
of whether that k-mer is present in the proteome of “HOST” is recorded in a “BUG vrs HOST.peptsrch”
file (i.e., a file whose name ends with “.peptsrch”). Each time the peptide is found in “HOST”, the protein
in which the instance is found and the position of the occurrence in that protein are recorded. Here exact
matches are sought, not “similar” or “approximate” ones as might be done with sequence alignment. Based
on the search for peptides, the overlap/intersection between “HOST” and “BUG” is produced and all the k-
mers that occurred in both organisms are included in a “BUG inters HOST” file (name follows the pattern
“BUG inters HOST”). On the other hand, those k-mers that exist in the peptide universe of “BUG” but do
not occur in the proteome of “HOST” are included in a “BUG diff HOST” file (name follows the pattern
“BUG diff HOST”).
Two different techniques are used to count the number of k-mers in the overlap of both proteomes. One
technique counts the distinct k-mers in the overlap of two proteomes. The other technique counts the number
of k-mers in the overlap (including duplicates) of both proteomes. The first technique only considers distinct
k-mer (from BUG’s peptide universe) occurrences in HOST’s proteome. That is, only one occurrence of
a k-mer is counted even if it appears several times in HOST’s proteome file. Alternatively, the number of
k-mers in the overlap (including duplicates) of both proteomes can be counted. For example, if a k-mer
from BUG’s peptide universe occurred 5 times in HOST’s proteome, the number of occurrences will be 5.
The first technique may cause some problems. For instance, if a k-mer appears 100 times, which means
it is very important and has quite high frequency, it is still counted only once. That is, each k-mer in the
library of one proteome is all treated the same. However, measures of overlaps should capture the situation
when one k-mer appears multiple times. Therefore, the repeating of a k-mer is considered in the second
technique. However, the second technique does not reflect the frequency distribution for each k-mer from
BUG’s peptide universe, only the total number of occurrences. For instance, a certain k-mer may appear
100 times either only in one protein of HOST or randomly distributed through the HOST’s proteome. Thus
both methods of counting overlaps have shortcomings.
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 Figure 3.1: Data flow chart of peptide universe generation for a given species.
 
Figure 3.2: Data flow chart for the generation of overlaps and non-overlaps between two
proteomes, i.e. those for organisms “HOST” and “BUG”.
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3.3 Computational and Algorithmic Issues
Since MHC-I molecules bind peptides ranging from 8 - 10 amino acids long and there are 20 different
amino acids, the size of the peptide universes vary from 208 to 2010 (2.56×1010 to 1.024×1013) peptides.
There are 5.12×1011 potential peptides using the 20 standard amino acids which represent the 9-mer peptide
universe. A similar result holds for peptides 5 to 6 amino acids long in the pathway of B cells. There are
3.2×106 to 6.4×107 potential peptides representing the peptide universe when using the standard 20 amino
acids. The longer the length of an k-mer peptide, the larger the size of the corresponding peptide universe.
When dealing with data of large size, time efficiency becomes an issue. When searching a peptide from
BUG’s peptide universe in HOST’s proteome, if a linear search algorithm is used for a given proteome BUG
of length m and proteome HOST of length n, time O(m × n) is required. With such an algorithm, it will
take a fairly long time to generate overlaps between two proteomes with data of large size (i.e., mouse and
human). Therefore, a data structure called a “suffix tree” [6] is employed in order to make the search more
efficient when using the peptide universe of BUG to scan through the proteome of HOST.
In general, any string of length l can be degenerated into l suffixes, and these suffixes can be stored in
a suffix tree. Creating this structure uses time O(l2) and searching for a pattern of length p in it requires
time O(p). For example, consider the suffix tree corresponding to the string “ATCATG”. It generates the
following suffixes: G, TG, ATG, CATG, TCATG and ATCATG. Then the suffix tree in Figure 3.3 is pro-
duced accordingly. Suppose we search for pattern “TG”, it will take two steps to find the node “TG” [6].
Moreover, a more sophisticated algorithm can be used to build the suffix tree in time O(l).
Figure 3.3: An example of suffix tree that are constructed for string “ATCATG”.
In our work, the entire proteome for HOST (length n) is stored in a suffix tree and the implementation
of building the suffix tree uses time O(n). It is built once for each run of the program from the proteome of
HOST and can be used for as many queries as needed. In this case each k-mer in the peptide universe of
BUG is used to search for the same k-mer in the suffix tree. Only k comparisons are needed to determine
whether the k-mer is found or not, which is extremely time efficient. Thus, this suffix tree-based search
algorithm requires O(k × SB), where k is the length of the peptide fragment in query and SB is the size
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of the peptide universe for proteome BUG. That is, after peptide universe of proteome BUG (length m)
is generated, there are SB queries and each query takes O(k) time. Since k is a constant from 5 to 9,
the suffix tree-based search actually requires only a linear time O(SB). These efficient programs were
developed by Chris Lewis of the Bioinformatics Research Lab at the University of Saskatchewan (for details
see http://homepage.usask.ca/∼ctl271/857/suffix tree.shtml).
3.4 Discussion
Size of overlaps between a host’s (usually human) and a pathogen’s 9-mer peptide universe varies from
0.1% - 0.2% with most pathogens, compared to the size of the peptide universe of the human proteome.
While size of overlaps between hosts (e.g. human and mouse), as well as between different bacterial species
is much higher, ranging from 30% - 40% [3]. These results are consistent with the idea that the overlap
between a host’s and pathogen’s peptide universe tends to be small, whereas overlap between peptide uni-
verses of mammalian species or similar pathogens tends to be much larger due to the ability of immune
system to descriminate self from nonself proteins. Overlaps of peptides from different organisms can have
important immunological consequences [3]. If a foreign peptide is also a self peptide, either the overall
T-cell pathway is tolerant to it or any T cell responses to it may lead to an autoimmune response. By de-
termining a host’s self universe and incorporating an epitope prediction model, we may form the basis of a
rapid, inexpensive and computationally driven system for the individuation of antigenic sequences that are
the targets of autoimmune responses [16]. Consequently, this proteomic strategy may serve as a general
method suitable to define/distinguish/screen disease-relevant or disease-irrelevant epitopes within potential
antigens [15]. Therefore, the level of potentially cross-reactive k-mers between pathogen and host is worth
investigating.
The k-mer peptides in the overlap between different pathogens are potentially cross-protective antigens.
If an immune response is generated in the host to an k-mer of one pathogen, the host will generate a sec-
ondary immune response against the identical k-mer from another pathogen. Comparing the overlap of
k-mers between different pathogens demonstrates the level of potential cross-protective antigens and is also
valuable to investigate.
The peptides in the overlap between host and pathogen peptide universes are not useful as vaccine
candidates since (1) immune responses are difficult to generate for these epitopes due to deletion of specific
T cells and (2) if immune responses are generated to these epitopes, self-reactive cells will be generated
leading to autoimmunity. However, the information is still useful for vaccine design because it indicates
peptides which should be avoided as vaccine candidates.
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CHAPTER 4
COMPARISON OF DIFFERENT FILTERING STRATEGIES
The protein sequences in protein databases are not perfect. Sometimes there are ambiguities during
sequencing as to which amino acid occurs at a particular position. These ambiguities are coded by char-
acters similar to those used to code unambiguous amino acids. Three types of ambiguous amino acids are
considered in the literature and the characters used to code them are listed in Table 4.1.
Table 4.1: Ambiguous amino acids and their corresponding representational characters
Character Ambiguous Amino Acids
B Asparagine or Aspartic acid
Z Glutamine or Glutamic acid
X Unknown Amino Acid
Presence of ambiguities can adversely affect the results of the comparisons of self, non-pathogenic
non-self and pathogenic non-self peptide universes. An ambiguity is considered as a unique symbol when
comparing k-mers; i.e. two k-mers containing ambiguities are considered to match if all symbols are the
same in all positions, including any instances of B, X, or Z. For instance, “CLXMHBZKC” and “CLXMH-
BZKC” are considered as match while ’X’, ’B’ and ’Z’ in these two 9-mers could represent different amino
acids. For ’B’ and ’Z’, there is a 50% probability that this match is correct while for ’X’, there is only a 5%
possibility that this match is correct. Thus, the ambiguities need to be filtered from proteome information
used to determine peptide universes or proteome overlap. Three types of filtering strategy are used in this
work to process all the k-mers of a given proteome. Comparison of these three filtering methodologies are
only done for 9-mers, and the results are expected to be similar when we extend to other values of k.
4.1 Three Filtering Strategies
Within the overall goal of characterizing self versus non-self peptides, we need to address the presence
of ambiguous amino acids in the sequence data. The focus here is to compare the merits of three possible
methods to deal with the ambiguity. Three filtering strategies are examined in the research work as follows:
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◦ The first is to include all proteins, irrespective of whether they contain ambiguous amino acids (B, X
or Z). Note that this would be considered ignoring the ambiguities.
◦ The second is to remove any proteins that contain any ambiguous amino acids (B, X or Z) [3]. Note
that no k-mers would be generated from such a protein during the analysis.
◦ The third is to remove only generated k-mers which contain ambiguous amino acids (B, X or Z).
Figure 4.1: Data flow chart of three filtering strategies in the generation of peptide uni-
verses for a given species. Method 1 does not perform any filtering; Method 2 includes
a protein filter to remove any proteins that contain ambiguous amino acids; Method 3 in-
cludes an k-mer filter to remove generated k-mers which contain ambiguous amino acids.
As shown in Figure 4.1, the first approach does not use any filtering. In the second approach, a protein
filter is added before the generation of the peptide universe. That is, given a “FASTA” file, a “filtered
FASTA” file (i.e., a file whose name ends in “ FILTERED.FASTA”) containing all the protein sequences
without any ambiguities is generated and then used as the input file to produce the peptide universe. In the
third approach, a k-mer filter is added after the generation of all the k-mers of a given proteome. That is,
after generating all the k-mers, we remove the k-mers which contain ambiguous amino acids.
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The first approach which does not do any filtering causes errors of mismatch as well as errors of missing
information. For example, suppose one peptide from BUG is “CLXMHNLKC” and two peptides from
HOST are “CLXMHNLKC” and “CLAMHNLKC”. As we know, “X” is considered as unknown amino
acid and thus it can actually represent any one of the 20 standard amino acids. However, in the first method,
“X” has become the 21st standard amino acid. Therefore, “CLXMHNLKC” and “CLXMHNLKC” will be
considered to match while “CLXMHNLKC” and “CLAMHNLKC” will not. In fact, “CLXMHNLKC” and
“CLXMHNLKC” should not match if first “X” and second “X” refer to different amino acids. Alternatively,
“CLXMHNLKC” and “CLAMHNLKC” should match if “X” refers to “A”. Matching “CLXMHNLKC”
and “CLXMHNLKC” when one should not is considered an error of mismatch (or false positive) while
not matching “CLXMHNLKC” with “CLAMHNLKC” when “X” is “A” is considered an error of missing
information (or false negative). In the worst case, if we have “XXXXXXXXX” appearing in either the
BUG or HOST proteome, only “XXXXXXXXX” is considered to match and the actual count of overlaps
between BUG and HOST is inaccurate. However, this strategy does not require any computational resources
to perform filtering.
The second approach is to remove any proteins that contain any ambiguous amino acids. Thus no k-
mers are generated from such a protein during the analysis and no erroneous matches would be reported
(e.g. the case ”CLXMHNLKC” and ”CLXMHNLKC” above). However, this filtering method causes errors
of missing information. For organisms whose proteome consists of a single polyprotein, if the polyprotein
contains even one ambiguous amino acid, the entire proteome is discarded. For organisms that have a limited
number of proteins, removing proteins that contain ambiguities has a significant effect on any sequence-
based analysis. In addition, this filtering method requires the cost of additional computational resources to
do the filtering work though it takes less time to generate the overlaps.
The third approach is to remove generated k-mers with ambiguous amino acids. Intuitively, this elim-
inates errors of mismatch while retaining as much of the organism’s proteome as possible. However, this
filtering method also causes errors of missing information. In addition, it also requires the cost of additional
computational resources to perform the filtering.
Now comes the question: which of the three approaches is the most desirable? On one hand, ambiguous
amino acids should not be given biological meaning in the analysis. They can only make results more
unpredictable and less accurate. In addition, since all the three filtering methods cause errors, the one with
the least errors is more appropriate for our subsequent work. On the other hand, we may not want to
spend significant computational resources on the filtering process. A decision on which strategy is more
appropriate is therefore also dependent on the added computational resources necessary in each case. When
determining which one is more appropriate, we consider the method with less errors first, and then check
whether or not the additional computational cost is acceptable. The comparison of time efficiency among
the three methods is given in Section 4.2.
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During the comparison of the errors among the three filtering methods, we consider the errors of mis-
match as false positives (FP) and the errors of missing information as false negatives (FN). First, both method
2 and method 3 don’t have errors of mismatch, but method 2 has more errors of missing information than
method 3. Therefore, method 3 is more appropriate than method 2. Then, comparing method 3 with method
1 reveals that method 1 has errors of mismatch while method 3 does not. Also, both methods have errors of
missing information. SupposemH is the number of k-mers in HOST,m∗H is the number of k-mers in HOST
after filtering ambiguities, mB is the number of k-mers in BUG and m∗B is the number of k-mers in BUG
after filtering ambiguities. Let Z be the total number of matches (including multiplicities) of matches in the
filtered case. Then Zm∗Hm∗B estimates the proportion of true matches between HOST and BUG proteomes.
There are (mH −m∗H)(mB −m∗B) potential matches left out. It is assumed that the proportion of potential
matches has the same probability as the proportion of true matches. The number of missing matches is
(mH −m∗H)(mB −m∗B) × Zm∗Hm∗B and the total number of true matches is mHmB ×
Z
m∗Hm
∗
B
. Dividing
the number of missing matches by the total number of true matches gives (1− m∗HmH )(1−
m∗B
mB
), which is the
probability of errors of missing information in method 3. In method 1, the probability of errors of missing
information is the probability (P (ambiguity|match)) of a k-mer with ambiguities given that this k-mer
from BUG’s proteome is a true match in the HOST’s proteome. Then we have P (ambiguity|match) =
1 − P (no ambiguity|match). It is assumed that the event of being a match between BUG and HOST
as well as the event of k-mer containing ambiguity are independent. We also assume that the event of a
k-mer from BUG’s proteome containing an ambiguity and the event of a k-mer from HOST’s proteome
containing an ambiguity are independent. Therefore, P (ambiguity|match) = 1 − P (no ambiguity) =
1−P (no ambiguity in HOST )P (no ambiguity in BUG) = 1− m∗HmH ×
m∗B
mB
. Subtracting the probability
of errors of missing information in method 1 from method 3 gives
m∗H(m
∗
B −mB) +m∗B(m∗H −mH)
mHmB
.
The result is negative and therefore method 1 has a higher probability of errors of missing information than
method 3. Moreover, method 1 has errors of mismatch while method 3 does not. In conclusion, method 3 is
the most appropriate filtering strategy among the three when considering the probability of errors.
In addition, ambiguities typically constitute a relatively small portion of a proteome. For instance, the
percentage of ambiguous amino acids (including B, X, and Z) in Homo sapiens is only 0.01%. Other organ-
isms contain fairly small numbers of ambiguities as well. Such information can be found at http://www.ebi.ac.
uk/integr8 by examining the amino acid composition of a specific organism. What’s more, although the sec-
ond and third approaches result in information loss, this loss may have little affect on relative values since
both HOST and BUG proteomes lose information.
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4.2 Comparison of Three Strategies
4.2.1 Materials
A number of proteomes of model organisms were downloaded from the EBI website. All the bacte-
rial and eukaryotic proteomes were from http://www.ebi.ac.uk/proteome, while viral proteomes were from
http://www.ebi.ac.uk/genomes/virus.html. Among all these proteomes, only those which contain ambigu-
ous amino acids were selected for the study, altogether 13 of them (see Appendix A). Based on the types of
ambiguous amino acids they have, they were divided into three groups (their Taxonomic ID is stated in the
parentheses):
◦ Group 1, proteomes that contain ‘X’:
Salmonella typhi (601), Arabidopsis thaliana (3702), Caenorhabditis elegans (6239), Rattus norvegi-
cus (10116), Plasmodium falciparum (36329), Thermoplasma volcanium (50339), Helicobacter py-
lori (85962), Chlamydia pneumoniae (115711), Bacillus subtilis (224308).
◦ Group 2, proteomes that contain ‘B’ and ‘X’:
Drosophila melanogaster (7227), Vibrio cholerae (243277)
◦ Group 3, proteomes that contain ‘B’, ‘X’, and ‘Z’:
Homo sapiens (9606), Mus musculus (10090)
4.2.2 Methodology
As we know, time efficiency can be significant when dealing with large amounts of data. The proteome
files of these 13 model organisms are fairly large ones. Therefore, time efficiency is an important factor in
the comparison of the three filtering strategies. To get the total run time (CPU time), T (A,B), which is used
when processing data, we need to record and then add times for individual processing steps. In Equation
4.1, TA is the time to generate A’s library; TB is the time to generate B’s library; TAB is the time to use A’s
library to scan through B’s proteome file and then remove the duplicates as well as determine the size of the
overlapping file; TBA is the time to use B’s library to scan through A’s proteome file and then remove the
duplicates as well as determine the size of the overlapping file.
T (A,B) = TA + TB + TAB + TBA (4.1)
The total time to complete a task involves many factors such as disk and memory accesses, I/O activities,
OS overheads, etc. Therefore, we need to record the time that the processor (CPU) is working only on our
programs since multiple processes are running at the same time. T (A,B) is calculated in terms of both “user
CPU time” (in user’s program) and “system CPU time” (in OS), i.e., the total number of CPU-seconds that
the process spent in user mode and system mode respectively. Overhead time for operations such as creating
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processes are negligible according to some preliminary experiments. Since the programs are data-intensive
and the time for reading and writing data may be significant, system CPU time should be included in the
calculation of total time. To lessen the effects of possible timing anomalies, T (A,B) is recorded 10 times
and the arithmetic mean is used to calculate a final, reported T (A,B). In general, if one method does a
better job of filtering the 9-mers (at the expense of more CPU time) while the increased computational time
is less than 50% as compared to the other method, it is considered to be acceptable.
4.2.3 Result
Three tables, one for each filtering method were compiled. The tables give summary information for
the 13 model organisms (see Appendix B). They include information about Taxonomic ID, organism name,
number of proteins, number of unique 9-mers and number of 9-mer occurrences for each organism.
As described in Section 3.2, two different techniques of counting 9-mers are used. For each technique,
three tables are produced according to each filtering strategy. These tables include information about the
number of 9-mers common to both organisms, the fraction of unique 9-mers for each organism which are
common to both, and the overlap degree between these two organisms. Table 4.2 describes the content of a
typical cell (for a pair of proteomes) of one of the two tables. The complete tables of 13× 13 organisms are
in Appendix C.
Table 4.2: The contents of each portion of a 2×2 unit cell for each pair of proteomes
number of 9-mers which occur in both pro-
teomes
number of 9-mers which occur in both pro-
teomes ÷ number of 9-mers in proteome of
organism in this column
number of 9-mers which occur in both pro-
teomes ÷ number of 9-mers in proteome of
organism in this row
(number of 9-mers which occur in both pro-
teomes)2÷ (number of 9-mers in proteome of
organism in this row × number of 9-mers in
proteome of organism in this column)
One pair of proteomes from each group of proteome files are randomly selected to compare the three
strategies. The pairs are: from Group 1, Helicobacter pylori (85962) and Chlamydia pneumoniae (115711);
from Group 2, Drosophila melanogaster (7227) and Vibrio cholerae (243277); from Group 3, Homo sapiens
(9606) and Mus musculus (10090). The resultant measures including user CPU time, system CPU time and
total time are listed in Appendix D.
In Table 4.3, for each pair of proteomes, Method 2 increased the total time by 4.31%, 0.14%, and 0.31%
when compared to Method 1. For each pair of proteomes, Method 3 increased the total time by 40.88%,
27.12%, 27.79% separately compared to Method 1. Since Method 2 perturbs the data most, it will not be
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used. According to the threshold (i.e., 50%) that we stated in Section 4.2.2, the comparison of timings for
Method 1 and Method 3 leads to the conclusion that it takes a reasonable amount of time to do filtering of
k-mers containing ambiguities..
Table 4.3: T (A,B) is the total time that is used to process data and count overlaps between
two proteomes for all three methods. Both user CPU time and system CPU time are in-
cluded. Pair 1 is Helicobacter pylori (85962) and Chlamydia pneumoniae (115711). Pair 2
is Drosophila melanogaster (7227) and Vibrio cholerae (243277). Pair 3 is Homo sapiens
(9606) andMus musculus (10090).
Proteomes Time T (A,B) (seconds)
Method 1 Method 2 Method 3
85962, 115711 14.624 15.255 20.603
7227, 243277 292.263 296.412 371.535
9606, 10090 835.921 838.517 1068.244
After comparing the probability of errors among the three filtering methods, we can conclude that
method 3 causes the least errors. However, method 3 costs additional computational time to do the filtering
because of the manner in which it is implemented. Filtering of k-mers can also be implemented during
the overlap determination, rather than as a separate filtration step, with a much lower implementation cost.
Implementation via a separate filtration step is used here because the set of k-mers is necessary for statistical
analysis. By examining the time efficiency of the three filtering strategies, we can determine whether the
filtering is worth the cost and which filtering strategy is more appropriate for each pair of organisms. Table
4.3 shows that the computational cost of the third strategy is within our set threshold compared to method 1.
Therefore, the third filtering strategy is used in further stages of the research work.
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CHAPTER 5
IMMUNOGENECITY VERSUS SELF(HOST) SIMILARITY
5.1 Proteomic Similarity Analysis
In the last decade, many algorithms have been developed to make use of the linear representation of
protein sequence information and search for epitopic motifs [5, 14, 17, 23]. These algorithms search the
amino acid sequence of a given protein for characteristics that are believed to be common to antigenic
peptides, locating regions that potentially induce cellular immune responses. We are using bioinformatics
technology platforms to identify epitopic peptide fragment(s) from disease-associated antigens by follow-
ing the hypothesis that peptide epitopicity might be regulated by the peptide similarity level to the host’s
proteome [18, 21, 27]. In order to identify epitopic peptide sequence(s) from disease-associated antigens, it
is necessary to consider their similarity to the host’s proteome [19, 20, 28]. In Chapter 3, the approximate
similarity level between host and pathogen, as well as between different pathogens, is calculated. Over-
lap between host (usually human) and a pathogen’s 9-mer peptides varies from 0.1% - 0.2% of the host’s
proteome for most bacteria. Overlap between hosts (e.g. human and mouse), as well as between different
pathogens, is much higher, ranging from 30% - 40% [3]. Based on this previous work, we are also able to
identify regions of low or high self-similarity, host-pathogen similarity, or inter-species similarity (host-host
and pathogen-pathogen). In order to determine these regions, expected numbers of matches between two
organisms need to be calculated and then compared with the actual numbers of matches between them. If
the actual number of matches is lower than expected, such a region is considered to be of low similarity;
otherwise, the region is of high similarity. On the other hand, within the sequences of antigens, there exist
regions of high concentration of agretopes, which are recognized by MHC molecules, as well as regions to
which antibodies or lymphocytes react. These are known as regions of immunological significance. The
theme that is investigated here is whether known regions of immunological significance (e.g. epitopes, agre-
topes, etc.) come from regions of low host-similarity. If the answer is “yes”, it would mean that we are
able to use the peptide similarity level to a host’s proteome to predict possible regions of immunological
significance. The predicted information could therefore be used in vaccine development or development of
therapies [3, 18, 21].
Further, pairs of organisms involving human and human viruses are explored. For these pairs, one
graph for each k-mer level is generated showing the actual numbers of matches between organisms versus
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the expected numbers. At random, one would expect an approximate linear relationship between size of
the viral proteome and the number of viral k-mers including repeats occurring in the human proteome. If
there are consistently more k-mer occurrences including duplicates in the overlap than what would expect
“at random”, this means that there is some form of evolutionary pressure applicable to all human viruses
which is generating this phenomenon. Such an observation motivates further bench and computational
investigation.
5.2 Methodology and Materials
5.2.1 Expected Number of Matches
In order to examine the significance of the level of overlap between two organisms, we need to deter-
mine the number of peptides appearing in both organisms under the assumption of random sampling. As
a first approximation, we consider the peptides of a given length in a proteome as a random sample (with
replacement) from the population of all possible peptides of that length. For k-mers, since each monomer
can be any of 20 amino acids, the population size N = 20k (N = 209 = 5.12×1011 when k = 9). If
two samples of size m and n taken randomly with replacement from the set of N objects, the asymptotic
behavior is studied when m, n and N all go to infinity, providing that N is much larger than m or n. For
each possible object i = 1, ..., N , letXi be the number of times the object is selected in the first sample, and
similarly, let Yi be the number of times the object is selected in the second sample. Then, E(Xi) = m/N ,
E(Yi) = n/N , and since Xi and Yi are assumed to be independent,
E(XiYi) = mn/N2.
As mentioned in Section 3.2, two different techniques of counting the overlaps between two organisms
are used. Thus, it is also interesting to study the number of distinct, common objects obtained from samples
of size m and n. In particular, if A and B are the sets of distinct objects, respectively, then the random
variable of interest is the cardinality of intersection between A and B. Call this random variable Z∗. For
each possible object i = 1, ..., N , let X∗i be the indicator of the event that object i was selected (at least
once) in the first sample
X∗i = 1i∈A
and similarly,
Y ∗i = 1i∈B .
Then we can write
Z∗ =
N∑
i=1
X∗i Y
∗
i .
Now, object i has m chances of being included in A, and the selections are independent. Thus, E(X∗i ) =
Pr {i ∈ A} and similarly,E(Y ∗i ) = Pr {i ∈ B}. Under the assumption thatX∗i ’s and Y ∗i ’s are independent,
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we can write
E(X∗i Y
∗
i ) = Pr {i ∈ A ∩B} = Pr {i ∈ A} × Pr {i ∈ B}.
The expected number of objects in the overlap is then given by
E(Z∗) =
N∑
i=1
E(X∗i )E(Y
∗
i ). (5.1)
If m is much smaller than N , then E(X∗i ) ≈ E(Xi) since the probability that Xi > 1 is negligible.
More precisely and in general, object i has m independent chances of being excluded from A, each with
probability 1− 1N , giving a probability of (1− 1N )m that it does not occur in the selections. Thus,
E(X∗i ) = 1− (1−
1
N
)m
=
m∑
j=1
(−1)j−1
(
m
j
)
N−j
=
m
N
 m∑
j=1
(−1)j−1N−j+1 (m− 1)!
j!(m− j)!

= E(Xi)
m−1∑
j=0
(−1)jN−j
j∏
k=1
m− k
1 + k
 .
(5.2)
For largem and N ,
E(X∗i ) = 1− (1−m/(Nm))m
≈ 1− lim
m→inf
(1− (m/N)/m)m
= 1− exp−m/N
That is, E(X∗i ) can be well approximated by 1− exp(−E(Xi)). If n is also large, then
E(Z∗) ≈ N(1− exp−m/N − exp−n/N − exp−(m+n)/N ).
Ifm is small but n is large, then E(Z∗) can be approximated bym(1− exp−n/N ).
The error in truncating the alternating series in Equation 5.2 is bounded by the first omitted term. Trun-
cating after the first and second terms thus gives
E(Xi)
(
1− m− 1
2N
)
≤ E(X∗i ) ≤ E(Xi)
(
1− m− 1
2N
+
(m− 1)(m− 2)
6N2
)
.
Ifm is large, we can just as well replace the lower bound by E(Xi)(1− E(Xi)/2).
If m is appreciably smaller than N , a remarkably good upper bound can be obtained by replacing the
product in Equation 5.2 with ((m−1)/2)j (approximating each term of the product by the first term) yielding
E(X∗i ) ≈
2m
2N +m− 1 ≈ E(Xi)
(
1
1 + E(Xi)/2
)
.
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The above expression is not necessarily an upper bound for small m, but suffices in practical situations.
Thus we have the following boundaries for E(X∗i ):
E(Xi)(1− E(Xi)/2) ≤ E(X∗i ) ≤ E(Xi)(1 + E(Xi)/2)−1 (5.3)
The same arguments will apply to E(Y ∗i ) = Pr {i ∈ B}.
To find the expected number of unique overlaps, deducing from Equation 5.1 and 5.3 gives
mn
N
(
1− m
2N
)(
1− n
2N
)
≤ E(Z∗) ≤ mn
N
(
1 + m2N
) (
1 + n2N
)
providing thatm N and n N . By ignoring terms of O(mn/N2), we get the simpler bounds
mn
N
(
1− m+ n
2N
)
≤ E(Z∗) ≤ mn
N + m+n2
.
Suppose that the total number of occurrences in the second sample (i.e.,“HOST”) of objects occurring at
least once in the first sample (i.e.,“BUG”) needs to be determined. Call this random variable Z. Then, we
get
E(Z) =
∑
i
E(X∗i )E(Yi) ≈
mn
N +m/2
(5.4)
by using the right-hand approximation in Equation 5.3. The number of expected matches between two
organisms is calculated using Equation 5.4 during further stages of the research work. The above method
was contributed by Dr. Mik Bickis in the Department of Mathematics and Statistics [1].
5.2.2 Epitopes
Compared to bacteria, well-studied human viruses contain more complete information of known epitopes
and thus are better candidate proteomes. Therefore, Human immunodeficiency virus 1 (HIV-1) (Taxonomic
ID: 11676) is selected to conduct the similarity analysis. The list of known epitopes which is used in the
analysis contains only CD8+ epitopes. That is, these epitopes are only known to be recognized by MHC-
I molecules. For HIV-1, the summary of known epitopes is downloaded from a database at Los Alamos
National Laboratory (LANL) (http://www.hiv.lanl.gov/content/immunology/tables/tables.html). The list of
all HIV CD8+ epitopes mapped to within a region of 21 amino acids or less is used to identify the regions
of immunological significance.
5.2.3 Host-similarity
As mentioned in Chapter 3, since most viruses have few overlaps with hosts at the 8-mer or 9-mer level
(too few to allow for statistically valid results), overlap at the 7-mer level is explored for the first theme.
Using lengths of 7 amino acids is acceptable since the T-cell immune system is known to also recognize
amino sequences of this length [7, 9]. The overlaps between HIV-1 and human proteome are counted and
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compared with the expected number of matches, then the regions of low host-similarity are determined. For
each position in the viral proteome, if the actual number of matches is less than the expected number of
matches or the actual number of matches is zero, it should be included in the regions of low host-similarity.
Once both regions are identified, a graph is generated to compare the regions of low host-similarity and
regions of immunological significance (i.e., epitopes). The overlap information as well as the number of epi-
topes for each position within the viral proteome is plotted. By graphing the above two sets of information,
a comparison between the regions of low host-similarity and the regions of known epitopes is produced.
Correlation of the two data sets y1 and y2 in the graph, which is used to essentially tell how close the
linearly related two data sets y1 and y2 are, is measured by “correlation coefficient” (r). The coefficient r is
a measure of the strength of the relationship. If two data sets y1 and y2 fell exactly on a line with negative
slope, r = −1. In this case we say that y1 and y2 are “perfectly negatively linear correlated”. If r = 0, we
say that y1 and y2 are “uncorrelated”. In general, r < −0.5 indicates y1 and y2 are approximately negatively
linear correlated. Also, a p-value is used for testing the hypothesis of no correlation. It is the probability of
getting a correlation as large as the observed value by random chance, when the true correlation is zero. If
p-value is small, say less than 0.05, then the correlation r is significant.
5.2.4 Actual Overlaps versus Expected Overlaps
For pairs involving human and human viruses, one graph at each k-mer level (where k = 5,6,7,8,9) is
generated showing the actual numbers of matches between organisms versus the expected numbers. These
results have been determined for 24 human viruses (listed in Appendix E). The length of these viral pro-
teomes varies from 1000 to 7000 amino acids. Expected number of matches including duplicates between
each pair of proteomes is calculated using Equation 5.4. Since the size of the viral proteome m  N in
each case, one would expect an approximate linear relationship between size of the viral proteome and the
number of viral k-mers including repeats occurring in the human proteome. That is, we get E(Z) ≈ mnN
from Equation 5.4 providing m  N . Also, n and N is constant at each k-mer level. Therefore, E(Z) is
expected to be approximately linearly related to m. Again, correlation of the two data sets x and y along
each line in the graph is measured by correlation coefficient (r). If two data sets x and y fell exactly on a
straight line with positive slope, then r = 1; while if they fell exactly on a line with negative slope, r = −1.
In these cases we say that x and y are “perfectly positively linear correlated” or “perfectly negatively linear
correlated”. If r = 0, we say that x and y are “uncorrelated”. In general, r > 0.5 indicates x and y are
approximately linear correlated. Also, a p-value less than 0.05 indicates that the correlation r is significant.
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5.3 Results and Discussion
5.3.1 Proteomic Similarity Analysis
The HIV-1 proteome consists of 3517 occurrences of 3079 unique 7-mers. Using Equation 5.4, the
expected number of overlaps between HIV-1 and human is
E(ZHIV−1) ≈ mn
N +m/2
=
3517× 16171995
1.28× 109 + 35172
≈ 44.
Then, for each 7-mer in HIV-1 proteome, the expected number of overlaps is 44÷3079 = 0.0143. Therefore,
if the actual number of overlaps is zero (< 0.0143) for any position in the HIV-1 proteome, it is considered
to be included in the regions of low host-similarity. The upper graph in Figure 5.1 indicates the overlapping
information between the HIV-1 and human proteomes for each position in the HIV-1 proteome. The lower
graph in Figure 5.1 indicates the known epitopes of HIV-1 for each position in the HIV-1 proteome. By
calculating the correlation coefficient r and the p-value, we have r = −0.0029 (> −0.5) and p-value
is 0.8819 (> 0.05). Therefore, results show that the correlation between regions of low host-similarity
and regions of known epitopes for HIV-1 proteome at the 7-mer level is not statistically significant. One
problem is that there are too many non-overlaps along the sequence of the viral proteome. Thus it is hard
to distinguish between the regions of low host-similarity and the regions of high host-similarity from Figure
5.1. In an attempt to circumvent this problem, the comparison within only one viral protein in HIV-1
proteome is performed. The Gag polyprotein is selected since it contains a relatively large number of
epitopes. In Figure 5.2, both number of epitopes and number of overlaps for each position in the protein Gag
polyprotein are indicated. Again, we have r = −0.0426 (> −0.5) and p-value is 0.3395 (> 0.05). Thus,
results show that the correlation between these two regions is not statistically significant either.
5.3.2 Actual Overlaps Versus Expected Overlaps
One graph at each k-mer level (where k ∈ [5..9]) is generated showing the actual numbers of matches
between organisms versus the expected numbers. In these graphs, the x-axis represents the sizes of the pep-
tide universes of the 24 viral proteomes, while the y-axis represents the count of viral k-mer occurrences
including duplicates in the human proteome. For each viral proteome, overlapping occurrences including re-
peats, number of involved human proteins, unique overlaps and expected overlapping occurrences including
repeats are plotted. According to the model in 5.3.1, one would expect an approximately linear relationship
between the size of the viral proteome and the number of viral k-mers including repeats occurring in the hu-
man proteome. All graphs show that there are consistently more k-mers in the overlap than what we would
expect “at random”. The correlation coefficients r as well as the p-values for each linear regression lines
in each graph are listed in Table 5.1. At the 5-mer level, for data sets of all four measurements in Figure
5.3, the correlation coefficient r ∈ (0.9..1) and the p-value is far less than 0.05. This means that the linear
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Figure 5.1: Two graphs showing counts of matches and counts of epitopes for each 7-mer
in the viral proteome. The x-axis represents the position of each 7-mer in HIV-1 in both
graphs. The y-axis represents the count of viral 7-mer occurrences in the human proteome
in the upper graph and the count of known epitopes in the lower one.
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Figure 5.2: A graph showing counts of matches versus counts of epitopes for each 7-mer
in the HIV-1 Gag polyprotein. The x-axis represents the position of each 7-mer in HIV-1
Gag polyprotein, while the left-hand y-axis represents the count of viral 7-mer occurrences
in the human proteome and the right-hand y-axis represents the count of known epitopes.
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correlation of data sets in each measurement is extremely significant. At the 6-mer level, the correlation
coefficient r ∈ (0.8..1) and the p-value is less than 0.05 for data sets of all four measurements in Figure 5.4.
Thus, the linear correlation of data sets in each measurement is highly significant. At the 7-mer level, the
correlation coefficient r ∈ (0.6..1) and the p-value is less than 0.05 for data sets of all four measurements in
Figure 5.5. Again, the linear correlation of data sets in each measurement is significant. Also, the expected
overlapping occurrences including repeats at each k-mer level is linearly correlated. However, at the 8-mer
and 9-mer levels, the correlation coefficients r of the actual overlapping occurrences including repeats are
all less than 0.5 and the p-values are larger than 0.05. This means that the linear correlations for them are not
significant. Similarly, the linear correlation of data sets in neither the number of involved human proteins
nor the unique overlaps at the 8-mer and 9-mer levels is significant.
In each graph, noteworthy viral proteomes are labeled with their accession number: Hepatitis C virus
(P26663), Infectious hematopoietic necrosis virus (X89213), Crimean-Congo hemorrhagic fever virus (Q52NX4),
Lake Victoria marburgvirus (Z12132), Human coronavirus strain SARS (P59641). These viral proteomes
tend to have higher values than the linear regression lines at each k-mer level.
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Table 5.1: Summary of the correlation coefficients r and p-values for each linear regression
lines in Figure 5.3, Figure 5.4, Figure 5.5, Figure 5.6 and Figure 5.7.
k-mers actual overlapping occurrences including repeats
r p-value
5-mer 0.9288 5.9044E-11
6-mer 0.8002 2.6741E-6
7-mer 0.5719 0.0035
8-mer 0.0906 0.6736
9-mer -0.1138 0.5966
k-mers # of human proteins involved in overlap
r p-value
5-mer 0.9087 8.2576E-10
6-mer 0.8603 7.0204E-8
7-mer 0.6466 0.0006
8-mer 0.1560 0.4665
9-mer 0.0832 0.6991
k-mers actual unique overlaps
r p-value
5-mer 0.9995 1.9302E-34
6-mer 0.9780 1.8366E-16
7-mer 0.8725 2.7423E-8
8-mer 0.2288 0.2822
9-mer -0.1420 0.5081
k-mers expected overlapping occurrences including repeats
r p-value
5-mer 0.9999 7.4658E-61
6-mer 0.9999 4.6644E-62
7-mer 0.9999 4.1053E-41
8-mer 0.9999 6.4987E-70
9-mer 0.9999 4.1854E-49
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Figure 5.3: A graph showing counts of matches between 24 viruses and human at the
5-mer level. Shown are overlapping occurrences, unique overlaps, expected overlapping
occurrences and number of human proteins involved. The x-axis represents the length of
the various viral proteomes, while the y-axis represents the count of viral 5-mer occurrences
in the human proteome or the count of involved human proteins.
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Figure 5.4: A graph showing counts of matches between 24 viruses and human at the
6-mer level. Shown are overlapping occurrences, unique overlaps, expected overlapping
occurrences and number of human proteins involved. The x-axis represents the length of
the various viral proteomes, while the y-axis represents the count of viral 6-mer occurrences
in the human proteome or the count of involved human proteins.
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Figure 5.5: A graph showing counts of matches between 24 viruses and human at the
7-mer level. Shown are overlapping occurrences, unique overlaps, expected overlapping
occurrences and number of human proteins involved. The x-axis represents the length of
the various viral proteomes, while the y-axis represents the count of viral 7-mer occurrences
in the human proteome or the count of involved human proteins.
33
 0
 20
 40
 60
 80
 100
 120
 140
 1000  2000  3000  4000  5000  6000  7000
P5
96
41
 
Z1
21
32
 
Q5
2N
X4
 
X
89
21
3 
P2
66
63
 
co
u
n
t
number of unique 8-mers in viral proteome
viral 8-mer occurrences in human proteome versus viral proteome length
specific proteomes
key:
actual overlapping occurrences including repeats
(linear regression of above)
human proteins involved in overlap
(linear regression of above)
actual unique overlaps
(linear regression of above)
expected overlapping occurrences including repeats
(linear regression of above)
Figure 5.6: A graph showing counts of matches between 24 viruses and human at the
8-mer level. Shown are overlapping occurrences, unique overlaps, expected overlapping
occurrences and number of human proteins involved. The x-axis represents the length of
the various viral proteomes, while the y-axis represents the count of viral 8-mer occurrences
in the human proteome or the count of involved human proteins.
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Figure 5.7: A graph showing counts of matches between 24 viruses and human at the
9-mer level. Shown are overlapping occurrences, unique overlaps, expected overlapping
occurrences and number of human proteins involved. The x-axis represents the length of
the various viral proteomes, while the y-axis represents the count of viral 9-mer occurrences
in the human proteome or the count of involved human proteins.
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CHAPTER 6
LOCALITY CLUSTERING
6.1 Structure In Overlap/Non-overlap Location
A detailed investigation of the overlaps between host and pathogenic species may reveal that the distribu-
tion of the locations of these overlaps within either the pathogenic proteome or host proteome has structure.
Therefore, another question that this thesis pursues is whether the locality clustering is statistically signifi-
cant. Here “structure” could refer to various aspects of overlaps such as locality clustering, tissue clustering,
etc. These regions are distinguished by having a level of overlap which varies significantly from what one
would expect assuming k-mers are distributed at random throughout the proteomes. Regions with signifi-
cantly more or fewer overlaps (i.e. both high and low similarity) are noteworthy. Host-similarity refers to
the overlap between pathogen and host (e.g. human or mouse). One could investigate structure in occur-
rences of low host-similarity, high host-similarity, or both. This work investigates structures in both cases.
Self-similarity refers to repeated patterns in the proteome of a single organism. It is relevant in the study
of autoimmune disease. A chi-square analysis is employed to analyze locality clustering. The chi-square
analysis techniques are described in detail in Section 6.2.2.
6.2 Chi-square Analysis of Structure
6.2.1 Summary of Viral Proteomes and Human Proteome
Host-similarity
Table 6.1 is the summary information of three viral proteomes (HIV-1 (Taxonomic ID:11676), HIV-
2 (Taxonomic ID:11709) and Influenza A virus (Taxonomic ID:93838)) and Homo Sapiens (Taxonomic
ID:9606).
Table 6.2 is the summary of overlaps between each viral proteome (HIV-1, HIV-2 and Influenza A virus)
and human proteome.
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Table 6.1: Summary information of three viral proteomes (HIV-1, HIV-2 and Influenza A
virus) and human proteome at the 5-, 6- and 7-mer level.
Taxonomic ID Name 5-mer
# of proteins # of unique 5-mers # of 5-mer occurrences
9606 Homo sapiens 37991 2388563 16249364
11676 HIV-1 9 3082 3535
11709 HIV-2 9 3285 3723
93838 Influenza A virus 10 4412 4427
Taxonomic ID Name 6-mer
# of proteins # of unique 6-mers # of 6-mer occurrences
9606 Homo sapiens 37991 8247275 16210640
11676 HIV-1 9 3084 3526
11709 HIV-2 9 3283 3714
93838 Influenza A virus 10 4408 4417
Taxonomic ID Name 7-mer
# of proteins # of unique 7-mers # of 7-mer occurrences
9606 Homo sapiens 37991 10431975 16171995
11676 HIV-1 9 3079 3517
11709 HIV-2 9 3278 3705
93838 Influenza A virus 10 4400 4407
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Table 6.2: Summary of overlaps between each viral proteome (HIV-1, HIV-2 and Influenza
A virus) and human proteome at the 5-, 6- and 7-mer level.
Viral Proteome 5-mer
# of unique overlaps # of overlapping occurrences # of human proteins involved
HIV-1 2792 36640 18158
HIV-2 2949 47099 19617
Influenza A virus 4036 46966 20909
Viral Proteome 6-mer
# of unique overlaps # of overlapping occurrences # of human proteins involved
HIV-1 904 2181 1873
HIV-2 1006 4746 2862
Influenza A virus 1191 2754 2404
Viral Proteome 7-mer
# of unique overlaps # of overlapping occurrences # of human proteins involved
HIV-1 96 167 152
HIV-2 121 1350 536
Influenza A virus 96 149 141
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Self-similarity
Table 6.3 is the summary information of human protein desmoglein-3 (Dsg3) and human proteome
without the desmoglein-3 human protein.
Table 6.3: Summary information of human protein desmoglein-3 (Dsg3) and human pro-
teome without the desmoglein-3 human protein at the 5-, 6- and 7-mer level.
Taxonomic ID Name 5-mer
# of proteins # of unique 5-mers # of 5-mer occurrences
9606 (except Dsg3) Homo sapiens 37990 2388524 16248369
Dsg3 Desmoglein-3 1 992 995
Taxonomic ID Name 6-mer
# of proteins # of unique 6-mers # of 6-mer occurrences
9606 (except Dsg3) Homo sapiens 37990 8246693 16209646
Dsg3 Desmoglein-3 1 994 994
Taxonomic ID Name 7-mer
# of proteins # of unique 7-mers # of 7-mer occurrences
9606 (except Dsg3) Homo sapiens 37990 10431100 16171002
Dsg3 Desmoglein-3 1 993 993
Table 6.4 is the summary of overlaps between the human protein desmoglein-3 (Dsg3) and human pro-
teome without the desmoglein-3 human protein.
Table 6.4: Summary of overlaps between the human protein desmoglein-3 (Dsg3) and
human proteome without the desmoglein-3 human protein at the 5-, 6- and 7-mer level.
Viral Proteome Dsg3
# of unique overlaps # of overlapping occurrences # of human proteins involved
5-mer 953 17700 10134
6-mer 412 2550 1494
7-mer 118 468 270
6.2.2 Methodology
Since regions with significantly more or fewer overlaps (i.e. both high and low similarity) are noteworthy
in the chi-square analysis, we need to calculate the expected number of matches for each region and then
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compare it with the corresponding observed number. If the observed number of matches is lower than the
expected number for the region, it is considered as low similarity. Otherwise, higher than expected indicates
high similarity. Given a single, linear sequence, the peptide universes and overlaps between the pair of
proteomes are generated. Then the single long proteomic sequence for each organism is divided into evenly-
sized segments. Each segment should have an expected number of non-overlaps/overlaps of 5 or more.
Therefore, no more than E/5 (where E is the expected number of non-overlaps/overlaps) segments will be
made and they will be merged into bigger segments if necessary. In the case of 5-mers, non-overlapping
5-mers are considered since there exists more overlaps than non-overlaps at the 5-mer level. However, with
6-mers and 7-mers, there are more non-overlapping k-mers than overlapping ones. Therefore, it makes
more sense to look at the distribution of the locations of 6-mers and 7-mers which also occur in human
(i.e., overlaps). Thus in the locality clustering analysis, when we talk about “overlap”, we actually mean
non-overlap in the 5-mer case and overlap in the 6-mer and 7-mer cases.
Suppose a “reasonable” number of overlaps (i.e., at least 10) exist between a pair of organisms. Then a
chi-square test can be used to analyze whether the structure (clustering) in the regions of low or high host-
similarity or self-similarity is statistically significant. Two types of chi-square analysis are used in the work.
One technique is to do the chi-square analysis by dividing the viral proteome into evenly-sized segments.
The other is to do the chi-square analysis by dividing the multi-protein viral proteome into segments of
individual proteins. That is, the segment boundary is the same as the protein boundary.
For the first technique, viral proteome is divided into evenly-sized segments. The expected number of
overlaps per segment is Ei = ((# of overlaps)÷(# of k-mers))×(segment size) for each segment i except for
the last segment may have a longer length and a different expected overlaps. In the 5-mer and 6-mer cases,
viral proteomes are broken up into segments of 100 amino acids. In the 7-mer case, if we break up the viral
proteome in the same way as 5-mer and 6-mer, the expected number of overlaps per segment might be less
than 5 because the number of overlap occurrences and overlapping unique k-mers are significantly lower
for 7-mers than for the 5-mers and 6-mers. The “rule of thumb” is that the expected number per segment
should be at least 5. Therefore, for 7-mers we break up the viral proteome into segments with length of
longer than 100 amino acids: 200 for HIV-1, 150 for HIV-2, 250 for Influenza A virus. In general, we
want the p-value to be small in order to find significance. Having a small p-value could be the following
two cases: the data set is significant, or the χ2 statistic is not approximate. Therefore, there is a trade-off
involved: for statistical significance, one wants lots of segments with small length to make the p-value small
in order to find significance; for precision, one wants fewer, large segments which have a larger expected
number of overlaps to make the χ2 statistic to be approximate. Thus, for HIV-1, we have 3517÷ 200 ≈ 18
segments andEi = (112÷3517)×200 ≈ 6.37 per segment; for HIV-2, we have 3705÷150 ≈ 25 segments
and Ei = (138 ÷ 3705) × 150 ≈ 5.587 per segment; for Influenza A virus, we have 4407 ÷ 250 ≈ 18
segments and Ei = (96 ÷ 4407) × 250 ≈ 5.446 per segment. The null hypothesis is: “the locations of
the observed overlapping k-mers (where k=5,6,7) are distributed at random amongst the segments; i.e., the
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locality clustering to the distribution of the overlapping k-mers is not significant.” Next,
χ2 =
∑
segment i
(Oi − Ei)2
Ei
(6.1)
will be calculated for each segment where Ei is the expected number of matches and Oi is the observed
number of matches. The degrees of freedom for the calculated χ2 value is one less than the number of
segments. In order to use the χ2 value to determine whether or not there is clustering in certain regions,
the calculated chi-square value is compared with the values in a standard chi-square table. If the calculated
value is greater, one can reject the null hypothesis and conclude that the number of overlaps appearing in the
segments is different from random. Further, following conventional criteria, p-values less than 0.05 will be
taken as statistically significant. For a viral proteome, if the locations of overlaps are distributed everywhere
along the proteomic sequence, no clustering is found, or alternatively, we have a large cluster which includes
the whole proteome.
In the above method, we can consider segments right up to the length (m) of the viral proteome (i.e., the
last k-mer starts at positionm− k+1). That is, the expected number of overlaps per segment for each viral
proteome is ((# of overlaps)÷(# of k-mers in viral proteome))×(length of each segment), except for the last
segment which has an expected value of Ei×(proportion of last segment). Then, the chi-square analysis is
performed except that for the last segment in the viral proteome, different value of Ei is used.
The above χ2 analysis is simpler if the proteome of each organism is a single, linear sequence. This is
already the case for viruses which have a polyprotein. However, for other organisms, their (multiple) protein
sequences result in a procedural problem. Some segments in the viral proteome may include one portion
from one viral protein and the other portion from another viral protein. If such a segment is determined to
be statistically significant, it is hard to tell which portion of the segment have clustering, or all portions of
the segment have clustering. To eliminate the problem, protein boundaries could be considered as segment
boundaries when dividing the viral proteome into segments.
A second chi-square analysis technique, in which each individual protein of an organism is analyzed, is
proposed to circumvent the “artificial peptide” problem described above. Instead of dividing the linearized
proteome into equally-spaced segments, one can make the segment boundaries correspond to protein bound-
aries. Some of the proteins in the proteomes of the multi-protein organisms are small and have fewer than
5 expected overlaps. These proteins will not be included in the second type of analysis. Then the first type
of analysis is repeated by using the Equation 6.1. The degrees of freedom are still one less than the number
of segments. The calculated χ2 values are then compared to tabulated values and a conclusion drawn on the
existence of clustering in the locations of low or high host-similarity. Again a p-value of less than 0.05 will
be taken as indicating a statistically significant result. For organisms which have a polyprotein (i.e., human
protein Desmoglein-3), the second technique is unnecessary since there will be only one segment to be an-
alyzed. For organisms with a multiple-protein proteome (i.e., HIV-1, HIV-2, Influenza A virus), the second
type of analysis is performed and the results from the two techniques are compared. There is a short-coming
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of the second technique: for a given organism, some areas of its proteome may be subjected to only the first
type of analysis.
It may occur that structure or clustering occurs preferentially with certain lengths of peptides. For
the vertebrate immune system, the typical length of peptides presented to CD8+ T cells by MHC class I
molecules is nine residues. Peptides of 7 or 8 amino acids are also presented, but not with the same prefer-
ence. However, after investigating the generated overlaps between selected viral proteomes and human, we
observed that there are too few overlaps at the 8-mer and 9-mer levels to conduct the χ2 analysis (see Table
F.4 and F.5 in Appendix F). Therefore, the clustering analysis most relevant to the T-cell immune system
is that performed at the 7-mer level. The B cell immune system can recognize peptides of 5 or 6 residues.
Thus, Observations of clustering at the 5-mer or 6-mer level may help to identify regions of immunological
significance in the B-cell immune system.
If it is found that the overlaps are not distributed at random using the χ2 analysis, the following question
naturally arises: are there any particular segments which have a statistically significant greater or lower
number of overlapping k-mers than expected? This question can be answered by analyzing each row of
tables in Appendix G. If (Oi −Ei)2/Ei ≥ 4 for row i, then we can conclude that the particular observation
is different from random with statistical significance. In the case of 5-mers, analysis considers extent of
non-overlaps and having significantly fewer non-overlaps than expected corresponds to being “humanlike”,
while having more non-overlaps than expected corresponds to being “non-humanlike”. However, in the
cases of 6-mers and 7-mers, analysis consider extent of overlaps and having significantly more overlaps
than expected corresponds to being “humanlike”, while having fewer overlaps than expected corresponds
to being “non-humanlike”. For well-studied areas of the viral proteomes, agreement between these regions
being humanlike/non-humanlike with their known characteristics needs to be validated. For areas of the
viral proteomes which are less studied or for which fewer biochemical results are available, the analyzed
results of these regions being humanlike/non-humanlike can be used to predict their biological functions or
attribute. The predictions may be useful in developing therapies for the diseases caused by the viruses or to
help life scientists understand the mechanisms of the diseases.
Similar chi-square analysis can be performed regarding the self-similarity of human protein Desmoglein
3 (Dsg3) to the remaining human proteome. Pemphigus is an autoimmune disorder that causes blistering and
raw sores on skin and mucous membranes. As with other autoimmune disorders, it is caused when the body’s
defenses mistake its own tissues as foreign, and attack the cells. The most common form of the disorder
is pemphigus vulgaris. It occurs when antibodies attack Desmoglein 3, a protein that keeps cells bound
together. Thus, cells simply fall apart, causing skin to slough off. By investigating the overlaps between
protein Dsg3 and other proteins in the human proteome, we can determine whether or not there is structure
(clustering) to the regions of self-similarity. Then certain regions of Dsg3 could be determined whether
or not being humanlike/non-humanlike. Our previous methodology can be used, with the human protein
Desmoglein 3 considered as “BUG” proteome while the human proteome except protein Desmoglein 3 is
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considered as the “HOST” proteome. Since protein Dsg3 contains only 999 amino acids and has no sub-
protein, we only perform the chi-square analysis by dividing Dsg3 into regions of certain length. All of
5-mer, 6-mer and 7-mer level analysis are performed and comparisons of the χ2 value with the values in
a standard chi-square table are conducted. Again a p-value of less than 0.05 will be taken as indicating a
statistically significant result.
6.2.3 Clustering Analysis and Results
The executive summary is that there is statistically significant clustering in the location of the overlapping/non-
overlapping k-mers. Note that in the second type of clustering analysis, the clustering (or non-clustering)
involves only certain proteins of a multi-protein organism.
Chi-square Analysis
A chi-square analysis on the distribution of overlapping/non-overlapping k-mers within each viral pro-
teome (HIV-1, HIV-2 and Influenza A Virus) are used by employing two different techniques. In the case
of 5-mers, non-overlapping 5-mers are considered since there exists more overlaps than non-overlaps at
the 5-mer level. However, with 6-mers and 7-mers, there are more non-overlapping k-mers than overlap-
ping ones. Therefore, it makes more sense to look at the distribution of the locations of 6-mers and 7-mers
which also occur in human (i.e., overlaps). The detailed summary information about the distribution of these
non-overlaps/overlaps is listed in Appendix G.
Table 6.5 contains the summary information of the calculated χ2 value, degrees of freedom (d.f.) and
p-value for each analysis. By conventional criteria, we can conclude that the result of each analysis except
the 7-mer of HIV-1 with technique 2 is considered statistically significant. That is, the number of over-
laps appearing in the segments is different from random. We reject the corresponding null hypothesis and
conclude that there is structure (clustering) to the location of overlapping k-mers within the viral proteomes.
Similarity to Human Proteome
Table 6.6, Table 6.7 and Table 6.8 contain information from analyzing the similarity to the human pro-
teome for HIV-1 at the 5-mer, 6-mer and 7-mer level respectively. Only observations that are different from
random with statistical significance have been listed and conclusions of being humanlike/non-humanlike are
drawn accordingly. Summarizing the above three tables for HIV-1 similarity analysis gives Table 6.9.
Table 6.10, Table 6.11 and Table 6.12 contain information from analyzing the similarity to the human
proteome for HIV-2 at the 5-mer, 6-mer and 7-mer level respectively. Only observations that are differ-
ent from random with statistical significance have been listed and conclusions of being humanlike/non-
humanlike are drawn accordingly. Summarizing the above three tables for HIV-2 similarity analysis gives
Table 6.13.
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Table 6.5: Summary of chi-square analysis for each viral proteome (HIV-1, HIV-2 and
Influenza A virus) at the 5-, 6- and 7-mer level. Two different techniques are conducted for
each viral proteome.
HIV-1
k-mers Technique 1 Technique 2
χ2 d.f. p-value χ2 d.f. p-value
5-mer 62.9146 34 1.8000E-3 36.7741 15 1.4000E-3
6-mer 86.5532 35 2.9534E-6 49.0854 15 1.6970E-5
7-mer 33.4024 16 6.5000E-3 14.7212 15 4.7170E-1
HIV-2
k-mers Technique 1 Technique 2
χ2 d.f. p-value χ2 d.f. p-value
5-mer 86.9650 36 4.1886E-6 30.1165 15 1.1500E-2
6-mer 110.9699 36 1.4367E-9 44.7155 15 8.4902E-5
7-mer 72.8199 24 8.1132E-7 55.7509 15 1.3349E-6
Influenza A virus
k-mers Technique 1 Technique 2
χ2 d.f. p-value χ2 d.f. p-value
5-mer 87.1936 43 7.7963E-5 23.1269 9 5.9000E-3
6-mer 72.4257 43 3.3000E-3 19.4674 9 2.1500E-2
7-mer 31.6968 16 1.0900E-2 19.4987 9 2.1300E-2
44
Table 6.6: Summary information from analyzing the similarity to the human proteome for
HIV-1 at the 5-mer level. Only observations that are different from random with statistical
significance have been listed and conclusions of being humanlike/non-humanlike are drawn
accordingly. First table uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 9.505 for 1 ≤ i ≤ 34;E35 = 12.8317. The second table uses the
technique of dividing the viral proteome into individual protein segments: the expected
matches vary in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei HIV-1 proteins Conclusion
0001-0100 2 5.925831142 Gag poly (p17) humanlike
0301-0400 18 7.592322462 Gag poly (p24) non-humanlike
0501-0600 3 4.451870068 Gag-Pol (p17) humanlike
0801-0900 17 5.910049974 Gag-Pol (p24,p2,p7,p1,p6) non-humanlike
1901-2000 16 4.438193056 Gag-Pol (Integrase), Env gp160 non-humanlike
2401-2500 3 4.451870068 Env gp160 humanlike
2801-2900 3 4.451870068 Nef humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei HIV-1 proteins Conclusion
0001-0131 4 (12.451) 5.736037346 Gag poly (p17) humanlike
0508-0638 4 (12.451) 5.736037346 Gag-Pol (p17) humanlike
0870-1006 21 (13.022) 4.887765627 Gag-Pol (p2,p7,p1,p6) non-humanlike
3162-3273 1 (10.646) 8.739931993 Rev humanlike
3274-3461 27 (17.869) 4.665910851 Vif non-humanlike
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Table 6.7: Summary information from analyzing the similarity to the human proteome for
HIV-1 at the 6-mer level. Only observations that are different from random with statistical
significance have been listed and conclusions of being humanlike/non-humanlike are drawn
accordingly. First table uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 29.75 for 1 ≤ i ≤ 35;E36 = 7.735. The second table uses the technique
of dividing the viral proteome into individual protein segments: the expected matches vary
in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei HIV-1 proteins Conclusion
0001-0100 46 8.876050420 Gag poly (p17) humanlike
0501-0600 42 5.044117647 Gag-Pol (p17) humanlike
2001-2100 15 7.313025210 Env gp160 non-humanlike
2101-2200 18 4.640756303 Env gp160 non-humanlike
2301-2400 17 5.464285714 Env gp160 non-humanlike
2601-2700 46 8.876050420 Env gp160 humanlike
2701-2800 41 4.254201681 Env gp160 humanlike
2801-2900 42 5.044117647 Nef humanlike
3101-3200 48 11.19537815 Vpu, Rev humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei HIV-1 proteins Conclusion
0001-0131 58 (38.973) 9.289167603 Gag poly (p17) humanlike
0507-0637 58 (38.973) 9.289167603 Gag-Pol (p17) humanlike
1665-1947 59 (84.194) 7.538988954 Gag-Pol (Integrase) non-humanlike
3156-3266 54 (33.023) 13.32509248 Rev humanlike
Table 6.8: Summary information from analyzing the similarity to the human proteome for
HIV-1 at the 7-mer level. Only observations that are different from random with statisti-
cal significance have been listed and conclusions of being humanlike/non-humanlike are
drawn accordingly. It uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 6.37 for 1 ≤ i ≤ 16;E17 = 10.1.
Position N (Ei −Oi)2/Ei HIV-1 proteins Conclusion
1601-1800 1 4.526985871 Gag-Pol (RT,Integrase) non-humanlike
2601-2800 17 17.7389168 Env gp160 humanlike
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Table 6.9: Summary of all the conclusions of regions/proteins from HIV-1 proteome being
humanlike/non-humanlike at the 5, 6, 7-mer levels.
k-mers Technique 1 Technique 2
humanlike non-humanlike humanlike non-humanlike
5-mer Gag poly (p17) Gag poly (p24) Gag poly (p17) Gag-Pol (p2,p7,p1,p6)
Gag-Pol (p17) Gag-Pol (p24) Gag-Pol (p17) Vif
Env gp160 Env gp160 Rev
Nef Gag-Pol(Integrase)
Gag-Pol (p2,p7,p1,p6)
6-mer Gag poly (p17) Env gp160 Gag poly (p17) Gag-Pol (Integrase)
Gag-Pol (p17) Gag-Pol (p17)
Env gp160 Rev
Nef
Vpu
Rev
7-mer Env gp160 Gag-Pol (RT)
Gag-Pol (Integrase)
Table 6.10: Summary information from analyzing the similarity to the human proteome for
HIV-2 at the 5-mer level. Only observations that are different from random with statistical
significance have been listed and conclusions of being humanlike/non-humanlike are drawn
accordingly. First table uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 10.26. Note that the last 23 k-mers are not included since there are no
non-overlaps beyond position 3700. The second table uses the technique of dividing the
viral proteome into individual protein segments: the expected matches vary in proportion
to the proteins’ length.
Position N (Ei −Oi)2/Ei HIV-2 proteins Conclusion
0201-0300 21 11.24245614 Env gp160 non-humanlike
0301-0400 25 21.17617934 Env gp160 non-humanlike
0501-0600 2 6.649863548 Env gp160 humanlike
1901-2000 3 5.137192982 Gag-Pol (RT) humanlike
2901-3000 17 4.427641326 Vif non-humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei HIV-2 proteins Conclusion
1367-1465 2 (10.158) 6.551778303 Gag-Pol (Protease) humanlike
2831-3041 33 (21.65) 5.950230947 Vif non-humanlike
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Table 6.11: Summary information from analyzing the similarity to the human proteome for
HIV-2 at the 6-mer level. Only observations that are different from random with statistical
significance have been listed and conclusions of being humanlike/non-humanlike are drawn
accordingly. First table uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 30.64 for 1 ≤ i ≤ 36;E37 = 34.9296. The second table uses the
technique of dividing the viral proteome into individual protein segments: the expected
matches vary in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei HIV-2 proteins Conclusion
0201-0300 11 12.58908616 Env gp160 non-humanlike
0301-0400 16 6.995091384 Env gp160 non-humanlike
0501-0600 48 9.835822454 Env gp160 humanlike
1101-1200 12 11.33973890 Gag-Pol (p24) non-humanlike
1201-1300 45 6.730078329 Gag-Pol (p24,p2,p7,p1,p6) humanlike
1301-1400 42 4.211801567 Gag-Pol (p2,p7,p1,p6,Protease) humanlike
2001-2100 16 6.995091384 Gag-Pol (RT,Integrase) non-humanlike
2301-2400 44 5.825378590 Gag-Pol (Integrase), Gag poly (p17) humanlike
2801-2900 17 6.072114883 Gag poly (p2,p7,p1,p6), Vif non-humanlike
3001-3100 46 7.700052219 Vif, Nef humanlike
3501-3600 44 5.825378590 Rev, Vpr humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei HIV-2 proteins Conclusion
0854-0987 55 (41.059) 4.733468448 Gag-Pol (p17) humanlike
1218-1365 64 (45.348) 7.671718797 Gag-Pol (p2,p7,p1,p6) humanlike
2024-2311 66 (88.246) 5.608010743 Gag-Pol (Integrase) non-humanlike
2312-2445 55 (41.059) 4.733468448 Gag poly (p17) humanlike
3508-3607 43 (30.641) 4.984983551 Vpr humanlike
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Table 6.12: Summary information from analyzing the similarity to the human proteome for
HIV-2 at the 7-mer level. Only observations that are different from random with statistical
significance have been listed and conclusions of being humanlike/non-humanlike are drawn
accordingly. First table uses the technique of dividing the viral proteome into evenly-sized
segments: Ei = 5.587 for 1 ≤ i ≤ 24;E25 = 3.9109. The second table uses the technique
of dividing the viral proteome into individual protein segments: the expected matches vary
in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei HIV-2 proteins Conclusion
0451-0600 11 5.244419008 Env gp160 humanlike
0601-0750 0 5.587000000 Env gp160 non-humanlike
0751-0900 11 5.244419008 Env gp160, Gag-Pol (p17) humanlike
1201-1350 17 23.31422391 Gag-Pol (p24,p2,p7,p1,p6) humanlike
3601-3705 11 12.85007001 Vpx humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei HIV-2 proteins Conclusion
1217-1364 16 (5.513) 19.94869744 Gag-Pol (p2,p7,p1,p6) humanlike
2674-2824 11 (5.624) 5.138935989 Gag poly (p2,p7,p1,p6) humanlike
3600-3705 11 (3.948) 12.59642958 Vpx humanlike
Table 6.13: Summary of all the conclusions of regions/proteins from HIV-2 proteome
being humanlike/non-humanlike at the 5, 6, 7-mer levels.
k-mers Technique 1 Technique 2
humanlike non-humanlike humanlike non-humanlike
5-mer Env gp160 Env gp160 Gag-Pol (Protease) Vif
Gag-Pol (RT) Vif
6-mer Env gp160 Env gp160 Gag-Pol (p17) Gag-Pol(Integrase)
Gag-Pol (p17) Gag-Pol (p24) Gag-Pol (p2,p7,p1,p6)
Gag-Pol (p2,p7,p1,p6) Gag poly (p2,p7,p1,p6)
Gag-Pol (Protease) Vif
Nef
Rev, Vpr
7-mer Env gp160 Env gp160 Gag-Pol (p2,p7,p1,p6)
Gag-Pol (p17) Gag poly (p2,p7,p1,p6)
Gag-Pol (p2,p7,p1,p6) Vpx
Vpx
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Table 6.14, Table 6.15 and Table 6.16 contain information from analyzing the similarity to the human
proteome for Influenza A virus at the 5-mer, 6-mer and 7-mer level respectively. Only observations that are
different from random with statistical significance have been listed and conclusions of being humanlike/non-
humanlike are drawn accordingly. Summarizing the above three tables for Influenza A virus similarity
analysis gives Table 6.17.
Table 6.14: Summary information from analyzing the similarity to the human proteome for
Influenza A virus at the 5-mer level. Only observations that are different from random with
statistical significance have been listed and conclusions of being humanlike/non-humanlike
are drawn accordingly. First table uses the technique of dividing the viral proteome into
evenly-sized segments: Ei = 8.49 for 1 ≤ i ≤ 43;E44 = 10.78. The second table uses
the technique of dividing the viral proteome into individual protein segments: the expected
matches vary in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0401-0500 2 4.961142521 Matrix 1 humanlike
0801-0900 18 10.65254417 Hemagglutinin non-humanlike
1501-1600 15 4.991766784 Neuraminidase non-humanlike
1601-1700 20 15.60425206 Neuraminidase non-humanlike
2301-2400 2 4.961142521 Polymerse (gene: None) humanlike
3301-3400 15 4.991766784 Polymerse (gene: PB1) non-humanlike
4301-4427 1 8.872764378 Polymerse (gene: PB2) humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0344-0591 9 (21.063) 6.908606039 Matrix 1 humanlike
1249-1713 58 (39.494) 8.671495316 Neuraminidase non-humanlike
Self-similarity
A chi-square analysis on the distribution of overlapping/non-overlapping k-mers within human protein
Dsg3 are performed using two different techniques of dividing into segments. In the case of 5-mers, non-
overlapping 5-mers are considered since there exists more overlaps than non-overlaps at the 5-mer level.
However, with 6-mers and 7-mers, there are more non-overlapping k-mers than overlapping ones. Therefore,
it makes more sense to look at the distribution of the locations of 6-mers and 7-mers which also occur in
the remaining human proteins. Table 6.18 contains summarized information of the calculated χ2 value,
degree of freedom (d.f.) and p-value for each analysis. By conventional criteria, the difference of analysis at
the 5-mer level is not considered statistically significant. However, the differences of analysis at the 6-mer
and 7-mer level are considered statistically significant. In summary, there is no structure (clustering) to the
regions of self-similarity at the 5-mer level while there is clustering at the 6-mer and 7-mer level.
50
Table 6.15: Summary information from analyzing the similarity to the human proteome for
Influenza A virus at the 6-mer level. Only observations that are different from random with
statistical significance have been listed and conclusions of being humanlike/non-humanlike
are drawn accordingly. First table uses the technique of dividing the viral proteome into
evenly-sized segments: Ei = 27.055 for 1 ≤ i ≤ 43;E44 = 31.654. The second table uses
the technique of dividing the viral proteome into individual protein segments: the expected
matches vary in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0901-1000 14 6.299501940 Hemagglutinin non-humanlike
1501-1600 14 6.299501940 Neuraminidase non-humanlike
2801-2900 39 5.273813528 Polymerse (gene: None) humanlike
3201-3300 16 4.517206616 Polymerse (gene: PB1) non-humanlike
3701-3800 13 7.301534836 Polymerse (gene: PB2) non-humanlike
3901-4000 38 4.427759194 Polymerse (gene: PB2) humanlike
4301-4417 46 6.506240126 Polymerse (gene: PB2) humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0342-0588 85 (66.825) 4.943219229 Matrix 1 humanlike
2912-3663 172 (203.45) 4.861649054 Polymerse (gene: PB1) non-humanlike
Table 6.16: Summary information from analyzing the similarity to the human proteome for
Influenza A virus at the 7-mer level. Only observations that are different from random with
statistical significance have been listed and conclusions of being humanlike/non-humanlike
are drawn accordingly. First table uses the technique of dividing the viral proteome into
evenly-sized segments: Ei = 5.446 for 1 ≤ i ≤ 16;E17 = 8.866. The second table uses
the technique of dividing the viral proteome into individual protein segments: the expected
matches vary in proportion to the proteins’ length.
Position N (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0001-0250 12 7.887424899 Nonstructural 1, Nonstrucrual 2 humanlike
2001-2250 11 5.664141755 Nucleocapsid, Polymerse (gene: None) humanlike
3501-3750 0 5.446000000 Polymerse (gene: PB1, gene: PB2) non-humanlike
Position N (ExpectedN ) (Ei −Oi)2/Ei Influenza A virus proteins Conclusion
0001-0224 10 (4.88) 5.371803279 Nonstructural 1 humanlike
2904-3654 5 (16.359) 7.887210771 Polymerse (gene: PB1) non-humanlike
51
Table 6.17: Summary of all the conclusions of regions/proteins from Influenza A virus
proteome being humanlike/non-humanlike at the 5, 6, 7-mer levels.
k-mers Technique 1 Technique 2
humanlike non-humanlike humanlike non-humanlike
5-mer Matrix 1 Hemagglutinin Matrix 1 Neuraminidase
Polymerse(gene:None) Neuraminidase
Polymerse(gene:PB2) Polymerse(gene:PB1)
6-mer Polymerse(gene:None) Hemagglutinin Matrix 1 Polymerse(gene:PB1)
Polymersegene: PB2) Neuraminidase
Polymerse(gene:PB1)
Polymerse(gene:PB2)
7-mer Nonstructural 1 Polymerse(gene:PB1) Nonstructural 1 Polymerse(gene:PB1)
Nonstructural 2 Polymerse(gene:PB2)
Nucleocapsid
Polymerse(gene:None)
Table 6.18: Summary of chi-square analysis for human protein Dsg3 at the 5-, 6- and
7-mer level.
k-mers Desmoglein 3
χ2 d.f. p-value
5-mer 4.0710 6 6.6710E-1
6-mer 17.1571 9 4.6300E-2
7-mer 45.7352 9 6.7434E-7
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6.2.4 Discussion
Given that the overlapping k-mers of the HIV-1 and HIV-2 proteomes are not distributed at random by
comparing the χ2 value with the values in a standard chi-square table, each segment is analyzed to indicate
whether or not being “humanlike” or “non-humanlike”. Table 6.9 and Table 6.13 give the summarized results
of the similarity analysis for HIV-1 proteome. It shows that portions of Env gp160 protein being humanlike
and the other portions of it being non-humanlike. Env gp160 contains two proteins: surface protein gp120
(SU) and trans-membrane protein gp41 (TM). The surface protein attaches the virus to the host lymphoid
cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating
a high affinity binding site. Thus, the surface protein being humanlike agrees with that it is not easy to be
recognized by MHC molecules and induces immune response. However, the other protein, transmembrane
protein gp41, acts as a class I viral fusion protein. Membranes fusion leads to delivery of the nucleocapsid
into the cytoplasm. As we know, nucleocapsid consists of a core of nucleic acid enclosed in a protein coat,
it protects the key information of the virus. The trans-membrane protein being non-humanlike agree with
that it can easily destroy the cell membrane and deliver the nucleocapsid into the cytoplasm.
Table 6.17 are also investigated similarly to give indications whether certain segments/regions are being
humanlike/non-humanlike. It shows that Matrix protein 1, Polymerse (gene: None), Polymerse (gene: PB2)
and Nonstructural protein 1 are humanlike while Hemagglutinin portein, Neuraminidase protein and Poly-
merse (gene: PB1) are non-humanlike. Matrix protein 1 plays critical roles in virus replication, from virus
entry and uncoating to assembly and budding of the virus particle. It forms a continuous shell on the inner
side of the layer where it binds the ribonucleocapsids. Therefore, Matrix protein 1 being non-humanlike
agrees with its major function of virus replication. In addition, Hemagglutinin protein, which is a Class I
viral fusion protein, is non-humanlike as well. It binds to sialic acid-containing receptors on the cell surface,
bringing about the attachment of the virus particle to the cell. It plays a major role in the determination
of host range restriction and virulence. Therefore, Hemagglutinin protein being non-humanlike also match
with its biological function that it destroy the cell surface and help with the delivery of virus particle.
More results from Table 6.9, Table 6.13 and Table 6.17 need to be validated if characteristics of certain
viral proteins are known. Such exploration needs collaborations with professionals from molecule biology
area.
53
CHAPTER 7
SUMMARY AND FUTURE WORK
7.1 Summary and Discussion
In this research work, we explored the theme of whether the regions of immunological significance come
from the regions of low host-similarity as well as the theme of whether the locality clustering of overlap-
ping occurrences in the viral proteome is statistically significant. The purpose of the thesis is a “survey
approach” to questions related to immunology, especially in the area of discriminating immunological self
from non-self. Similar work is also explored by other researchers. One scientist studied the question of
whether the peptides of nine amino acids (9-mers) that are typically used in MHC class I presentation are
sufficiently unique for self:non-self discrimination. Her results show that the 9-mers used in MHC class I
presentation tend to carry sufficient information to detect non-self peptides amongst self peptides [3]. By
enumerating distinct 9-mers for a variety of microorganisms, she found that the probability that a foreign
peptide also occurs in the human self is about 0.2%. A small overlap between self and nonself makes sense
for several reasons. First, if more foreign epitope that overlaps with self, the chances of autoimmunity will
increase. Second, if we have smaller overlap between self and nonself, more peptides will remain as poten-
tial targets for detecting the presence of the pathogen. Another scientist studied the targets of the immune
response in autoimmune diseases by applying the principle of nonself-discrimination in the identification of
the autoimmunogenic peptide sequences. Her results show that low level of sequence similarity to the host’s
proteome may modulate peptide epitopicity [16]. It motivates the themes that are investigated in my thesis
and provides some validations of results from wet lab experiments.
7.2 Future Work
7.2.1 Peptide Universes and Corresponding Overlaps
If the proteome of each organism is a single, linear sequence, there is no problem when generating pep-
tide universe for an organism or the overlaps. This is already the case for viruses which have a polyprotein.
However, for other organisms, their (multiple) protein sequences result in a procedural problem. The pro-
teins in the proteome can be linearized into a single, long sequence of amino acids easily enough: if the
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protein sequences are stored in a multi-FASTA file, the sequence header information for all but the first
sequence is deleted. Unfortunately, a problem arises due to the linearization. Artificial peptides may be
produced which may affect the results of the clustering analysis. These artificial peptides come from sub-
sequences consisting of the end of one protein and the beginning of the following protein. For example,
Salmonella typhi (Taxonomic ID:601) contains 4716 proteins. The first protein sequence, with identifier
Q56114, ends with amino acids “LCEAIVAVL” and the second protein sequence, with identifier P40674,
starts with amino acids “SLNFLDFEQ”. Linearizing the protein sequences of Salmonella typhi creates the
artificial amino acid subsequence “LCEAIVAVLSLNFLDFEQ” as part of the overall sequence. When the
k-mers of Salmonella typhi are produced, peptides from this artificial amino acid subsequence are also pro-
duced. An improved technique needs to be proposed to circumvent the “artificial peptide” problem described
above.
7.2.2 Filtering of Ambiguities
As discussed in Section 4.1, all three filtering strategies have advantages as well as disadvantages. The
first method causes errors of mismatch, which will make the counting of overlaps between two organisms
incorrect, and errors of missing information. The other two methods lose information when performing the
filtering. Although it shows that the computational cost of the third strategy is within our set threshold while
maintaining the minimum information loss, it is possible that we could try possible matches and leave the
ambiguities in the proteome file.
7.2.3 Expected Number of Overlaps
In Section 5.2.1, the expression of calculating the expected number of overlaps is developed. The upper
bound is used to calculate the expected unique overlaps and thus this expected number is mostly higher than
one should be. Also, random sampling is assumed when deriving the equation for calculating the expected
number of overlapping occurrences including duplicates. Therefore, this expected number is mostly lower
than one should be. In order to make these expected numbers be more statistically accurate, a more refined
analysis would take into account the dependence caused by the overlap of neighboring protein sequences and
the relative frequency of occurrence of individual amino acids. That is, the amino acids that tend to appear in
human proteome are more likely to appear in viral proteomes as well. The dependency between two samples
could cause the expected number of overlapping occurrences including duplicates become lower than one
should be. In further stage of the work, the equations for calculating the expected number of overlaps could
be refined and reformulated.
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7.2.4 Proteomic Similarity Analysis
In chapter 5, the host-similarity between viral proteom (HIV-1) and human proteome is investigated and
it turns out that there is no correlation between the regions of low host-similarity and immunodominants.
One possible reason is that there is too few overlaps between HIV-1 and human at the 7-mer level. Thus,
overlaps at the 5-mer and 6-mer levels could be investigated in the future. As introduced in Chapter 2, the
typical length of peptides presented to CD8+ T cells by MHC-I molecules is 8 - 13 residues while to B cells
is 5 - 6 residues. Therefore, to perform the similarity analysis at the 5-mer and 6-mer level, the list of all
HIV antibody binding sites mapped to within a region of 21 amino acids or less should be used to indicate
regions of immunological significance.
Further, more human viral proteomes can be explored such as Influenza A virus, HCV, SARS etc. Since
we need to compare the regions of low host-similarity with regions of immunological significance, com-
pletely and well-studied viruses are good candidates.
7.2.5 Locality Clustering Analysis
In an organism’s proteome, there typically exist regions such as amino sequences of “LLLLLLLLL”.
These are called “low complexity regions”. Low complexity regions are portions of protein sequence of bi-
ased composition including homo-polymeric runs, short-period repeats, and more subtle over-representations
of one or a few residues. These low complexity regions appear frequently in proteome data. Therefore, they
may cause violation of some of the assumptions made when looking for statistically significant sequences.
They should be eliminated from the similarity analysis for this reason. Thus in the future, a filtering tech-
nique may be introduced for this purpose.
In chapter 6, structure (clustering) to the regions of host-similarity is investigated. Only three viral
proteomes are investigated at the 5-, 6- and 7-mer levels. No analysis is done for 8- and 9-mer levels since
there do not exist enough overlaps between viral and human proteomes. In future, more human affected
viruses could be analyzed, even well-studied bacteria. As mentioned earlier, bacteria usually have more
overlaps with human at the 8- and 9-mer levels. Therefore, such clustering analysis could be done for
bacteria at the 9-mer level. Also, for self-similarity analysis, more human proteins which are known to be
involved in autoimmune diseases could be explored in the future.
7.2.6 Phylogenetic Analysis
The degree of overlap (similarity) between the generated peptide universes could be used for building
phylogenetic trees especially relevant to the immunological context. It would be interesting if the resultant
trees differed from trees generated by more usual techniques (multi-sequence alignment of genomic or
protein sequences). In the future, such an investigation will be considered.
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APPENDIX A
MODEL ORGANISM PROTEOME DESCRIPTIONS
601.FASTA 4716 proteins from Salmonella typhi downloaded from
http://www.ebi.ac.uk/proteome/index.html on June 29, 2004
3702.FASTA 26150 proteins from Arabidopsis thaliana downloaded from
http://www.ebi.ac.uk/integr8 on November 7, 2004
6239.FASTA 21821 proteins for Caenorhabditis elegans downloaded from
http://www.ebi.ac.uk/proteome/index.html on June 22, 2004
7227.FASTA 19964 proteins from Drosophila melanogaster downloaded from
http://www.ebi.ac.uk/integr8 on November 7, 2004
9606.FASTA 34044 proteins for Homo sapiens downloaded from
http://www.ebi.ac.uk/integr8 on November 11, 2004
10090.FASTA 29051 proteins fromMus musculus downloaded from
http://www.ebi.ac.uk/integr8 on November 7, 2004
10116.FASTA 5863 proteins from Rattus norvegicus downloaded from
http://www.ebi.ac.uk/integr8 on July 9, 2004
36329.FASTA 5250 proteins from Plasmodium falciparum downloaded from
http://www.ebi.ac.uk/integr8 on November 7, 2004
50339.FASTA 1524 proteins from Thermoplasma volcanium (Accession number BA000011)
downloaded from http://www.ebi.ac.uk/integr8 on November 14, 2004
85962.FASTA 1555 proteins from Helicobacter pylori (Campylobacter pylori)
(Accession number AE000511) downloaded from http://www.ebi.ac.uk/integr8 on November 14, 2004
115711.FASTA 1110 proteins from Chlamydia pneumoniae strain AR39
(Accession number AE002161) downloaded from
http://www.ebi.ac.uk/integr8 on November 14, 2004
224308.FASTA 4105 proteins from Bacillus subtilis (Accession number AL009126)
downloaded from http://www.ebi.ac.uk/integr8 on November 14, 2004
243277.FASTA 3785 proteins from Vibrio cholerae downloaded from
http://www.ebi.ac.uk/integr8 on November 14, 2004
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APPENDIX B
SUMMARY INFORMATION FOR 13 MODEL ORGANISMS
This appendix contains 3 tables giving summary information for the 13 model organisms at the 9-mer
level, one for each filtering strategy.
Table B.1: Summary information of the 13 model organisms for the filtering strategy of
including all proteins, irrespective of whether they contain ambiguous amino acids (B, X
or Z).
Taxonomic ID Name # of proteins # of unique 9-mers # of 9-mer occurrences
601 Salmonella typhi 4716 1353971 1369302
3702 Arabidopsis thaliana 26150 9805060 11127054
6239 Caenorhabditis elegans 21821 7808847 9360910
10116 Rattus norvegicus 5863 2573426 2827972
36329 Plasmodium falciparum 5250 3738541 3948101
50339 Thermoplasma volcanium 1524 437512 440589
85962 Helicobacter pylori 1555 473803 479483
115711 Chlamydia pneumoniae 1110 353233 354710
224308 Bacillus subtilis 4105 1179278 1189168
7227 drosophila melanogaster 19964 7217497 10741502
243277 Vibrio cholerae 3785 1115331 1124273
9606 Homo sapiens 34044 10744680 15367806
10090 Mus musculus 29051 9503051 12842290
Table B.2: Summary information of the 13 model organisms for the filtering strategy of
removing any proteins that contain any ambiguous amino acids (B, X or Z).
Taxonomic ID Name # of proteins # of unique 9-mers # of 9-mer occurrences
601 Salmonella typhi 4714 1353169 1368473
3702 Arabidopsis thaliana 26145 9804087 11124178
6239 Caenorhabditis elegans 21809 7806071 9356423
10116 Rattus norvegicus 5786 2542425 2793097
Continued. . .
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Table B.2 – continued from previous page
Taxonomic ID Name # of proteins # of unique 9-mers # of 9-mer occurrences
36329 Plasmodium falciparum 5245 3735883 3945141
50339 Thermoplasma volcanium 1523 437176 440200
85962 Helicobacter pylori 1544 469880 474271
115711 Chlamydia pneumoniae 1093 344862 346245
224308 Bacillus subtilis 4103 1178837 1188706
7227 drosophila melanogaster 19926 7208445 10709861
243277 Vibrio cholerae 3772 1106020 1114925
9606 Homo sapiens 33800 10670465 15224726
10090 Mus musculus 28816 9444529 12721665
Table B.3: Summary information of the 13 model organisms for the filtering strategy of
removing only generated 9-mers which contain ambiguous amino acids (B, X or Z).
Taxonomic ID Name # of proteins # of unique 9-mers # of 9-mer occurrences
601 Salmonella typhi 4716 1353953 1369284
3702 Arabidopsis thaliana 26150 9805006 11127000
6239 Caenorhabditis elegans 21821 7808774 9360801
10116 Rattus norvegicus 5863 2572460 2826217
36329 Plasmodium falciparum 5250 3738467 3947981
50339 Thermoplasma volcanium 1524 437503 440580
85962 Helicobacter pylori 1555 473682 479362
115711 Chlamydia pneumoniae 1110 353071 354548
224308 Bacillus subtilis 4105 1179260 1189150
7227 drosophila melanogaster 19964 7216967 10740972
243277 Vibrio cholerae 3785 1115183 1124125
9606 Homo sapiens 34044 10739022 15359070
10090 Mus musculus 29051 9399769 12838611
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APPENDIX C
OVERLAP TABLES FOR 13 MODEL ORGANISMS
The following table is the comparison of 13 × 13 pairs of model organisms by using the first filtering
strategy. The technique of counting the unique 9-mers in the overlap of both proteomes is used here. See
next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1353971 9805060 7808847 2573426 3738541 437512 473803 353233 1179278 7217497 1115331 10744680 9503051
S. typhi 3839 3.915E-04 1717 2.199E-04 1073 4.170E-04 894 2.391E-04 536 1.225E-03 2496 5.268E-03 1452 4.111E-03 5409 4.587E-03 2235 3.097E-04 50474 4.525E-02 2613 2.432E-04 2136 2.248E-04
601 1353971 2.835E-03 1.110E-06 1.268E-03 2.788E-07 7.925E-04 3.304E-07 6.603E-04 1.579E-07 3.959E-04 4.850E-07 1.843E-03 9.711E-06 1.072E-03 4.408E-06 3.995E-03 1.832E-05 1.651E-03 5.112E-07 3.728E-02 1.687E-03 1.930E-03 4.693E-07 1.578E-03 3.546E-07
A. thaliana 3839 2.835E-03 23329 2.988E-03 14200 5.518E-03 12930 3.459E-03 779 1.781E-03 1532 3.233E-03 1383 3.915E-03 3422 2.902E-03 30158 4.178E-03 3347 3.001E-03 35912 3.342E-03 34201 3.599E-03
3702 9805060 3.915E-04 1.110E-06 2.379E-03 7.108E-06 1.448E-03 7.991E-06 1.319E-03 4.561E-06 7.945E-05 1.415E-07 1.562E-04 5.052E-07 1.410E-04 5.522E-07 3.490E-04 1.013E-06 3.076E-03 1.285E-05 3.414E-04 1.024E-06 3.663E-03 1.224E-05 3.488E-03 1.255E-05
C. elegans 1717 1.268E-03 23329 2.379E-03 34388 1.336E-02 9798 2.621E-03 530 1.211E-03 622 1.313E-03 533 1.509E-03 1418 1.202E-03 63286 8.768E-03 1653 1.482E-03 68134 6.341E-03 65690 6.913E-03
6239 7808847 2.199E-04 2.788E-07 2.988E-03 7.108E-06 4.404E-03 5.885E-05 1.255E-03 3.288E-06 6.787E-05 8.222E-08 7.965E-05 1.046E-07 6.826E-05 1.030E-07 1.816E-04 2.183E-07 8.104E-03 7.106E-05 2.117E-04 3.137E-07 8.725E-03 5.533E-05 8.412E-03 5.815E-05
R. norvegicus 1073 7.925E-04 14200 1.448E-03 34388 4.404E-03 5856 1.566E-03 274 6.263E-04 393 8.295E-04 347 9.824E-04 985 8.353E-04 55280 7.659E-03 922 8.267E-04 1224571 1.140E-01 1661771 1.749E-01
10116 2573426 4.170E-04 3.304E-07 5.518E-03 7.991E-06 1.336E-02 5.885E-05 2.276E-03 3.564E-06 1.065E-04 6.668E-08 1.527E-04 1.267E-07 1.348E-04 1.325E-07 3.828E-04 3.197E-07 2.148E-02 1.645E-04 3.583E-04 2.962E-07 4.759E-01 5.423E-02 6.457E-01 1.129E-01
P. falciparum 894 6.603E-04 12930 1.319E-03 9798 1.255E-03 5856 2.276E-03 344 7.863E-04 510 1.076E-03 419 1.186E-03 823 6.979E-04 11651 1.614E-03 845 7.576E-04 12072 1.124E-03 11749 1.236E-03
36329 3738541 2.391E-04 1.579E-07 3.459E-03 4.561E-06 2.621E-03 3.288E-06 1.566E-03 3.564E-06 9.201E-05 7.235E-08 1.364E-04 1.468E-07 1.121E-04 1.329E-07 2.201E-04 1.536E-07 3.116E-03 5.031E-06 2.260E-04 1.712E-07 3.229E-03 3.628E-06 3.143E-03 3.885E-06
T. volcani 536 3.959E-04 779 7.945E-05 530 6.787E-05 274 1.065E-04 344 9.201E-05 234 4.939E-04 136 3.850E-04 754 6.394E-04 518 7.177E-05 337 3.022E-04 629 5.854E-05 585 6.156E-05
50339 437512 1.225E-03 4.850E-07 1.781E-03 1.415E-07 1.211E-03 8.222E-08 6.263E-04 6.668E-08 7.863E-04 7.235E-08 5.348E-04 2.641E-07 3.108E-04 1.197E-07 1.723E-03 1.102E-06 1.184E-03 8.497E-08 7.703E-04 2.327E-07 1.438E-03 8.416E-08 1.337E-03 8.231E-08
H. pylori 2496 1.843E-03 1532 1.562E-04 622 7.965E-05 393 1.527E-04 510 1.364E-04 234 5.348E-04 879 2.488E-03 2033 1.724E-03 722 1.000E-04 2239 2.007E-03 843 7.846E-05 801 8.429E-05
85962 473803 5.268E-03 9.711E-06 3.233E-03 5.052E-07 1.313E-03 1.046E-07 8.295E-04 1.267E-07 1.076E-03 1.468E-07 4.939E-04 2.641E-07 1.855E-03 4.617E-06 4.291E-03 7.397E-06 1.524E-03 1.524E-07 4.726E-03 9.487E-06 1.779E-03 1.396E-07 1.691E-03 1.425E-07
1452 1.072E-03 1383 1.410E-04 533 6.826E-05 347 1.348E-04 419 1.121E-04 136 3.108E-04 879 1.855E-03 1390 1.179E-03 661 9.158E-05 1289 1.156E-03 723 6.729E-05 705 7.419E-05
115711 353233 4.111E-03 4.408E-06 3.915E-03 5.522E-07 1.509E-03 1.030E-07 9.824E-04 1.325E-07 1.186E-03 1.329E-07 3.850E-04 1.197E-07 2.488E-03 4.617E-06 3.935E-03 4.638E-06 1.871E-03 1.714E-07 3.649E-03 4.217E-06 2.047E-03 1.377E-07 1.996E-03 1.481E-07
B. subtilis 5409 3.995E-03 3422 3.490E-04 1418 1.816E-04 985 3.828E-04 823 2.201E-04 754 1.723E-03 2033 4.291E-03 1390 3.935E-03 1583 2.193E-04 4460 3.999E-03 1908 1.776E-04 1765 1.857E-04
224308 1179278 4.587E-03 1.832E-05 2.902E-03 1.013E-06 1.202E-03 2.183E-07 8.353E-04 3.197E-07 6.979E-04 1.536E-07 6.394E-04 1.102E-06 1.724E-03 7.397E-06 1.179E-03 4.638E-06 1.342E-03 2.944E-07 3.782E-03 1.512E-05 1.618E-03 2.873E-07 1.497E-03 2.780E-07
2235 1.651E-03 30158 3.076E-03 63286 8.104E-03 55280 2.148E-02 11651 3.116E-03 518 1.184E-03 722 1.524E-03 661 1.871E-03 1583 1.342E-03 1686 1.512E-03 127941 1.191E-02 122322 1.287E-02
7227 7217497 3.097E-04 5.112E-07 4.178E-03 1.285E-05 8.768E-03 7.106E-05 7.659E-03 1.645E-04 1.614E-03 5.031E-06 7.177E-05 8.497E-08 1.000E-04 1.524E-07 9.158E-05 1.714E-07 2.193E-04 2.944E-07 2.336E-04 3.531E-07 1.773E-02 2.111E-04 1.695E-02 2.182E-04
V. cholerae 50474 3.728E-02 3347 3.414E-04 1653 2.117E-04 922 3.583E-04 845 2.260E-04 337 7.703E-04 2239 4.726E-03 1289 3.649E-03 4460 3.782E-03 1686 2.336E-04 1966 1.830E-04 1813 1.908E-04
243277 1115331 4.525E-02 1.687E-03 3.001E-03 1.024E-06 1.482E-03 3.137E-07 8.267E-04 2.962E-07 7.576E-04 1.712E-07 3.022E-04 2.327E-07 2.007E-03 9.487E-06 1.156E-03 4.217E-06 3.999E-03 1.512E-05 1.512E-03 3.531E-07 1.763E-03 3.225E-07 1.626E-03 3.101E-07
H. sapiens 2613 1.930E-03 35912 3.663E-03 68134 8.725E-03 1224571 4.759E-01 12072 3.229E-03 629 1.438E-03 843 1.779E-03 723 2.047E-03 1908 1.618E-03 127941 1.773E-02 1966 1.763E-03 3791399 3.990E-01
9606 10744680 2.432E-04 4.693E-07 3.342E-03 1.224E-05 6.341E-03 5.533E-05 1.140E-01 5.423E-02 1.124E-03 3.628E-06 5.854E-05 8.416E-08 7.846E-05 1.396E-07 6.729E-05 1.377E-07 1.776E-04 2.873E-07 1.191E-02 2.111E-04 1.830E-04 3.225E-07 3.529E-01 1.408E-01
M. musculus 2136 1.578E-03 34201 3.488E-03 65690 8.412E-03 1661771 6.457E-01 11749 3.143E-03 585 1.337E-03 801 1.691E-03 705 1.996E-03 1765 1.497E-03 122322 1.695E-02 1813 1.626E-03 3791399 3.529E-01
10090 9503051 2.248E-04 3.546E-07 3.599E-03 1.255E-05 6.913E-03 5.815E-05 1.749E-01 1.129E-01 1.236E-03 3.885E-06 6.156E-05 8.231E-08 8.429E-05 1.425E-07 7.419E-05 1.481E-07 1.857E-04 2.780E-07 1.287E-02 2.182E-04 1.908E-04 3.101E-07 3.990E-01 1.408E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of unique 
9-mers
C. 
pneumoniae
D. 
melanogaster
The following table is the comparison of 13 × 13 pairs of model organisms by using the first filtering
strategy. The technique of counting the number of 9-mers in the overlap (including duplicates) of both
proteomes is used here. See next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1369302 11127054 9360910 2827972 3948101 440589 479483 354710 1189168 10741502 1124273 15367806 12842290
S. typhi 5642 5.071E-04 2566 2.741E-04 1391 4.919E-04 1062 2.690E-04 586 1.330E-03 2634 5.493E-03 1544 4.353E-03 5940 4.995E-03 5394 5.022E-04 52015 4.627E-02 4167 2.712E-04 3475 2.706E-04
601 1369302 4.120E-03 2.089E-06 1.874E-03 5.137E-07 1.016E-03 4.997E-07 7.756E-04 2.086E-07 4.280E-04 5.692E-07 1.924E-03 1.057E-05 1.128E-03 4.908E-06 4.338E-03 2.167E-05 3.939E-03 1.978E-06 3.799E-02 1.757E-03 3.043E-03 8.252E-07 2.538E-03 6.867E-07
A. thaliana 5642 4.120E-03 48163 5.145E-03 32190 1.138E-02 34557 8.753E-03 1183 2.685E-03 2363 4.928E-03 2205 6.216E-03 5430 4.566E-03 73240 6.818E-03 5194 4.620E-03 80252 5.222E-03 75459 5.876E-03
3702 11127054 5.071E-04 2.089E-06 4.328E-03 2.227E-05 2.893E-03 3.293E-05 3.106E-03 2.718E-05 1.063E-04 2.855E-07 2.124E-04 1.047E-06 1.982E-04 1.232E-06 4.880E-04 2.228E-06 6.582E-03 4.488E-05 4.668E-04 2.157E-06 7.212E-03 3.766E-05 6.782E-03 3.985E-05
C. elegans 2566 1.874E-03 48163 4.328E-03 61552 2.177E-02 23267 5.893E-03 657 1.491E-03 1003 2.092E-03 923 2.602E-03 2269 1.908E-03 128253 1.194E-02 2634 2.343E-03 143961 9.368E-03 133331 1.038E-02
6239 9360910 2.741E-04 5.137E-07 5.145E-03 2.227E-05 6.575E-03 1.431E-04 2.486E-03 1.465E-05 7.019E-05 1.047E-07 1.071E-04 2.241E-07 9.860E-05 2.566E-07 2.424E-04 4.625E-07 1.370E-02 1.636E-04 2.814E-04 6.592E-07 1.538E-02 1.441E-04 1.424E-02 1.479E-04
R. norvegicus 1391 1.016E-03 32190 2.893E-03 61552 6.575E-03 12030 3.047E-03 338 7.672E-04 500 1.043E-03 454 1.280E-03 1287 1.082E-03 109610 1.020E-02 1321 1.175E-03 1697757 1.105E-01 2170610 1.690E-01
10116 2827972 4.919E-04 4.997E-07 1.138E-02 3.293E-05 2.177E-02 1.431E-04 4.254E-03 1.296E-05 1.195E-04 9.169E-08 1.768E-04 1.844E-07 1.605E-04 2.055E-07 4.551E-04 4.925E-07 3.876E-02 3.955E-04 4.671E-04 5.489E-07 6.003E-01 6.632E-02 7.676E-01 1.297E-01
P. falciparum 1062 7.756E-04 34557 3.106E-03 23267 2.486E-03 12030 4.254E-03 387 8.784E-04 598 1.247E-03 504 1.421E-03 1010 8.493E-04 36929 3.438E-03 1064 9.464E-04 31568 2.054E-03 30823 2.400E-03
36329 3948101 2.690E-04 2.086E-07 8.753E-03 2.718E-05 5.893E-03 1.465E-05 3.047E-03 1.296E-05 9.802E-05 8.610E-08 1.515E-04 1.889E-07 1.277E-04 1.814E-07 2.558E-04 2.173E-07 9.354E-03 3.216E-05 2.695E-04 2.550E-07 7.996E-03 1.642E-05 7.807E-03 1.874E-05
T. volcanium 586 4.280E-04 1183 1.063E-04 657 7.019E-05 338 1.195E-04 387 9.802E-05 248 5.172E-04 144 4.060E-04 845 7.106E-04 880 8.193E-05 388 3.451E-04 936 6.091E-05 843 6.564E-05
50339 440589 1.330E-03 5.692E-07 2.685E-03 2.855E-07 1.491E-03 1.047E-07 7.672E-04 9.169E-08 8.784E-04 8.610E-08 5.629E-04 2.911E-07 3.268E-04 1.327E-07 1.918E-03 1.363E-06 1.997E-03 1.636E-07 8.806E-04 3.039E-07 2.124E-03 1.294E-07 1.913E-03 1.256E-07
H. pylori 2634 1.924E-03 2363 2.124E-04 1003 1.071E-04 500 1.768E-04 598 1.515E-04 248 5.629E-04 899 2.534E-03 2232 1.877E-03 1239 1.153E-04 2760 2.455E-03 1261 8.205E-05 1249 9.726E-05
85962 479483 5.493E-03 1.057E-05 4.928E-03 1.047E-06 2.092E-03 2.241E-07 1.043E-03 1.844E-07 1.247E-03 1.889E-07 5.172E-04 2.911E-07 1.875E-03 4.752E-06 4.655E-03 8.737E-06 2.584E-03 2.981E-07 5.756E-03 1.413E-05 2.630E-03 2.158E-07 2.605E-03 2.533E-07
1544 1.128E-03 2205 1.982E-04 923 9.860E-05 454 1.605E-04 504 1.277E-04 144 3.268E-04 899 1.875E-03 1490 1.253E-03 1437 1.338E-04 1412 1.256E-03 1440 9.370E-05 1232 9.593E-05
115711 354710 4.353E-03 4.908E-06 6.216E-03 1.232E-06 2.602E-03 2.566E-07 1.280E-03 2.055E-07 1.421E-03 1.814E-07 4.060E-04 1.327E-07 2.534E-03 4.752E-06 4.201E-03 5.263E-06 4.051E-03 5.420E-07 3.981E-03 4.999E-06 4.060E-03 3.804E-07 3.473E-03 3.332E-07
B. subtilis 5940 4.338E-03 5430 4.880E-04 2269 2.424E-04 1287 4.551E-04 1010 2.558E-04 845 1.918E-03 2232 4.655E-03 1490 4.201E-03 3087 2.874E-04 5360 4.768E-03 3245 2.112E-04 2939 2.289E-04
224308 1189168 4.995E-03 2.167E-05 4.566E-03 2.228E-06 1.908E-03 4.625E-07 1.082E-03 4.925E-07 8.493E-04 2.173E-07 7.106E-04 1.363E-06 1.877E-03 8.737E-06 1.253E-03 5.263E-06 2.596E-03 7.460E-07 4.507E-03 2.149E-05 2.729E-03 5.762E-07 2.471E-03 5.656E-07
5394 3.939E-03 73240 6.582E-03 128253 1.370E-02 109610 3.876E-02 36929 9.354E-03 880 1.997E-03 1239 2.584E-03 1437 4.051E-03 3087 2.596E-03 4767 4.240E-03 280626 1.826E-02 257459 2.005E-02
7227 10741502 5.022E-04 1.978E-06 6.818E-03 4.488E-05 1.194E-02 1.636E-04 1.020E-02 3.955E-04 3.438E-03 3.216E-05 8.193E-05 1.636E-07 1.153E-04 2.981E-07 1.338E-04 5.420E-07 2.874E-04 7.460E-07 4.438E-04 1.882E-06 2.613E-02 4.771E-04 2.397E-02 4.805E-04
V. cholerae 52015 3.799E-02 5194 4.668E-04 2634 2.814E-04 1321 4.671E-04 1064 2.695E-04 388 8.806E-04 2760 5.756E-03 1412 3.981E-03 5360 4.507E-03 4767 4.438E-04 3591 2.337E-04 3334 2.596E-04
243277 1124273 4.627E-02 1.757E-03 4.620E-03 2.157E-06 2.343E-03 6.592E-07 1.175E-03 5.489E-07 9.464E-04 2.550E-07 3.451E-04 3.039E-07 2.455E-03 1.413E-05 1.256E-03 4.999E-06 4.768E-03 2.149E-05 4.240E-03 1.882E-06 3.194E-03 7.464E-07 2.965E-03 7.699E-07
H. sapiens 4167 3.043E-03 80252 7.212E-03 143961 1.538E-02 1697757 6.003E-01 31568 7.996E-03 936 2.124E-03 1261 2.630E-03 1440 4.060E-03 3245 2.729E-03 280626 2.613E-02 3591 3.194E-03 5664630 4.411E-01
9606 15367806 2.712E-04 8.252E-07 5.222E-03 3.766E-05 9.368E-03 1.441E-04 1.105E-01 6.632E-02 2.054E-03 1.642E-05 6.091E-05 1.294E-07 8.205E-05 2.158E-07 9.370E-05 3.804E-07 2.112E-04 5.762E-07 1.826E-02 4.771E-04 2.337E-04 7.464E-07 3.686E-01 1.626E-01
M. musculus 3475 2.538E-03 75459 6.782E-03 133331 1.424E-02 2170610 7.676E-01 30823 7.807E-03 843 1.913E-03 1249 2.605E-03 1232 3.473E-03 2939 2.471E-03 257459 2.397E-02 3334 2.965E-03 5664630 3.686E-01
10090 12842290 2.706E-04 6.867E-07 5.876E-03 3.985E-05 1.038E-02 1.479E-04 1.690E-01 1.297E-01 2.400E-03 1.874E-05 6.564E-05 1.256E-07 9.726E-05 2.533E-07 9.593E-05 3.332E-07 2.289E-04 5.656E-07 2.005E-02 4.805E-04 2.596E-04 7.699E-07 4.411E-01 1.626E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of unique 
9-mers
C. 
pneumoniae
D. 
melanogaster
The following table is the comparison of 13× 13 pairs of model organisms by using the second filtering
strategy. The technique of counting the unique 9-mers in the overlap of both proteomes is used here. See
next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1353169 9804087 7806071 2542425 3735883 437176 469880 344862 1178837 7208445 1106020 10670465 9444529
S. typhi 3833 3.910E-04 1711 2.192E-04 1038 4.083E-04 894 2.393E-04 536 1.226E-03 2495 5.310E-03 1443 4.184E-03 5406 4.586E-03 2233 3.098E-04 50372 4.554E-02 2602 2.439E-04 2124 2.249E-04
601 1353169 2.833E-03 1.107E-06 1.264E-03 2.772E-07 7.671E-04 3.132E-07 6.607E-04 1.581E-07 3.961E-04 4.856E-07 1.844E-03 9.790E-06 1.066E-03 4.462E-06 3.995E-03 1.832E-05 1.650E-03 5.112E-07 3.723E-02 1.695E-03 1.923E-03 4.689E-07 1.570E-03 3.530E-07
A. thaliana 3833 2.833E-03 23327 2.988E-03 14052 5.527E-03 12855 3.441E-03 778 1.780E-03 1532 3.260E-03 1370 3.973E-03 3422 2.903E-03 30143 4.182E-03 3334 3.014E-03 35867 3.361E-03 34134 3.614E-03
3702 9804087 3.910E-04 1.107E-06 2.379E-03 7.110E-06 1.433E-03 7.922E-06 1.311E-03 4.512E-06 7.935E-05 1.412E-07 1.563E-04 5.095E-07 1.397E-04 5.551E-07 3.490E-04 1.013E-06 3.075E-03 1.286E-05 3.401E-04 1.025E-06 3.658E-03 1.230E-05 3.482E-03 1.258E-05
C. elegans 1711 1.264E-03 23327 2.379E-03 34080 1.340E-02 9759 2.612E-03 530 1.212E-03 622 1.324E-03 532 1.543E-03 1418 1.203E-03 63265 8.777E-03 1647 1.489E-03 68022 6.375E-03 65538 6.939E-03
6239 7806071 2.192E-04 2.772E-07 2.988E-03 7.110E-06 4.366E-03 5.852E-05 1.250E-03 3.266E-06 6.790E-05 8.231E-08 7.968E-05 1.055E-07 6.815E-05 1.051E-07 1.817E-04 2.185E-07 8.105E-03 7.113E-05 2.110E-04 3.142E-07 8.714E-03 5.555E-05 8.396E-03 5.826E-05
R. norvegicus 1038 7.671E-04 14052 1.433E-03 34080 4.366E-03 5708 1.528E-03 269 6.153E-04 393 8.364E-04 329 9.540E-04 959 8.135E-04 54798 7.602E-03 871 7.875E-04 1207789 1.132E-01 1634994 1.731E-01
10116 2542425 4.083E-04 3.132E-07 5.527E-03 7.922E-06 1.340E-02 5.852E-05 2.245E-03 3.430E-06 1.058E-04 6.510E-08 1.546E-04 1.293E-07 1.294E-04 1.235E-07 3.772E-04 3.069E-07 2.155E-02 1.638E-04 3.426E-04 2.698E-07 4.751E-01 5.377E-02 6.431E-01 1.113E-01
P. falciparum 894 6.607E-04 12855 1.311E-03 9759 1.250E-03 5708 2.245E-03 344 7.869E-04 508 1.081E-03 417 1.209E-03 823 6.981E-04 11592 1.608E-03 844 7.631E-04 12003 1.125E-03 11677 1.236E-03
36329 3735883 2.393E-04 1.581E-07 3.441E-03 4.512E-06 2.612E-03 3.266E-06 1.528E-03 3.430E-06 9.208E-05 7.245E-08 1.360E-04 1.470E-07 1.116E-04 1.350E-07 2.203E-04 1.538E-07 3.103E-03 4.990E-06 2.259E-04 1.724E-07 3.213E-03 3.614E-06 3.126E-03 3.864E-06
T. volcanium 536 3.961E-04 778 7.935E-05 530 6.790E-05 269 1.058E-04 344 9.208E-05 234 4.980E-04 135 3.915E-04 751 6.371E-04 517 7.172E-05 337 3.047E-04 626 5.867E-05 582 6.162E-05
50339 437176 1.226E-03 4.856E-07 1.780E-03 1.412E-07 1.212E-03 8.231E-08 6.153E-04 6.510E-08 7.869E-04 7.245E-08 5.353E-04 2.666E-07 3.088E-04 1.209E-07 1.718E-03 1.094E-06 1.183E-03 8.482E-08 7.709E-04 2.349E-07 1.432E-03 8.401E-08 1.331E-03 8.204E-08
H. pylori 2495 1.844E-03 1532 1.563E-04 622 7.968E-05 393 1.546E-04 508 1.360E-04 234 5.353E-04 878 2.546E-03 2028 1.720E-03 722 1.002E-04 2234 2.020E-03 838 7.853E-05 800 8.471E-05
85962 469880 5.310E-03 9.790E-06 3.260E-03 5.095E-07 1.324E-03 1.055E-07 8.364E-04 1.293E-07 1.081E-03 1.470E-07 4.980E-04 2.666E-07 1.869E-03 4.757E-06 4.316E-03 7.425E-06 1.537E-03 1.539E-07 4.754E-03 9.603E-06 1.783E-03 1.401E-07 1.703E-03 1.442E-07
1443 1.066E-03 1370 1.397E-04 532 6.815E-05 329 1.294E-04 417 1.116E-04 135 3.088E-04 878 1.869E-03 1374 1.166E-03 659 9.142E-05 1273 1.151E-03 717 6.719E-05 702 7.433E-05
115711 344862 4.184E-03 4.462E-06 3.973E-03 5.551E-07 1.543E-03 1.051E-07 9.540E-04 1.235E-07 1.209E-03 1.350E-07 3.915E-04 1.209E-07 2.546E-03 4.757E-06 3.984E-03 4.644E-06 1.911E-03 1.747E-07 3.691E-03 4.249E-06 2.079E-03 1.397E-07 2.036E-03 1.513E-07
B. subtilis 5406 3.995E-03 3422 3.490E-04 1418 1.817E-04 959 3.772E-04 823 2.203E-04 751 1.718E-03 2028 4.316E-03 1374 3.984E-03 1583 2.196E-04 4440 4.014E-03 1904 1.784E-04 1762 1.866E-04
224308 1178837 4.586E-03 1.832E-05 2.903E-03 1.013E-06 1.203E-03 2.185E-07 8.135E-04 3.069E-07 6.981E-04 1.538E-07 6.371E-04 1.094E-06 1.720E-03 7.425E-06 1.166E-03 4.644E-06 1.343E-03 2.949E-07 3.766E-03 1.512E-05 1.615E-03 2.882E-07 1.495E-03 2.789E-07
2233 1.650E-03 30143 3.075E-03 63265 8.105E-03 54798 2.155E-02 11592 3.103E-03 517 1.183E-03 722 1.537E-03 659 1.911E-03 1583 1.343E-03 1683 1.522E-03 127647 1.196E-02 121846 1.290E-02
7227 7208445 3.098E-04 5.112E-07 4.182E-03 1.286E-05 8.777E-03 7.113E-05 7.602E-03 1.638E-04 1.608E-03 4.990E-06 7.172E-05 8.482E-08 1.002E-04 1.539E-07 9.142E-05 1.747E-07 2.196E-04 2.949E-07 2.335E-04 3.553E-07 1.771E-02 2.118E-04 1.690E-02 2.181E-04
V. cholerae 50372 3.723E-02 3334 3.401E-04 1647 2.110E-04 871 3.426E-04 844 2.259E-04 337 7.709E-04 2234 4.754E-03 1273 3.691E-03 4440 3.766E-03 1683 2.335E-04 1957 1.834E-04 1809 1.915E-04
243277 1106020 4.554E-02 1.695E-03 3.014E-03 1.025E-06 1.489E-03 3.142E-07 7.875E-04 2.698E-07 7.631E-04 1.724E-07 3.047E-04 2.349E-07 2.020E-03 9.603E-06 1.151E-03 4.249E-06 4.014E-03 1.512E-05 1.522E-03 3.553E-07 1.769E-03 3.245E-07 1.636E-03 3.133E-07
H. sapiens 2602 1.923E-03 35867 3.658E-03 68022 8.714E-03 1207789 4.751E-01 12003 3.213E-03 626 1.432E-03 838 1.783E-03 717 2.079E-03 1904 1.615E-03 127637 1.771E-02 1957 1.769E-03 3759302 3.980E-01
9606 10670465 2.439E-04 4.689E-07 3.361E-03 1.230E-05 6.375E-03 5.555E-05 1.132E-01 5.377E-02 1.125E-03 3.614E-06 5.867E-05 8.401E-08 7.853E-05 1.401E-07 6.719E-05 1.397E-07 1.784E-04 2.882E-07 1.196E-02 2.118E-04 1.834E-04 3.245E-07 3.523E-01 1.402E-01
M. musculus 2124 1.570E-03 34134 3.482E-03 65538 8.396E-03 1634994 6.431E-01 11677 3.126E-03 582 1.331E-03 800 1.703E-03 702 2.036E-03 1762 1.495E-03 121846 1.690E-02 1809 1.636E-03 3759302 3.523E-01
10090 9444529 2.249E-04 3.530E-07 3.614E-03 1.258E-05 6.939E-03 5.826E-05 1.731E-01 1.113E-01 1.236E-03 3.864E-06 6.162E-05 8.204E-08 8.471E-05 1.442E-07 7.433E-05 1.513E-07 1.866E-04 2.789E-07 1.290E-02 2.181E-04 1.915E-04 3.133E-07 3.980E-01 1.402E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of unique 
9-mers
C. 
pneumoniae
D. 
melanogaster
The following table is the comparison of 13× 13 pairs of model organisms by using the second filtering
strategy. The technique of counting the number of 9-mers in the overlap (including duplicates) of both
proteomes is used here. See next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1368473 11124178 9356423 2793097 3945141 440200 474271 346245 1188706 10709861 1114925 15224726 12721665
S. typhi 5634 5.065E-04 2560 2.736E-04 1352 4.841E-04 1062 2.692E-04 586 1.331E-03 2633 5.552E-03 1533 4.428E-03 5937 4.995E-03 5332 4.979E-04 51911 4.656E-02 4149 2.725E-04 3437 2.702E-04
601 1368473 4.117E-03 2.085E-06 1.871E-03 5.118E-07 9.880E-04 4.782E-07 7.760E-04 2.089E-07 4.282E-04 5.700E-07 1.924E-03 1.068E-05 1.120E-03 4.960E-06 4.338E-03 2.167E-05 3.896E-03 1.940E-06 3.793E-02 1.766E-03 3.032E-03 8.262E-07 2.512E-03 6.785E-07
A. thaliana 5634 4.117E-03 48154 5.147E-03 31855 1.140E-02 34458 8.734E-03 1182 2.685E-03 2363 4.982E-03 2179 6.293E-03 5430 4.568E-03 73033 6.819E-03 5176 4.642E-03 80103 5.261E-03 75244 5.915E-03
3702 11124178 5.065E-04 2.085E-06 4.329E-03 2.228E-05 2.864E-03 3.266E-05 3.098E-03 2.706E-05 1.063E-04 2.853E-07 2.124E-04 1.058E-06 1.959E-04 1.233E-06 4.881E-04 2.230E-06 6.565E-03 4.477E-05 4.653E-04 2.160E-06 7.201E-03 3.789E-05 6.764E-03 4.001E-05
C. elegans 2560 1.871E-03 48154 4.329E-03 60956 2.182E-02 23214 5.884E-03 657 1.493E-03 1003 2.115E-03 922 2.663E-03 2269 1.909E-03 127955 1.195E-02 2624 2.354E-03 143581 9.431E-03 132852 1.044E-02
6239 9356423 2.736E-04 5.118E-07 5.147E-03 2.228E-05 6.515E-03 1.422E-04 2.481E-03 1.460E-05 7.022E-05 1.048E-07 1.072E-04 2.267E-07 9.854E-05 2.624E-07 2.425E-04 4.629E-07 1.368E-02 1.634E-04 2.804E-04 6.600E-07 1.535E-02 1.447E-04 1.420E-02 1.483E-04
R. norvegicus 1352 9.880E-04 31855 2.864E-03 60956 6.515E-03 11302 2.865E-03 332 7.542E-04 499 1.052E-03 436 1.259E-03 1255 1.056E-03 108335 1.012E-02 1267 1.136E-03 1672778 1.099E-01 2134784 1.678E-01
10116 2793097 4.841E-04 4.782E-07 1.140E-02 3.266E-05 2.182E-02 1.422E-04 4.046E-03 1.159E-05 1.189E-04 8.965E-08 1.787E-04 1.880E-07 1.561E-04 1.966E-07 4.493E-04 4.744E-07 3.879E-02 3.923E-04 4.536E-04 5.155E-07 5.989E-01 6.580E-02 7.643E-01 1.283E-01
P. falciparum 1062 7.760E-04 34458 3.098E-03 23214 2.481E-03 11302 4.046E-03 385 8.746E-04 596 1.257E-03 502 1.450E-03 1009 8.488E-04 36715 3.428E-03 1063 9.534E-04 31281 2.055E-03 30542 2.401E-03
36329 3945141 2.692E-04 2.089E-07 8.734E-03 2.706E-05 5.884E-03 1.460E-05 2.865E-03 1.159E-05 9.759E-05 8.535E-08 1.511E-04 1.898E-07 1.272E-04 1.845E-07 2.558E-04 2.171E-07 9.306E-03 3.190E-05 2.694E-04 2.569E-07 7.929E-03 1.629E-05 7.742E-03 1.859E-05
T. volcanium 586 4.282E-04 1182 1.063E-04 657 7.022E-05 332 1.189E-04 385 9.759E-05 248 5.229E-04 142 4.101E-04 842 7.083E-04 838 7.825E-05 388 3.480E-04 932 6.122E-05 834 6.556E-05
50339 440200 1.331E-03 5.700E-07 2.685E-03 2.853E-07 1.493E-03 1.048E-07 7.542E-04 8.965E-08 8.746E-04 8.535E-08 5.634E-04 2.946E-07 3.226E-04 1.323E-07 1.913E-03 1.355E-06 1.904E-03 1.490E-07 8.814E-04 3.067E-07 2.117E-03 1.296E-07 1.895E-03 1.242E-07
H. pylori 2633 1.924E-03 2363 2.124E-04 1003 1.072E-04 499 1.787E-04 596 1.511E-04 248 5.634E-04 898 2.594E-03 2227 1.873E-03 1239 1.157E-04 2754 2.470E-03 1254 8.237E-05 1240 9.747E-05
85962 474271 5.552E-03 1.068E-05 4.982E-03 1.058E-06 2.115E-03 2.267E-07 1.052E-03 1.880E-07 1.257E-03 1.898E-07 5.229E-04 2.946E-07 1.893E-03 4.911E-06 4.696E-03 8.797E-06 2.612E-03 3.022E-07 5.807E-03 1.434E-05 2.644E-03 2.178E-07 2.615E-03 2.548E-07
1533 1.120E-03 2179 1.959E-04 922 9.854E-05 436 1.561E-04 502 1.272E-04 142 3.226E-04 898 1.893E-03 1473 1.239E-03 1434 1.339E-04 1392 1.249E-03 1431 9.399E-05 1228 9.653E-05
115711 346245 4.428E-03 4.960E-06 6.293E-03 1.233E-06 2.663E-03 2.624E-07 1.259E-03 1.966E-07 1.450E-03 1.845E-07 4.101E-04 1.323E-07 2.594E-03 4.911E-06 4.254E-03 5.272E-06 4.142E-03 5.545E-07 4.020E-03 5.019E-06 4.133E-03 3.885E-07 3.547E-03 3.423E-07
B. subtilis 5937 4.338E-03 5430 4.881E-04 2269 2.425E-04 1255 4.493E-04 1009 2.558E-04 842 1.913E-03 2227 4.696E-03 1473 4.254E-03 3040 2.839E-04 5337 4.787E-03 3237 2.126E-04 2929 2.302E-04
224308 1188706 4.995E-03 2.167E-05 4.568E-03 2.230E-06 1.909E-03 4.629E-07 1.056E-03 4.744E-07 8.488E-04 2.171E-07 7.083E-04 1.355E-06 1.873E-03 8.797E-06 1.239E-03 5.272E-06 2.557E-03 7.259E-07 4.490E-03 2.149E-05 2.723E-03 5.790E-07 2.464E-03 5.673E-07
5332 3.896E-03 73033 6.565E-03 127955 1.368E-02 108335 3.879E-02 36715 9.306E-03 838 1.904E-03 1239 2.612E-03 1434 4.142E-03 3040 2.557E-03 4752 4.262E-03 279291 1.834E-02 255896 2.011E-02
7227 10709861 4.979E-04 1.940E-06 6.819E-03 4.477E-05 1.195E-02 1.634E-04 1.012E-02 3.923E-04 3.428E-03 3.190E-05 7.825E-05 1.490E-07 1.157E-04 3.022E-07 1.339E-04 5.545E-07 2.839E-04 7.259E-07 4.437E-04 1.891E-06 2.608E-02 4.784E-04 2.389E-02 4.806E-04
V. cholerae 51911 3.793E-02 5176 4.653E-04 2624 2.804E-04 1267 4.536E-04 1063 2.694E-04 388 8.814E-04 2754 5.807E-03 1392 4.020E-03 5337 4.490E-03 4752 4.437E-04 3576 2.349E-04 3307 2.600E-04
243277 1114925 4.656E-02 1.766E-03 4.642E-03 2.160E-06 2.354E-03 6.600E-07 1.136E-03 5.155E-07 9.534E-04 2.569E-07 3.480E-04 3.067E-07 2.470E-03 1.434E-05 1.249E-03 5.019E-06 4.787E-03 2.149E-05 4.262E-03 1.891E-06 3.207E-03 7.534E-07 2.966E-03 7.710E-07
H. sapiens 4149 3.032E-03 80103 7.201E-03 143581 1.535E-02 1672778 5.989E-01 31281 7.929E-03 932 2.117E-03 1254 2.644E-03 1431 4.133E-03 3237 2.723E-03 279291 2.608E-02 3576 3.207E-03 5603713 4.405E-01
9606 15224726 2.725E-04 8.262E-07 5.261E-03 3.789E-05 9.431E-03 1.447E-04 1.099E-01 6.580E-02 2.055E-03 1.629E-05 6.122E-05 1.296E-07 8.237E-05 2.178E-07 9.399E-05 3.885E-07 2.126E-04 5.790E-07 1.834E-02 4.784E-04 2.349E-04 7.534E-07 3.681E-01 1.621E-01
M. musculus 3437 2.512E-03 75244 6.764E-03 132852 1.420E-02 2134784 7.643E-01 30542 7.742E-03 834 1.895E-03 1240 2.615E-03 1228 3.547E-03 2929 2.464E-03 255896 2.389E-02 3307 2.966E-03 5603713 3.681E-01
10090 12721665 2.702E-04 6.785E-07 5.915E-03 4.001E-05 1.044E-02 1.483E-04 1.678E-01 1.283E-01 2.401E-03 1.859E-05 6.556E-05 1.242E-07 9.747E-05 2.548E-07 9.653E-05 3.423E-07 2.302E-04 5.673E-07 2.011E-02 4.806E-04 2.600E-04 7.710E-07 4.405E-01 1.621E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of 9-mer 
occurrences
C. 
pneumoniae
D. 
melanogaster
The following table is the comparison of 13 × 13 pairs of model organisms using the third filtering
strategy. The technique of counting the unique 9-mers in the overlap of both proteomes is used here. See
next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1353953 9805006 7808774 2572460 3738467 437503 473682 353071 1179260 7216967 1115183 10739022 9499769
S. typhi 3839 3.915E-04 1717 2.199E-04 1073 4.171E-04 894 2.391E-04 536 1.225E-03 2496 5.269E-03 1452 4.112E-03 5409 4.587E-03 2235 3.097E-04 50474 4.526E-02 2613 2.433E-04 2136 2.248E-04
601 1353953 2.835E-03 1.110E-06 1.268E-03 2.788E-07 7.925E-04 3.306E-07 6.603E-04 1.579E-07 3.959E-04 4.850E-07 1.843E-03 9.714E-06 1.072E-03 4.410E-06 3.995E-03 1.832E-05 1.651E-03 5.112E-07 3.728E-02 1.687E-03 1.930E-03 4.696E-07 1.578E-03 3.547E-07
A. thaliana 3839 2.835E-03 23329 2.988E-03 14200 5.520E-03 12930 3.459E-03 779 1.781E-03 1532 3.234E-03 1383 3.917E-03 3422 2.902E-03 30158 4.179E-03 3347 3.001E-03 35912 3.344E-03 34201 3.600E-03
3702 9805006 3.915E-04 1.110E-06 2.379E-03 7.108E-06 1.448E-03 7.994E-06 1.319E-03 4.561E-06 7.945E-05 1.415E-07 1.562E-04 5.053E-07 1.411E-04 5.525E-07 3.490E-04 1.013E-06 3.076E-03 1.285E-05 3.414E-04 1.025E-06 3.663E-03 1.225E-05 3.488E-03 1.256E-05
C. elegans 1717 1.268E-03 23329 2.379E-03 34388 1.337E-02 9798 2.621E-03 530 1.211E-03 622 1.313E-03 533 1.510E-03 1418 1.202E-03 63286 8.769E-03 1653 1.482E-03 68134 6.345E-03 65690 6.915E-03
6239 7808774 2.199E-04 2.788E-07 2.988E-03 7.108E-06 4.404E-03 5.887E-05 1.255E-03 3.289E-06 6.787E-05 8.222E-08 7.965E-05 1.046E-07 6.826E-05 1.030E-07 1.816E-04 2.184E-07 8.104E-03 7.107E-05 2.117E-04 3.138E-07 8.725E-03 5.536E-05 8.412E-03 5.817E-05
R. norvegicus 1073 7.925E-04 14200 1.448E-03 34388 4.404E-03 5855 1.566E-03 274 6.263E-04 393 8.297E-04 347 9.828E-04 985 8.353E-04 55280 7.660E-03 922 8.268E-04 1224570 1.140E-01 1661768 1.749E-01
10116 2572460 4.171E-04 3.306E-07 5.520E-03 7.994E-06 1.337E-02 5.887E-05 2.276E-03 3.565E-06 1.065E-04 6.671E-08 1.528E-04 1.268E-07 1.349E-04 1.326E-07 3.829E-04 3.198E-07 2.149E-02 1.646E-04 3.584E-04 2.963E-07 4.760E-01 5.428E-02 6.460E-01 1.130E-01
P. falciparum 894 6.603E-04 12930 1.319E-03 9798 1.255E-03 5855 2.276E-03 344 7.863E-04 510 1.077E-03 419 1.187E-03 823 6.979E-04 11651 1.614E-03 845 7.577E-04 12069 1.124E-03 11747 1.237E-03
36329 3738467 2.391E-04 1.579E-07 3.459E-03 4.561E-06 2.621E-03 3.289E-06 1.566E-03 3.565E-06 9.202E-05 7.235E-08 1.364E-04 1.469E-07 1.121E-04 1.330E-07 2.201E-04 1.536E-07 3.117E-03 5.031E-06 2.260E-04 1.713E-07 3.228E-03 3.628E-06 3.142E-03 3.886E-06
T. volcanium 536 3.959E-04 779 7.945E-05 530 6.787E-05 274 1.065E-04 344 9.202E-05 234 4.940E-04 136 3.852E-04 754 6.394E-04 518 7.178E-05 337 3.022E-04 629 5.857E-05 585 6.158E-05
50339 437503 1.225E-03 4.850E-07 1.781E-03 1.415E-07 1.211E-03 8.222E-08 6.263E-04 6.671E-08 7.863E-04 7.235E-08 5.349E-04 2.642E-07 3.109E-04 1.197E-07 1.723E-03 1.102E-06 1.184E-03 8.498E-08 7.703E-04 2.328E-07 1.438E-03 8.421E-08 1.337E-03 8.234E-08
H. pylori 2496 1.843E-03 1532 1.562E-04 622 7.965E-05 393 1.528E-04 510 1.364E-04 234 5.349E-04 879 2.490E-03 2033 1.724E-03 722 1.000E-04 2239 2.008E-03 843 7.850E-05 801 8.432E-05
85962 473682 5.269E-03 9.714E-06 3.234E-03 5.053E-07 1.313E-03 1.046E-07 8.297E-04 1.268E-07 1.077E-03 1.469E-07 4.940E-04 2.642E-07 1.856E-03 4.620E-06 4.292E-03 7.399E-06 1.524E-03 1.525E-07 4.727E-03 9.490E-06 1.780E-03 1.397E-07 1.691E-03 1.426E-07
1452 1.072E-03 1383 1.411E-04 533 6.826E-05 347 1.349E-04 419 1.121E-04 136 3.109E-04 879 1.856E-03 1390 1.179E-03 661 9.159E-05 1289 1.156E-03 723 6.732E-05 705 7.421E-05
115711 353071 4.112E-03 4.410E-06 3.917E-03 5.525E-07 1.510E-03 1.030E-07 9.828E-04 1.326E-07 1.187E-03 1.330E-07 3.852E-04 1.197E-07 2.490E-03 4.620E-06 3.937E-03 4.640E-06 1.872E-03 1.715E-07 3.651E-03 4.220E-06 2.048E-03 1.379E-07 1.997E-03 1.482E-07
B. subtilis 5409 3.995E-03 3422 3.490E-04 1418 1.816E-04 985 3.829E-04 823 2.201E-04 754 1.723E-03 2033 4.292E-03 1390 3.937E-03 1583 2.193E-04 4460 3.999E-03 1908 1.777E-04 1765 1.858E-04
224308 1179260 4.587E-03 1.832E-05 2.902E-03 1.013E-06 1.202E-03 2.184E-07 8.353E-04 3.198E-07 6.979E-04 1.536E-07 6.394E-04 1.102E-06 1.724E-03 7.399E-06 1.179E-03 4.640E-06 1.342E-03 2.944E-07 3.782E-03 1.513E-05 1.618E-03 2.875E-07 1.497E-03 2.781E-07
2235 1.651E-03 30158 3.076E-03 63286 8.104E-03 55280 2.149E-02 11651 3.117E-03 518 1.184E-03 722 1.524E-03 661 1.872E-03 1583 1.342E-03 1686 1.512E-03 127941 1.191E-02 122322 1.288E-02
7227 7216967 3.097E-04 5.112E-07 4.179E-03 1.285E-05 8.769E-03 7.107E-05 7.660E-03 1.646E-04 1.614E-03 5.031E-06 7.178E-05 8.498E-08 1.000E-04 1.525E-07 9.159E-05 1.715E-07 2.193E-04 2.944E-07 2.336E-04 3.532E-07 1.773E-02 2.112E-04 1.695E-02 2.182E-04
V. cholerae 50474 3.728E-02 3347 3.414E-04 1653 2.117E-04 922 3.584E-04 845 2.260E-04 337 7.703E-04 2239 4.727E-03 1289 3.651E-03 4460 3.782E-03 1686 2.336E-04 1966 1.831E-04 1813 1.908E-04
243277 1115183 4.526E-02 1.687E-03 3.001E-03 1.025E-06 1.482E-03 3.138E-07 8.268E-04 2.963E-07 7.577E-04 1.713E-07 3.022E-04 2.328E-07 2.008E-03 9.490E-06 1.156E-03 4.220E-06 3.999E-03 1.513E-05 1.512E-03 3.532E-07 1.763E-03 3.227E-07 1.626E-03 3.103E-07
H. sapiens 2613 1.930E-03 35912 3.663E-03 68134 8.725E-03 1224570 4.760E-01 12069 3.228E-03 629 1.438E-03 843 1.780E-03 723 2.048E-03 1908 1.618E-03 127941 1.773E-02 1966 1.763E-03 3791379 3.991E-01
9606 10739022 2.433E-04 4.696E-07 3.344E-03 1.225E-05 6.345E-03 5.536E-05 1.140E-01 5.428E-02 1.124E-03 3.628E-06 5.857E-05 8.421E-08 7.850E-05 1.397E-07 6.732E-05 1.379E-07 1.777E-04 2.875E-07 1.191E-02 2.112E-04 1.831E-04 3.227E-07 3.530E-01 1.409E-01
M. musculus 2136 1.578E-03 34201 3.488E-03 65690 8.412E-03 1661768 6.460E-01 11747 3.142E-03 585 1.337E-03 801 1.691E-03 705 1.997E-03 1765 1.497E-03 122322 1.695E-02 1813 1.626E-03 3791379 3.530E-01
10090 9499769 2.248E-04 3.547E-07 3.600E-03 1.256E-05 6.915E-03 5.817E-05 1.749E-01 1.130E-01 1.237E-03 3.886E-06 6.158E-05 8.234E-08 8.432E-05 1.426E-07 7.421E-05 1.482E-07 1.858E-04 2.781E-07 1.288E-02 2.182E-04 1.908E-04 3.103E-07 3.991E-01 1.409E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of unique 
9-mers
C. 
pneumoniae
D. 
melanogaster
The following table is the comparison of 13 × 13 pairs of model organisms using the third filtering
strategy. The technique of counting the number of 9-mers in the overlap (including duplicates) of both
proteomes is used here. See next page for the complete table.
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601 3702 6239 10116 36329 50339 85962 115711 224308 7227 243277 9606 10090
1369284 11127000 9360801 2826217 3947981 440580 479362 354548 1189150 10740972 1124125 15359070 12838611
S. typhi 5642 5.071E-04 2566 2.741E-04 1391 4.922E-04 1062 2.690E-04 586 1.330E-03 2634 5.495E-03 1544 4.355E-03 5940 4.995E-03 5394 5.022E-04 52015 4.627E-02 4167 2.713E-04 3475 2.707E-04
601 1369284 4.120E-03 2.089E-06 1.874E-03 5.137E-07 1.016E-03 5.000E-07 7.756E-04 2.086E-07 4.280E-04 5.692E-07 1.924E-03 1.057E-05 1.128E-03 4.911E-06 4.338E-03 2.167E-05 3.939E-03 1.978E-06 3.799E-02 1.758E-03 3.043E-03 8.256E-07 2.538E-03 6.869E-07
A. thaliana 5642 4.120E-03 48163 5.145E-03 32190 1.139E-02 34557 8.753E-03 1183 2.685E-03 2363 4.929E-03 2205 6.219E-03 5430 4.566E-03 73240 6.819E-03 5194 4.620E-03 80252 5.225E-03 75459 5.878E-03
3702 11127000 5.071E-04 2.089E-06 4.328E-03 2.227E-05 2.893E-03 3.295E-05 3.106E-03 2.718E-05 1.063E-04 2.855E-07 2.124E-04 1.047E-06 1.982E-04 1.232E-06 4.880E-04 2.228E-06 6.582E-03 4.488E-05 4.668E-04 2.157E-06 7.212E-03 3.769E-05 6.782E-03 3.986E-05
C. elegans 2566 1.874E-03 48163 4.328E-03 61552 2.178E-02 23267 5.893E-03 657 1.491E-03 1003 2.092E-03 923 2.603E-03 2269 1.908E-03 128253 1.194E-02 2634 2.343E-03 143961 9.373E-03 133331 1.039E-02
6239 9360801 2.741E-04 5.137E-07 5.145E-03 2.227E-05 6.576E-03 1.432E-04 2.486E-03 1.465E-05 7.019E-05 1.047E-07 1.071E-04 2.242E-07 9.860E-05 2.567E-07 2.424E-04 4.625E-07 1.370E-02 1.636E-04 2.814E-04 6.593E-07 1.538E-02 1.441E-04 1.424E-02 1.479E-04
R. norvegicus 1391 1.016E-03 32190 2.893E-03 61552 6.576E-03 11611 2.941E-03 338 7.672E-04 500 1.043E-03 454 1.281E-03 1287 1.082E-03 109610 1.020E-02 1321 1.175E-03 1697242 1.105E-01 2170120 1.690E-01
10116 2826217 4.922E-04 5.000E-07 1.139E-02 3.295E-05 2.178E-02 1.432E-04 4.108E-03 1.208E-05 1.196E-04 9.175E-08 1.769E-04 1.845E-07 1.606E-04 2.057E-07 4.554E-04 4.929E-07 3.878E-02 3.958E-04 4.674E-04 5.493E-07 6.005E-01 6.636E-02 7.679E-01 1.298E-01
P. falciparum 1062 7.756E-04 34557 3.106E-03 23267 2.486E-03 11611 4.108E-03 387 8.784E-04 598 1.247E-03 504 1.422E-03 1010 8.493E-04 36929 3.438E-03 1064 9.465E-04 31422 2.046E-03 30706 2.392E-03
36329 3947981 2.690E-04 2.086E-07 8.753E-03 2.718E-05 5.893E-03 1.465E-05 2.941E-03 1.208E-05 9.802E-05 8.610E-08 1.515E-04 1.890E-07 1.277E-04 1.815E-07 2.558E-04 2.173E-07 9.354E-03 3.216E-05 2.695E-04 2.551E-07 7.959E-03 1.628E-05 7.778E-03 1.860E-05
T. volcanium 586 4.280E-04 1183 1.063E-04 657 7.019E-05 338 1.196E-04 387 9.802E-05 248 5.174E-04 144 4.062E-04 845 7.106E-04 880 8.193E-05 388 3.452E-04 936 6.094E-05 843 6.566E-05
50339 440580 1.330E-03 5.692E-07 2.685E-03 2.855E-07 1.491E-03 1.047E-07 7.672E-04 9.175E-08 8.784E-04 8.610E-08 5.629E-04 2.912E-07 3.268E-04 1.327E-07 1.918E-03 1.363E-06 1.997E-03 1.636E-07 8.807E-04 3.040E-07 2.124E-03 1.295E-07 1.913E-03 1.256E-07
H. pylori 2634 1.924E-03 2363 2.124E-04 1003 1.071E-04 500 1.769E-04 598 1.515E-04 248 5.629E-04 899 2.536E-03 2232 1.877E-03 1239 1.154E-04 2760 2.455E-03 1261 8.210E-05 1249 9.728E-05
85962 479362 5.495E-03 1.057E-05 4.929E-03 1.047E-06 2.092E-03 2.242E-07 1.043E-03 1.845E-07 1.247E-03 1.890E-07 5.174E-04 2.912E-07 1.875E-03 4.755E-06 4.656E-03 8.740E-06 2.585E-03 2.982E-07 5.758E-03 1.414E-05 2.631E-03 2.160E-07 2.606E-03 2.535E-07
1544 1.128E-03 2205 1.982E-04 923 9.860E-05 454 1.606E-04 504 1.277E-04 144 3.268E-04 899 1.875E-03 1490 1.253E-03 1437 1.338E-04 1412 1.256E-03 1440 9.376E-05 1232 9.596E-05
115711 354548 4.355E-03 4.911E-06 6.219E-03 1.232E-06 2.603E-03 2.567E-07 1.281E-03 2.057E-07 1.422E-03 1.815E-07 4.062E-04 1.327E-07 2.536E-03 4.755E-06 4.203E-03 5.266E-06 4.053E-03 5.422E-07 3.983E-03 5.002E-06 4.062E-03 3.808E-07 3.475E-03 3.334E-07
B. subtilis 5940 4.338E-03 5430 4.880E-04 2269 2.424E-04 1287 4.554E-04 1010 2.558E-04 845 1.918E-03 2232 4.656E-03 1490 4.203E-03 3087 2.874E-04 5360 4.768E-03 3245 2.113E-04 2939 2.289E-04
224308 1189150 4.995E-03 2.167E-05 4.566E-03 2.228E-06 1.908E-03 4.625E-07 1.082E-03 4.929E-07 8.493E-04 2.173E-07 7.106E-04 1.363E-06 1.877E-03 8.740E-06 1.253E-03 5.266E-06 2.596E-03 7.461E-07 4.507E-03 2.149E-05 2.729E-03 5.765E-07 2.472E-03 5.658E-07
5394 3.939E-03 73240 6.582E-03 128253 1.370E-02 109610 3.878E-02 36929 9.354E-03 880 1.997E-03 1239 2.585E-03 1437 4.053E-03 3087 2.596E-03 4767 4.241E-03 280626 1.827E-02 257478 2.005E-02
7227 10740972 5.022E-04 1.978E-06 6.819E-03 4.488E-05 1.194E-02 1.636E-04 1.020E-02 3.958E-04 3.438E-03 3.216E-05 8.193E-05 1.636E-07 1.154E-04 2.982E-07 1.338E-04 5.422E-07 2.874E-04 7.461E-07 4.438E-04 1.882E-06 2.613E-02 4.774E-04 2.397E-02 4.807E-04
V. cholerae 52015 3.799E-02 5194 4.668E-04 2634 2.814E-04 1321 4.674E-04 1064 2.695E-04 388 8.807E-04 2760 5.758E-03 1412 3.983E-03 5360 4.507E-03 4767 4.438E-04 3591 2.338E-04 3334 2.597E-04
243277 1124125 4.627E-02 1.758E-03 4.620E-03 2.157E-06 2.343E-03 6.593E-07 1.175E-03 5.493E-07 9.465E-04 2.551E-07 3.452E-04 3.040E-07 2.455E-03 1.414E-05 1.256E-03 5.002E-06 4.768E-03 2.149E-05 4.241E-03 1.882E-06 3.194E-03 7.469E-07 2.966E-03 7.702E-07
H. sapiens 4167 3.043E-03 80252 7.212E-03 143961 1.538E-02 1697242 6.005E-01 31422 7.959E-03 936 2.124E-03 1261 2.631E-03 1440 4.062E-03 3245 2.729E-03 280626 2.613E-02 3591 3.194E-03 5664397 4.412E-01
9606 15359070 2.713E-04 8.256E-07 5.225E-03 3.769E-05 9.373E-03 1.441E-04 1.105E-01 6.636E-02 2.046E-03 1.628E-05 6.094E-05 1.295E-07 8.210E-05 2.160E-07 9.376E-05 3.808E-07 2.113E-04 5.765E-07 1.827E-02 4.774E-04 2.338E-04 7.469E-07 3.688E-01 1.627E-01
M. musculus 3475 2.538E-03 75459 6.782E-03 133331 1.424E-02 2170120 7.679E-01 30706 7.778E-03 843 1.913E-03 1249 2.606E-03 1232 3.475E-03 2939 2.472E-03 257478 2.397E-02 3334 2.966E-03 5664397 3.688E-01
10090 12838611 2.707E-04 6.869E-07 5.878E-03 3.986E-05 1.039E-02 1.479E-04 1.690E-01 1.298E-01 2.392E-03 1.860E-05 6.566E-05 1.256E-07 9.728E-05 2.535E-07 9.596E-05 3.334E-07 2.289E-04 5.658E-07 2.005E-02 4.807E-04 2.597E-04 7.702E-07 4.412E-01 1.627E-01
Proteome 
Name
Taxonomic 
ID
Taxonomic 
ID
# of 9-mer 
occurrences
C. 
pneumoniae
D. 
melanogaster
APPENDIX D
TIME FOR DATA PROCESSING
This appendix contains 3 tables giving CPU time information for the three pairs of organisms at the
9-mer level, one for each filtering strategy. Time information includes user CPU time, system CPU time and
total time for either generating the peptide universes or counting the overlaps.
Table D.1: Time information for the 3 pairs of organisms at the 9-mer level using the first
filtering strategy.
Proteome(s) User CPU Time System CPU Time Total Time
85962 4.666 0.193 4.859
115711 3.394 0.156 3.550
7227 175.321 4.535 179.856
243277 11.573 0.416 11.989
9606 244.163 6.699 250.862
10090 204.120 4.761 208.881
85962,115711 2.800 0.134 2.934
115711,85962 3.160 0.121 3.281
7227,243277 27.340 1.442 28.782
243277,7227 70.300 1.336 71.636
9606,10090 169.922 5.495 175.417
10090,9606 194.482 6.279 200.761
Table D.2: Time information for the 3 pairs of organisms at the 9-mer level using the
second filtering strategy.
Proteome(s) User CPU Time System CPU Time Total Time
85962 4.827 0.282 5.109
115711 3.456 0.215 3.671
7227 177.048 5.722 182.77
243277 11.972 0.606 12.578
9606 245.941 8.821 254.762
Continued. . .
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Table D.2 – continued from previous page
Proteome(s) User CPU Time System CPU Time Total Time
10090 201.827 7.046 208.873
85962,115711 2.932 0.182 3.114
115711,85962 3.244 0.117 3.361
7227,243277 27.35 1.796 29.146
243277,7227 70.178 1.74 71.918
9606,10090 169.946 7.161 177.107
10090,9606 192.192 5.583 197.775
Table D.3: Time information for the 3 pairs of organisms at the 9-mer level using the third
filtering strategy.
Proteome(s) User CPU Time System CPU Time Total Time
85962 7.543 0.262 7.805
115711 5.506 0.224 5.730
7227 238.405 6.318 244.723
243277 18.080 0.584 18.664
9606 341.490 11.967 353.457
10090 278.348 7.864 286.212
85962,115711 3.261 0.192 3.453
115711,85962 3.463 0.152 3.615
7227,243277 33.517 2.098 35.615
243277,7227 71.023 1.510 72.533
9606,10090 195.456 5.800 201.256
10090,9606 220.496 6.823 227.319
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APPENDIX E
VIRAL PROTEOME DESCRIPTIONS
11926.FASTA polyprotein from Human T-cell leukemia virus type I strain ATK (HTLV-I)
(Accession number P03362, Name POL HTL1A) downloaded from
http://www.expasy.org/uniprot/ on November 9, 2005
11177.FASTA 4 proteins from Newcastle disease virus strain Australia-Victoria/32 (NDVA)
downloaded from http://ca.expasy.org/uniprot/ on September 23, 2005.
12132.FASTA polyprotein from Human rhinovirus 89 (HRV-89)
(Accession number P07210, Name POLG HRV89) downloaded from
http://www.ncbi.nlm.nih.gov/entrez on November 3, 2005
31915.FASTA polyprotein from Human enterovirus 70 (EV70) strain J670/71
(Accession number P32537, Name POLG HE701) downloaded from
http://www.ebi.uniprot.org/ on October 28, 2005
10581.FASTA 8 proteins from Human papillomavirus type 16 (HPV16)(Accession number K02718)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on May 5, 2005.
11105.FASTA polyprotein from Hepatitis C virus genotype 1b (Accession number P26663)
(isolate BK) downloaded from http://www.ebi.uniprot.org/uniprot on December 21, 2005
11053.FASTA polyprotein from Dengue virus type 1 (Accession number U88536)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on November 14, 2004
11290.FASTA 6 proteins from Infectious hematopoietic necrosis virus(Accession number X89213)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11089.FASTA polyprotein from Yellow fever virus (Accession number X03700)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on November 14, 2004
Sequences is identical to that for P03314 (YEFV1)
11079.FASTA polyprotein from Murray Valley encephalitis virus (Accession number AF161266)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11075.FASTA polyprotein from Japanese encephalitis virus (strain Jaoars982)
(Accession number P32886) downloaded from http://ca.expasy.org/uniprot on June 6, 2006
11082.FASTA polyprotein from West Nile virus (Accession number P06935)
downloaded from http://ca.expasy.org/uniprot on June 6, 2006
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11029.FASTA 2 proteins from Ross River virus (Accession number M20162)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
59301.FASTA 3 proteins from Mayaro virus (Accession number AF237947)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11027.FASTA 2 proteins from O’nyong-nyong virus (Accession number AF079456)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11593.FASTA RNA-dependent RNA polymerase from Crimean-Congo hemorrhagic fever virus
(Accession number Q52NX4) downloaded from http://ca.expasy.org/uniprot on June 6, 2006
162145.FASTA 9 proteins from Human metapneumovirus (Accession number AF371337)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
12814.FASTA 10 proteins from Respiratory syncytial virus (Accession number U39661)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
93838.FASTA 10 proteins from Influenza A virus (A/Goose/Guangdong/1/96(H5N1))
(Accession numbers AF144300, AF144301, AF144302, AF144303, AF144304, AF144305, AF144306,
AF144307) downloaded from http://www.ebi.ac.uk/genomes/virus.html on September 14, 2006
11216.FASTA 6 proteins from Human parainfluenza virus 3 (Accession number AB012132)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11269.FASTA 7 proteins from Lake Victoria marburgvirus (Accession number Z12132)
downloaded from http://www.ebi.ac.uk/genomes/virus.html on August 2, 2006
11137.FASTA polyprotein from Human coronavirus (strain 229E)(Accession number Q05002)
(HCoV-229E) downloaded from http://ca.expasy.org/uniprot/Q05002 on June 15, 2006
227859.FASTA polyprotein from Human coronavirus strain SARS (HCoV-SARS) (SARS-CoV)
(Accession number P59641, Name R1AB CVHSA) downloaded from
http://www.expasy.org/uniprot on November 16, 2005
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APPENDIX F
SUMMARY OF ACTUAL AND EXPECTED OVERLAPS BETWEEN
HUMAN AND HUMAN VIRUSES
This appendix contains 5 tables giving summary information for degrees of overlapping between the
human proteome and human viruses. For each viral proteome and for k from 5 to 9, the following data
are recorded: unique k-mers in viral proteome, viral occurrences (including duplicates) in human proteins,
human proteins involved in overlap, number of overlapping k-mers (including duplicates) assuming ran-
dom model, number of unique overlapping k-mers and occurrences of k-mers in viral proteome (including
duplicates).
Table F.1: Table of data which is used to generate Figure 5.3. col 1: Proteome ID; col 2:
unique 5-mers in viral proteome; col 3: viral occurrences (including duplicates) in human
proteins; col 4: human proteins involved in overlap; col 5: number of overlapping 5-mers
(including duplicates) assuming random model; col 6: number of unique overlapping 5-
mers; col 7: occurrences of 5-mers in viral proteome (including duplicates).
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11926 892 15244 10238 4529 822 892
11177 1864 25691 14722 9473 1764 1866
12132 2156 24818 14457 10965 1961 2160
31915 2177 23484 13983 11061 1985 2179
12080 2203 24074 14115 11193 2016 2205
10581 2419 29802 15931 12284 2245 2420
11105 3000 48165 21094 15252 2753 3005
11053 3386 38449 19041 17195 3058 3388
11290 3393 51909 21178 17241 3170 3397
11089 3400 44621 20228 17291 3069 3407
11079 3422 43949 20434 17408 3091 3430
11075 3423 42147 20228 17398 3112 3428
11082 3424 43196 20291 17388 3096 3426
11029 3622 43621 20150 18433 3297 3632
59301 3663 43205 20116 18625 3349 3670
11027 3743 42712 20153 19016 3395 3747
Continued. . .
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Table F.1 – continued from previous page
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11593 3930 56902 22136 20000 3682 3941
162145 4120 54555 21531 20943 3779 4127
12814 4389 46317 20422 22358 4031 4406
93838 4412 46966 20909 22464 4036 4427
11216 4807 54534 21980 24447 4418 4818
11269 4808 68972 23857 24447 4439 4818
227859 7042 79925 25748 35856 6389 7069
Table F.2: Table of data which is used to generate Figure 5.4. col 1: Proteome ID; col 2:
unique 6-mers in viral proteome; col 3: viral occurrences (including duplicates) in human
proteins; col 4: human proteins involved in overlap; col 5: number of overlapping 6-mers
(including duplicates) assuming random model; col 6: number of unique overlapping 6-
mers; col 7: occurrences of 6-mers in viral proteome (including duplicates).
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11926 891 1092 928 226 320 891
11177 1862 1596 1436 472 622 1862
12132 2158 1545 1372 547 623 2159
31915 2176 1385 1259 551 580 2176
12080 2204 1523 1320 558 619 2204
10581 2412 2069 1757 610 739 2412
11105 3004 4383 3233 761 1037 3004
11053 3387 2329 2045 858 960 3387
11290 3391 4084 3141 859 1126 3391
11089 3406 2777 2406 863 1005 3406
11079 3429 2858 2491 869 1017 3429
11075 3427 2532 2223 868 976 3427
11082 3425 2701 2339 867 990 3425
11029 3613 2779 2367 915 1069 3613
59301 3666 2637 2292 929 1061 3668
11027 3744 2607 2224 948 1099 3744
11593 3940 3559 2960 998 1263 3940
Continued. . .
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Table F.2 – continued from previous page
Proteome col 2 col 3 col 4 col 5 col 6 col 7
162145 4117 3351 2805 1043 1245 4118
12814 4393 2765 2359 1113 1191 4396
93838 4408 2754 2404 1119 1191 4417
11216 4812 3288 2802 1218 1350 4812
11269 4811 5828 3809 1219 1497 4811
11137 6750 4047 3394 1710 1695 6753
227859 7064 7655 4523 1790 1952 7068
Table F.3: Table of data which is used to generate Figure 5.5. col 1: Proteome ID; col 2:
unique 7-mers in viral proteome; col 3: viral occurrences (including duplicates) in human
proteins; col 4: human proteins involved in overlap; col 5: number of overlapping 7-mers
(including duplicates) assuming random model; col 6: number of unique overlapping 7-
mers; col 7: occurrences of 7-mers in viral proteome (including duplicates).
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11926 890 120 90 11 57 890
11177 1858 80 68 23 51 1858
12132 2158 85 79 27 58 2158
31915 2173 77 73 27 49 2173
12080 2203 145 128 28 69 2203
10581 2404 167 125 30 102 2404
11105 3003 429 382 38 133 3003
11053 3386 163 157 43 98 3386
11290 3385 523 371 43 124 3385
11089 3405 172 161 43 96 3405
11079 3428 158 148 43 85 3428
11075 3426 151 147 43 91 3426
11082 3424 181 174 43 98 3424
11029 3595 188 173 45 119 3595
59301 3666 177 160 46 104 3666
11027 3741 190 179 47 114 3741
11593 3939 259 227 50 127 3939
Continued. . .
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Table F.3 – continued from previous page
Proteome col 2 col 3 col 4 col 5 col 6 col 7
162145 4109 236 214 52 123 4109
12814 4386 189 162 55 107 4386
93838 4400 149 141 56 96 4407
11216 4806 202 179 61 126 4806
11269 4804 301 268 61 151 4804
11137 6751 251 235 85 156 6752
227859 7067 630 563 89 202 7067
Table F.4: Table of data which is used to generate Figure 5.6. col 1: Proteome ID; col 2:
unique 8-mers in viral proteome; col 3: viral occurrences (including duplicates) in human
proteins; col 4: human proteins involved in overlap; col 5: number of overlapping 8-mers
(including duplicates) assuming random model; col 6: number of unique overlapping 8-
mers; col 7: occurrences of 8-mers in viral proteome (including duplicates).
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11926 889 23 16 0.560 12 889
11177 1854 7 7 1.168 4 1854
12132 2157 6 6 1.359 5 2157
31915 2170 4 4 1.368 3 2170
12080 2202 17 16 1.388 11 2202
10581 2396 28 4 1.510 27 2396
11105 3002 29 28 1.892 11 3002
11053 3385 5 5 2.133 5 3385
11290 3379 125 100 2.129 14 3379
11089 3404 9 9 2.145 7 3404
11079 3427 10 10 2.160 7 3427
11075 3425 4 4 2.158 3 3425
11082 3423 7 7 2.157 6 3423
11029 3577 10 9 2.254 7 3577
59301 3664 16 16 2.309 8 3664
11027 3738 11 9 2.356 6 3738
11593 3938 25 21 2.482 15 3938
Continued. . .
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Proteome col 2 col 3 col 4 col 5 col 6 col 7
162145 4100 14 13 2.584 11 4100
12814 4376 10 9 2.758 8 4376
93838 4392 5 3 2.771 5 4397
11216 4800 21 17 3.025 13 4800
11269 4797 31 27 3.023 17 4797
11137 6751 15 13 4.255 9 6751
227859 7066 37 35 4.453 20 7066
Table F.5: Table of data which is used to generate Figure 5.7. col 1: Proteome ID; col 2:
unique 9-mers in viral proteome; col 3: viral occurrences (including duplicates) in human
proteins; col 4: human proteins involved in overlap; col 5: number of overlapping 9-mers
(including duplicates) assuming random model; col 6: number of unique overlapping 9-
mers; col 7: occurrences of 9-mers in viral proteome (including duplicates).
Proteome col 2 col 3 col 4 col 5 col 6 col 7
11926 888 7 3 0.028 5 888
11177 1850 0 0 0.058 0 1850
12132 2156 0 0 0.067 0 2156
31915 2167 0 0 0.068 0 2167
12080 2201 1 1 0.069 1 2201
10581 2388 16 1 0.075 16 2388
11105 3001 0 0 0.094 0 3001
11053 3384 0 0 0.106 0 3384
11290 3373 13 11 0.106 4 3373
11089 3403 0 0 0.107 0 3403
11079 3426 0 0 0.108 0 3426
11075 3424 0 0 0.108 0 3424
11082 3422 0 0 0.108 0 3422
11029 3559 1 1 0.112 1 3559
59301 3662 0 0 0.115 0 3662
11027 3735 2 2 0.117 1 3735
11593 3937 4 4 0.124 2 3937
Continued. . .
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Table F.5 – continued from previous page
Proteome col 2 col 3 col 4 col 5 col 6 col 7
162145 4091 1 1 0.129 1 4091
12814 4366 1 1 0.137 1 4366
93838 4384 2 1 0.138 2 4387
11216 4794 4 1 0.151 1 4790
11137 6750 2 2 0.212 1 6750
227859 7065 2 1 0.222 2 7065
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APPENDIX G
SUMMARY OF CHI-SQUARE ANALYSIS
This appendix contains 9 tables giving summary information for counts of overlaps/nonoverlaps between
viral proteomes ( HIV-1, HIV-2 or Influenza A virus) and the human proteome at different peptide lengths
(i.e., 5-, 6- and 7-mer).
The HIV-1 proteome is broken up into 36 segments of 100 amino acids in length at the 5-mer level.
Table G.1: Table of counts of nonoverlapping 5-mers by dividing the HIV-1 proteome into
evenly-sized (i.e., 100 amino acids) segments. N is the observed number of 5-mers in the
segment with no overlap in the human proteome.
Position N HIV-1 protein
0001-0100 2 Gag poly (p17)
0101-0200 8 Gag poly (p17, p24)
0201-0300 10 Gag poly (p24)
0301-0400 18 Gag poly (p24, p2, p7, p1, p6)
0401-0500 9 Gag poly (p2, p7, p1, p6)
0501-0600 3 Gag-Pol (p17)
0601-0700 7 Gag-Pol (p17, p24)
0701-0800 11 Gag-Pol (p24)
0801-0900 17 Gag-Pol (p24, p2, p7, p1, p6)
0901-1000 13 Gag-Pol (p2, p7, p1, p6)
1001-1100 8 Gag-Pol (Protease)
1101-1200 6 Gag-Pol (RT)
1201-1300 8 Gag-Pol (RT)
1301-1400 9 Gag-Pol (RT)
1401-1500 6 Gag-Pol (RT)
1501-1600 14 Gag-Pol (RT)
1601-1700 6 Gag-Pol (RT, Integrase)
1701-1800 15 Gag-Pol (Integrase)
1801-1900 4 Gag-Pol (Integrase)
1901-2000 16 Gag-Pol (Integrase), Env gp160
2001-2100 13 Env gp160
2101-2200 9 Env gp160
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Position N HIV-1 protein
2201-2300 10 Env gp160
2301-2400 14 Env gp160
2401-2500 3 Env gp160
2501-2600 10 Env gp160
2601-2700 10 Env gp160
2701-2800 6 Env gp160
2801-2900 3 Nef
2901-3000 15 Nef
3001-3100 10 Tat, Vpu
3101-3200 6 Vpu, Rev
3201-3300 12 Rev, Vif
3301-3400 10 Vif
3401-3500 12 Vif, Vpr
3501-3535 3 Vpr
The HIV-1 proteome is broken up into separate proteins at the 5-mer level.
Table G.2: Table of counts of non-overlapping 5-mers by dividing the HIV-1 proteome
into individual protein segments. N is the observed number of 5-mers starting within the
protein with no overlap in the human proteome. Expected N is calculated as (total # of
non-overlaps)×(# of 5-mer from this protein)÷(total # of 5-mers) = 336×(# of 5-mer from
this protein)÷3535.
Protein Position N Expected N
Gag poly (p17) 0001-0131 4 12.451
Gag poly (p24) 0132-0362 26 21.956
Gag poly (p2, p7, p1, p6) 0363-0507 18 13.782
Gag-Pol (p17) 0508-0638 4 12.451
Gag-Pol (p24) 0639-0869 26 21.956
Gag-Pol (p2, p7, p1, p6) 0870-1006 21 13.022
Gag-Pol (Protease) 1007-1105 8 9.410
Gag-Pol (RT) 1106-1665 44 53.228
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Protein Position N Expected N
Gag-Pol (Integrase) 1666-1949 25 26.994
Env gp160 1950-2801 89 80.982
Nef 2802-3002 18 19.105
Tat 3003-3084 10 7.794
Vpu 3085-3161 6 7.319
Rev 3162-3273 1 10.646
Vif 3274-3461 27 17.869
Vpr 3462-3535 9 7.034
The HIV-1 proteome is broken up into 36 segments of 100 amino acids in length at the 6-mer level.
Table G.3: Table of counts of overlapping 6-mers by dividing the HIV-1 proteome into
evenly-sized (i.e., 100 amino acids) segments. N is the observed number of 6-mers in the
segment which overlap the human proteome.
Position N HIV-1 protein
0001-0100 46 Gag poly (p17)
0101-0200 32 Gag poly (p17, p24)
0201-0300 29 Gag poly (p24)
0301-0400 25 Gag poly (p24, p2, p7, p1, p6)
0401-0500 38 Gag poly (p2, p7, p1, p6)
0501-0600 42 Gag-Pol (p17)
0601-0700 37 Gag-Pol (p17, p24)
0701-0800 28 Gag-Pol (p24)
0801-0900 25 Gag-Pol (p24, p2, p7, p1, p6)
0901-1000 30 Gag-Pol (p2, p7, p1, p6)
1001-1100 26 Gag-Pol (Protease)
1101-1200 22 Gag-Pol (RT)
1201-1300 25 Gag-Pol (RT)
1301-1400 33 Gag-Pol (RT)
1401-1500 30 Gag-Pol (RT))
1501-1600 21 Gag-Pol (RT)
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Position N HIV-1 protein
1601-1700 20 Gag-Pol (RT, Integrase)
1701-1800 22 Gag-Pol (Integrase)
1801-1900 20 Gag-Pol (Integrase)
1901-2000 21 Gag-Pol (Integrase), Env gp160
2001-2100 15 Env gp160
2101-2200 18 Env gp160
2201-2300 28 Env gp160
2301-2400 17 Env gp160
2401-2500 31 Env gp160
2501-2600 34 Env gp160
2601-2700 46 Env gp160
2701-2800 41 Env gp160
2801-2900 42 Nef
2901-3000 24 Nef
3001-3100 31 Tat, Vpu
3101-3200 48 Vpu, Rev
3201-3300 32 Rev, Vif
3301-3400 28 Vif
3401-3500 34 Vif, Vpr
3501-3526 8 Vpr
The HIV-1 proteome is broken up into separate proteins at the 6-mer level.
Table G.4: Table of counts of overlapping 6-mers by dividing the HIV-1 proteome into
individual protein segments. N is the observed number of 6-mers starting within the
protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 6-mer from this protein)÷(total # of 6-mers) = 1049×(# of 6-mer from
this protein)÷3526.
Protein Position N Expected N
Gag poly (p17) 0001-0131 58 38.973
Gag poly (p24) 0132-0362 68 68.723
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Protein Position N Expected N
Gag poly (p2, p7, p1, p6) 0363-0506 45 42.841
Gag-Pol (p17) 0507-0637 58 38.973
Gag-Pol (p24) 0638-0868 68 68.723
Gag-Pol (p2, p7, p1, p6) 0869-1005 35 40.758
Gag-Pol (Protease) 1006-1104 27 29.453
Gag-Pol (RT) 1105-1664 146 166.602
Gag-Pol (Integrase) 1665-1947 59 84.194
Env gp160 1948-2798 237 253.176
Nef 2799-2998 66 59.501
Tat 2999-3079 23 24.098
Vpu 3080-3155 32 22.61
Rev 3156-3266 54 33.023
Vif 3267-3453 53 55.633
Vpr 3454-3526 20 21.718
The HIV-1 proteome is broken up into 18 segments of 200 amino acids in length at the 7-mer level.
Table G.5: Table of counts of overlapping 7-mers by dividing the HIV-1 proteome into
evenly-sized (i.e., 200 amino acids) segments. N is the observed number of 7-mers in the
segment which overlap the human proteome.
Position N HIV-1 protein
0001-0200 7 Gag poly (p17)
0201-0400 8 Gag poly (p17, p24)
0401-0600 9 Gag poly (p2, p7, p1, p6), Gag-Pol (p17)
0601-0800 5 Gag-Pol (p17, p24)
0801-1000 7 Gag-Pol (p24, p2, p7, p1, p6)
1001-1200 3 Gag-Pol (Protease, RT)
1201-1400 7 Gag-Pol (RT)
1401-1600 8 Gag-Pol (RT)
1601-1800 1 Gag-Pol (RT, Integrase)
1801-2000 3 Gag-Pol (Integrase), Env gp160
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2001-2200 3 Env gp160
2201-2400 4 Env gp160
2401-2600 6 Env gp160
2601-2800 17 Env gp160
2801-3000 5 Nef
3001-3200 10 Tat, Vpu, Rev
3201-3400 5 Rev, Vif
3401-3517 4 Vif, Vpr
The HIV-1 proteome is broken up into separate proteins at the 7-mer level.
Table G.6: Table of counts of overlapping 7-mers by dividing the HIV-1 proteome into
individual protein segments. N is the observed number of 7-mers starting within the
protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 7-mer from this protein)÷(total # of 7-mers) = 112×(# of 7-mer from
this protein)÷3517.
Protein Position N Expected N
Gag poly (p17) 0001-0131 7 4.172
Gag poly (p24) 0132-0362 7 7.356
Gag poly (p2, p7, p1, p6) 0363-0505 6 4.554
Gag-Pol (p17) 0506-0636 7 4.172
Gag-Pol (p24) 0637-0867 7 7.356
Gag-Pol (p2, p7, p1, p6) 0868-1004 2 4.363
Gag-Pol (Protease) 1005-1103 3 3.153
Gag-Pol (RT) 1104-1663 15 17.833
Gag-Pol (Integrase) 1664-1945 3 8.98
Env gp160 1946-2795 31 27.069
Nef 2796-2994 5 6.337
Tat 2995-3074 3 2.548
Vpu 3075-3149 4 2.388
Rev 3150-3259 6 3.503
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Protein Position N Expected N
Vif 3260-3445 5 5.923
Vpr 3446-3517 1 2.293
The HIV-2 proteome is broken up into 37 segments of 100 amino acids in length at the 5-mer level.
Table G.7: Table of counts of non-overlapping 5-mers by dividing the HIV-2 proteome
into evenly-sized (i.e., 100 amino acids) segments. N is the observed number of 5-mers in
the segment with no overlap in the human proteome.
Position N HIV-2 protein
0001-0100 9 Env gp160
0101-0200 8 Env gp160
0201-0300 21 Env gp160
0301-0400 25 Env gp160
0401-0500 12 Env gp160
0501-0600 2 Env gp160
0601-0700 13 Env gp160
0701-0800 10 Env gp160
0801-0900 6 Env gp160, Gag-Pol (p17)
0901-1000 9 Gag-Pol (p17, p24)
1001-1100 11 Gag-Pol (p24)
1101-1200 15 Gag-Pol (p24)
1201-1300 11 Gag-Pol (p24, p2, p7, p1, p6)
1301-1400 4 Gag-Pol (p2, p7, p1, p6, Protease)
1401-1500 5 Gag-Pol (Protease, RT)
1501-1600 6 Gag-Pol (RT)
1601-1700 11 Gag-Pol (RT)
1701-1800 8 Gag-Pol (RT)
1801-1900 15 Gag-Pol (RT)
1901-2000 3 Gag-Pol (RT)
2001-2100 14 Gag-Pol (RT, Integrase)
2101-2200 12 Gag-Pol (Integrase)
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2201-2300 7 Gag-Pol (Integrase)
2301-2400 7 Gag-Pol (Integrase), Gag poly (p17)
2401-2500 8 Gag poly (p17, p24)
2501-2600 12 Gag poly (p24)
2601-2700 10 Gag poly (p24, p2, p7, p1, p6)
2701-2800 12 Gag poly (p2, p7, p1, p6)
2801-2900 15 Gag poly (p2, p7, p1, p6), Vif
2901-3000 17 Vif
3001-3100 4 Vif, Nef
3101-3200 16 Nef
3201-3300 11 Nef, Tat
3301-3400 11 Tat
3401-3500 5 Tat, Rev
3501-3600 4 Rev, Vpr
3601-3700 13 Vpr, Vpx
The HIV-2 proteome is broken up into separate proteins at the 5-mer level.
Table G.8: Table of counts of non-overlapping 5-mers by dividing the HIV-2 proteome
into individual protein segments. N is the observed number of 5-mers starting within the
protein with no overlap in the human proteome. Expected N is calculated as (total # of
non-overlaps)×(# of 5-mer from this protein)÷(total # of 5-mers) = 382×(# of 5-mer from
this protein)÷3723.
Protein Position N Expected N
Env gp160 0001-0854 105 87.625
Gag-Pol (p17) 0855-0988 9 13.749
Gag-Pol (p24) 0989-1218 28 23.599
Gag-Pol (p2,p7,p1,p6) 1219-1366 14 15.186
Gag-Pol (Protease) 1367-1465 2 10.158
Gag-Pol (RT) 1466-2024 47 57.356
Gag-Pol (Integrase) 2025-2313 32 29.653
Continued. . .
85
Table G.8 – continued from previous page
Protein Position N Expected N
Gag poly (p17) 2314-2447 9 13.749
Gag poly (p24) 2448-2677 28 23.599
Gag poly (p2,p7,p1,p6) 2678-2830 12 15.699
Vif 2831-3041 33 21.65
Nef 3042-3292 30 25.754
Tat 3293-3418 11 12.928
Rev 3419-3514 5 9.85
Vpr 3515-3615 5 10.363
Vpx 3616-3723 12 11.081
The HIV-2 proteome is broken up into 37 segments of 100 amino acids in length at the 6-mer level.
Table G.9: Table of counts of overlapping 6-mers by dividing the HIV-2 proteome into
evenly-sized (i.e., 100 amino acids) segments. N is the observed number of 6-mers in the
segment which overlap the human proteome.
Position N HIV-2 protein
0001-0100 22 Env gp160
0101-0200 36 Env gp160
0201-0300 11 Env gp160
0301-0400 16 Env gp160
0401-0500 22 Env gp160
0501-0600 48 Env gp160
0601-0700 28 Env gp160
0701-0800 31 Env gp160
0801-0900 41 Env gp160, Gag-Pol (p17)
0901-1000 38 Gag-Pol (p17, p24)
1001-1100 29 Gag-Pol (p24)
1101-1200 12 Gag-Pol (p24)
1201-1300 45 Gag-Pol (p24, p2, p7, p1, p6)
1301-1400 42 Gag-Pol (p2, p7, p1, p6, Protease)
1401-1500 32 Gag-Pol (Protease, RT)
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1501-1600 35 Gag-Pol (RT)
1601-1700 27 Gag-Pol (RT)
1701-1800 30 Gag-Pol (RT)
1801-1900 23 Gag-Pol (RT)
1901-2000 34 Gag-Pol (RT)
2001-2100 16 Gag-Pol (RT, Integrase)
2101-2200 26 Gag-Pol (Integrase)
2201-2300 24 Gag-Pol (Integrase)
2301-2400 44 Gag-Pol (Integrase), Gag poly (p17)
2401-2500 31 Gag poly (p17, p24)
2501-2600 22 Gag poly (p24)
2601-2700 29 Gag poly (p24, p2, p7, p1, p6)
2701-2800 36 Gag poly (p2, p7, p1, p6)
2801-2900 17 Gag poly (p2, p7, p1, p6), Vif
2901-3000 27 Vif
3001-3100 46 Vif, Nef
3101-3200 31 Nef
3201-3300 26 Nef, Tat
3301-3400 41 Tat
3401-3500 34 Tat, Rev
3501-3600 44 Rev, Vpr
3601-3700 30 Vpr, Vpx
3701-3714 12 Vpx
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The HIV-2 proteome is broken up into separate proteins at the 6-mer level.
Table G.10: Table of counts of overlapping 6-mers by dividing the HIV-2 proteome into
individual protein segments. N is the observed number of 6-mers starting within the
protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 6-mer from this protein)÷(total # of 6-mers) = 1138×(# of 6-mer from
this protein)÷3714.
Protein Position N Expected N
Env gp160 0001-0853 235 261.366
Gag-Pol (p17) 0854-0987 55 41.059
Gag-Pol (p24) 0988-1217 55 70.474
Gag-Pol (p2,p7,p1,p6) 1218-1365 64 45.348
Gag-Pol (Protease) 1366-1464 29 30.334
Gag-Pol (RT) 1465-2023 170 171.282
Gag-Pol (Integrase) 2024-2311 66 88.246
Gag poly (p17) 2312-2445 55 41.059
Gag poly (p24) 2446-2675 55 70.474
Gag poly (p2,p7,p1,p6) 2676-2827 53 46.574
Vif 2828-3037 58 64.346
Nef 3038-3287 76 76.602
Tat 3288-3412 50 38.301
Rev 3413-3507 35 29.109
Vpr 3508-3607 43 30.641
Vpx 3608-3714 39 32.786
The HIV-2 proteome is broken up into 25 segments of 150 amino acids in length at the 7-mer level.
Table G.11: Table of counts of overlapping 7-mers by dividing the HIV-2 proteome into
evenly-sized (i.e., 150 amino acids) segments. N is the observed number of 7-mers in the
segment which overlap the human proteome.
Position N HIV-2 protein
0001-0150 6 Env gp160
0151-0300 1 Env gp160
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0301-0450 2 Env gp160
0451-0600 11 Env gp160
0601-0750 0 Env gp160
0751-0900 11 Env gp160, Gag-Pol (p17)
0901-1050 5 Gag-Pol (p17, p24)
1051-1200 3 Gag-Pol (p24)
1201-1350 17 Gag-Pol (p24, p2, p7, p1, p6)
1351-1500 5 Gag-Pol (p2, p7, p1, p6, Protease, RT)
1501-1650 2 Gag-Pol (RT)
1651-1800 4 Gag-Pol (RT)
1801-1950 5 Gag-Pol (RT)
1951-2100 2 Gag-Pol (RT, Integrase)
2101-2250 2 Gag-Pol (Integrase)
2251-2400 7 Gag-Pol (Integrase), Gag poly (p17)
2401-2550 5 Gag poly (p17, p24)
2551-2700 7 Gag poly (p24, p2, p7, p1, p6)
2701-2850 8 Gag poly (p2, p7, p1, p6), Vif
2851-3000 2 Vif
3001-3150 6 Vif, Nef
3151-3300 3 Nef, Tat
3301-3450 7 Tat, Rev
3451-3600 6 Rev, Vpr
3601-3705 11 Vpx
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The HIV-2 proteome is broken up into separate proteins at the 7-mer level.
Table G.12: Table of counts of overlapping 7-mers by dividing the HIV-2 proteome into
individual protein segments. N is the observed number of 7-mers starting within the
protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 7-mer from this protein)÷(total # of 7-mers) = 138×(# of 7-mer from
this protein)÷3705.
Protein Position N Expected N
Env gp160 0001-0852 27 31.734
Gag-Pol (p17) 0853-0986 8 4.991
Gag-Pol (p24) 0987-1216 6 8.567
Gag-Pol (p2,p7,p1,p6) 1217-1364 16 5.513
Gag-Pol (Protease) 1365-1463 2 3.687
Gag-Pol (RT) 1464-2022 14 20.821
Gag-Pol (Integrase) 2023-2309 5 10.690
Gag poly (p17) 2310-2443 8 4.991
Gag poly (p24) 2444-2673 6 8.567
Gag poly (p2,p7,p1,p6) 2674-2824 11 5.624
Vif 2825-3033 3 7.785
Nef 3034-3282 7 9.274
Tat 3283-3406 3 4.619
Rev 3407-3500 5 3.501
Vpr 3501-3599 6 3.687
Vpx 3600-3705 11 3.948
The Influenza A virus proteome is broken up into 45 segments of 100 amino acids in length at the 5-mer
level.
Table G.13: Table of counts of non-overlapping 5-mers by dividing the Influenza A virus
proteome into evenly-sized (i.e., 100 amino acids) segments. N is the observed number of
5-mers in the segment with no overlap in the human proteome.
Position N Influenza A virus protein
0001-0100 13 Nonstructural 1
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Position N Influenza A virus protein
0101-0200 6 Nonstructural 1
0201-0300 8 Nonstructural 1, Nonstructural 2
0301-0400 3 Nonstructural 2, Matrix 1
0401-0500 2 Matrix 1
0501-0600 6 Matrix 1, Matrix 2
0601-0700 11 Matrix 2, Hemagglutinin
0701-0800 9 Hemagglutinin
0801-0900 18 Hemagglutinin
0901-1000 12 Hemagglutinin
1001-1100 7 Hemagglutinin
1101-1200 7 Hemagglutinin
1201-1300 8 Hemagglutinin, Neuraminidase
1301-1400 8 Neuraminidase
1401-1500 9 Neuraminidase
1501-1600 15 Neuraminidase
1601-1700 20 Neuraminidase
1701-1800 7 Neuraminidase, Nucleocapsid
1801-1900 12 Nucleocapsid
1901-2000 10 Nucleocapsid
2001-2100 8 Nucleocapsid
2101-2200 6 Nucleocapsid
2201-2300 8 Nucleocapsid, Polymerse (gene: None)
2301-2400 2 Polymerse (gene: None)
2401-2500 8 Polymerse (gene: None)
2501-2600 8 Polymerse (gene: None)
2601-2700 10 Polymerse (gene: None)
2701-2800 8 Polymerse (gene: None)
2801-2900 5 Polymerse (gene: None)
2901-3000 10 Polymerse (gene: None), Polymerse (gene: PB1)
3001-3100 8 Polymerse (gene: PB1)
3101-3200 6 Polymerse (gene: PB1)
3201-3300 14 Polymerse (gene: PB1)
3301-3400 15 Polymerse (gene: PB1)
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3401-3500 11 Polymerse (gene: PB1)
3501-3600 7 Polymerse (gene: PB1)
3601-3700 3 Polymerse (gene: PB1), Polymerse (gene: PB2)
3701-3800 11 Polymerse (gene: PB2)
3801-3900 4 Polymerse (gene: PB2)
3901-4000 7 Polymerse (gene: PB2)
4001-4100 4 Polymerse (gene: PB2)
4101-4200 8 Polymerse (gene: PB2)
4201-4300 13 Polymerse (gene: PB2)
4301-4400 0 Polymerse (gene: PB2)
4401-4427 1 Polymerse (gene: PB2)
The Influenza A virus proteome is broken up into separate proteins at the 5-mer level.
Table G.14: Table of counts of non-overlapping 5-mers by dividing the Influenza A virus
proteome into individual protein segments. N is the observed number of 5-mers starting
within the protein with no overlap in the human proteome. Expected N is calculated as
(total # of non-overlaps)×(# of 5-mer from this protein)÷(total # of 5-mers) = 376×(# of
5-mer from this protein)÷4427.
Protein Position N Expected N
Nonstructural 1 0001-0226 21 19.195
Nonstructural 2 0227-0343 8 9.937
Matrix 1 0344-0591 9 21.063
Matrix 2 0592-0684 10 7.900
Hemagglutinin 0685-1248 58 47.902
Neuraminidase 1249-1713 58 39.494
Nucleocapsid 1714-2207 41 41.957
Polymerse (gene: None) 2208-2919 53 60.473
Polymerse (gene: PB1) 2920-3672 68 63.955
Polymerse (gene: PB2) 3673-4427 50 64.125
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The Influenza A virus proteome is broken up into 45 segments of 100 amino acids in length at the 6-mer
level.
Table G.15: Table of counts of overlapping 6-mers by dividing the Influenza A virus pro-
teome into evenly-sized (i.e., 100 amino acids) segments. N is the observed number of
6-mers in the segment which overlap the human proteome.
Position N Influenza A virus protein
0001-0100 34 Nonstructural 1
0101-0200 33 Nonstructural 1
0201-0300 28 Nonstructural 1, Nonstructural 2
0301-0400 35 Nonstructural 2, Matrix 1
0401-0500 32 Matrix 1
0501-0600 33 Matrix 1, Matrix 2
0601-0700 32 Matrix 2, Hemagglutinin
0701-0800 25 Hemagglutinin
0801-0900 21 Hemagglutinin
0901-1000 14 Hemagglutinin
1001-1100 31 Hemagglutinin
1101-1200 27 Hemagglutinin
1201-1300 31 Hemagglutinin, Neuraminidase
1301-1400 28 Neuraminidase
1401-1500 28 Neuraminidase
1501-1600 14 Neuraminidase
1601-1700 22 Neuraminidase
1701-1800 32 Neuraminidase, Nucleocapsid
1801-1900 22 Nucleocapsid
1901-2000 25 Nucleocapsid
2001-2100 28 Nucleocapsid
2101-2200 22 Nucleocapsid
2201-2300 18 Polymerse (gene: None)
2301-2400 30 Polymerse (gene: None)
2401-2500 31 Polymerse (gene: None)
2501-2600 28 Polymerse (gene: None)
2601-2700 22 Polymerse (gene: None)
2701-2800 24 Polymerse (gene: None)
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2801-2900 39 Polymerse (gene: None)
2901-3000 22 Polymerse (gene: None), Polymerse (gene: PB1)
3001-3100 23 Polymerse (gene: PB1)
3101-3200 34 Polymerse (gene: PB1)
3201-3300 16 Polymerse (gene: PB1)
3301-3400 22 Polymerse (gene: PB1)
3401-3500 25 Polymerse (gene: PB1)
3501-3600 18 Polymerse (gene: PB1)
3601-3700 27 Polymerse (gene: PB1), Polymerse (gene: PB2)
3701-3800 13 Polymerse (gene: PB2)
3801-3900 34 Polymerse (gene: PB2)
3901-4000 38 Polymerse (gene: PB2)
4001-4100 29 Polymerse (gene: PB2)
4101-4200 25 Polymerse (gene: PB2)
4201-4300 34 Polymerse (gene: PB2)
4301-4400 40 Polymerse (gene: PB2)
4401-4417 6 Polymerse (gene: PB2)
The Influenza A virus proteome is broken up into separate proteins at the 6-mer level.
Table G.16: Table of counts of overlapping 6-mers by dividing the Influenza A virus pro-
teome into individual protein segments. N is the observed number of 6-mers starting within
the protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 6-mer from this protein)÷(total # of 6-mers) = 1195×(# of 6-mer from
this protein)÷4417.
Protein Position N Expected N
Nonstructural 1 0001-0225 75 60.873
Nonstructural 2 0226-0341 33 31.383
Matrix 1 0342-0588 85 66.825
Matrix 2 0589-0680 23 24.890
Hemagglutinin 0681-1243 144 152.317
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Neuraminidase 1244-1707 111 125.533
Nucleocapsid 1708-2200 126 133.379
Polymerse (gene: None) 2201-2911 195 192.358
Polymerse (gene: PB1) 2912-3663 172 203.450
Polymerse (gene: PB2) 3664-4417 231 203.991
The Influenza A virus proteome is broken up into 18 segments of 250 amino acids in length at the 7-mer
level.
Table G.17: Table of counts of overlapping 7-mers by dividing the Influenza A virus pro-
teome into evenly-sized (i.e., 250 amino acids) segments. N is the observed number of
7-mers in the segment which overlap the human proteome.
Position N Influenza A virus protein
0001-0250 12 Nonstructural 1, Nonstrucrual 2
0251-0500 5 Nonstrucrual 2, Matrix 1
0501-0750 2 Matrix 1, Matrix 2, Hemagglutinin
0751-1000 4 Hemagglutinin
1001-1250 9 Hemagglutinin, Neuraminidase
1251-1500 4 Neuraminidase
1501-1750 4 Neuraminidase, Nucleocapsid
1751-2000 5 Nucleocapsid
2001-2250 11 Nucleocapsid, Polymerse (gene: None)
2251-2500 8 Polymerse (gene: None)
2501-2750 3 Polymerse (gene: None)
2751-3000 6 Polymerse (gene: None), Polymerse (gene: PB1)
3001-3250 3 Polymerse (gene: PB1)
3251-3500 2 Polymerse (gene: PB1)
3501-3750 0 Polymerse (gene: PB1), Polymerse (gene: PB2)
3751-4000 8 Polymerse (gene: PB2)
4001-4250 5 Polymerse (gene: PB2)
4251-4407 5 Polymerse (gene: PB2)
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The Influenza A virus proteome is broken up into separate proteins at the 7-mer level.
Table G.18: Table of counts of overlapping 7-mers by dividing the Influenza A virus pro-
teome into individual protein segments. N is the observed number of 7-mers starting within
the protein with overlap in the human proteome. Expected N is calculated as (total # of
overlaps)×(# of 7-mer from this protein)÷(total # of 7-mers) = 96×(# of 7-mer from this
protein)÷4407.
Protein Position N Expected N
Nonstructural 1 0001-0224 10 4.880
Nonstructural 2 0225-0339 4 2.505
Matrix 1 0340-0585 4 5.359
Matrix 2 0586-0676 1 1.982
Hemagglutinin 0677-1238 12 12.242
Neuraminidase 1239-1701 7 10.086
Nucleocapsid 1702-2193 16 10.717
Polymerse (gene: None) 2194-2903 19 15.466
Polymerse (gene: PB1) 2904-3654 5 16.359
Polymerse (gene: PB2) 3655-4407 18 16.403
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